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Introduction 
The biofilm mode of growth 
Several characteristics of bacteria contribute to their survival strategy in the human host. 
They have the ability to persist intracellulary within several types of non-professional 
phagocytic cells1, specifically neutrophils2. Adhesins like fibronectin-binding protein A and 
B (fnbpA/B) have been shown indispensable for adhesion to and internalization by these 
cells1,3. The intracellular survival of Staphylococcus aureus relies on protective antioxidants2 
such as catalase4, staphyloxanthin5 and the eponymous golden carotenoid pigment6,7. 
Especially the small colony variants (SCVs) have been associated with intracellular survival, 
probably due to their decreased metabolic activity and enhanced expression of adhesins8. 
Other protection mechanisms of micro-organisms to circumvent host defenses and thera-
peutic intervention involve: (i), the expression of efflux pumps9,10; (ii), the (hy-
per)production of antibiotic degrading enzymes like beta-lactamases11; (iii), the formation 
of capsular polysaccharides (CPs)12,13 – functioning as important cell wall components that 
can resist uptake and killing by phagocytes14 – and the inhibition of antibody- and com-
plement-mediated phagocytosis15; (iv), the release of virulence factors15; (v), the modifica-
tion or genetic diversification of antibiotic target proteins such as penicillin-binding pro-
teins (PBPs)16; and (vi), the biofilm mode of growth. 
During the last decade convincing evidence showed that the capability of bacteria to 
form biofilm is of unprecedented importance in order to protect themselves against the 
host immune system and antibiotics. Very likely, bacteria strike back by a mixture of strate-
gies, which could act synergistically. It is believed that conventional resistance mecha-
nisms also contribute to the success of biofilm communities17. For example, in case of 
mucosal infections it has been noticed that biofilm aggregates attach to the epithelium to 
reside in the mucus layer or sequestrate into intracellular aggregates for persistence18. 
Demonstrated intracellular localisation of bacteria inside dysfunctional leucocytes en-
closed within a biofilm highlights the relevance of additionally employed strategies by 
bacteria to limit the efficacy of antibiotics19. Another example of a mixed protection system 
is the identification of a biofilm specific efflux pump in Pseudomonas aeruginosa17,20. How-
ever, the observation that the acquisition of plasmids bearing genes encoding for particu-
lar classes of beta-lactamases might lead to a reduced capacity to form biomass21, suggests 
that gaining certain resistance genes could suppress other survival opportunities. Never-
theless, high levels of beta-lactamases entrapped within the biofilm matrix have been 
observed due to secretion or lysis of biofilm-resident cells22,23. 
Biofilm formation represents a protected mode of growth that allows bacterial cells to 
stay alive in both hostile natural environments as in the human host24, and enables them 
to disperse and colonize new niches whenever needed. Biofilm embedded bacteria are 
therefore often causative for recurrent and persistent (or chronic) infections25. Biofilm are 
mostly adhered to surfaces, including those from natural origin such as oral, respiratory, 
corneal or urogenital epithelium. These tissues seem to be more prone to bacterial adher-
ence when altered or damaged26. Embedded micro-organisms on any surface constitute 
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profound implications for the host, because the sessile micro-organisms that are surviving 
in these matrix-enclosed aggregates are recalcitrant to antibiotic treatment and demon-
strate persistence in spite of sustained host defences18. Another critical issue of biofilm-
based infections is that biofilm can contain both multiple bacteria and fungi25,27. It is be-
lieved that micro-organisms inside these polymicrobial or multispecies communities gain a 
fitness advantage28, possibly via the facilitation of microevolutionary processes and mutual 
horizontal gene transfer29. However, model simulations suggest that within-species coop-
eration could enhance or disfavour the ability to compete with other species30. A known 
negative interaction involves a subset of Staphylococcus epidermidis which can inhibit S. 
aureus nasal colonization and consequently biofilm formation by secreting the serine 
protease Esp31. Nevertheless, both species cooperated in biofilm infected arthroplasties32. 
Biofilm formation has not only been demonstrated for S. aureus, but also for numerous 
other pathogens. This thesis focuses on monospecies biofilm formation by S. aureus. 
 
The development of biofilm is thought to consist of four consecutive stages: (i), initial 
attachment to a foreign body or tissue; (ii), accumulation of extracellular polymeric sub-
stances and aggregation; (iii), biofilm maturation including expansion and channel forma-
tion; and (iv), dispersal. Dispersal involves the release of microbes from the biofilm, which 
might start all over again the vicious cycle33. 
 
Initial interactions with a surface are believed to occur via non-specific physiochemical 
forces such as charge, van der Waals forces and hydrophobic interactions34. Initial adher-
ence has also been attributed to bacterial surface proteins35,36. Microbial surface compo-
nents recognizing adhesive matrix molecules (MSCRAMMs), surface-anchored adhesins 
like, among others, fibronectin binding protein A and B (fnbpA/B)37,38, fibrinogen binding 
protein (fbpA)39, clumping factor A and B (clfA/B)40, bone sialoprotein-binding protein 
(bbp)41, serine-aspartate repeat-containing proteins C, D and E (sdrC/D/E)42, elastin-binding 
protein (ebpS)43, collagen-binding adhesin (cna)44, biofilm-associated protein (bap)45,46, 
laminin binding protein (eno)47 and other adhesins like staphylococcal protein A (spa)48, 
autolysin adhesion protein (aaa)49, extracellular matrix binding homologue (ebh)50, ex-
tracellular fibrinogen-binding protein (efb)51, extracellular matrix binding protein (emp)51 
and extracellular adherence protein (Eap)52 are utilized to initiate initial adherence or ag-
gregation and strongly adhere to surfaces with a conditioning film of environmental pro-
teins like fibrinogen, fibronectin, collagen and platelets48,52–54. Also non-proteinaceous 
adhesions, comprising PIA (polysaccharide intercellular adhesin) and wall teichoic and 
lipoteichoic acids, are able to participate in adherence55. Continued growth of bacterial 
cells on a surface leads to the development of mature biofilm colonies containing tightly 
packed cells gathered into pillar- and mushroom-shaped masses and surrounded by an 
extracellular polymeric substance (EPS) matrix18,56. In case of S. aureus, the accumulated 
extracellular material could consists of a combination of (i) selfproduced Poly-ß(1,6)-N-
acetyl-D-glucosamine (PNAG), also referred as slime or PIA57; (ii), extracellular DNA (eDNA)58 
originated from a “sacrification” procedure called autolysis59–61; (iii), proteins34,62 (e.g. sur-
face protein G, SasG)63,64; (iv), cell wall teichoic acids34; (v), lipids65, and (vi), other substances 
taken from the environment65. There is also some evidence that S. aureus can alternate the 
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composition of the matrix, depending upon the extracellular niche66. Enzymes necessary to 
synthesize PIA are normally not abundantly present67 due to generally low expression 
levels of S. aureus encoded icaADBC within a biofilm66. Consequently, polysaccharide inde-
pendent S. aureus biofilm do also exist33,68. The embedded bacteria in matrix structures are 
interspersed with fluid-filled channels which act as a primitive circulatory system, allowing 
for the exchange of nutrients, oxygen and waste products with their environment34. As a 
consequence of continuous adaptation to: (i), gradients in acidity; (ii), oxygen deficiency; 
(iii), concentrations of bacterial extruded signalling molecules and waste materials; and (iv), 
gradients in nutrient availability from the outer to the inner clusters of the interior of the 
biofilm18,69, numerous micro-environments exist within the biofilm with bacterial cells in 
fluctuating physiological states70. As a result of carbohydrate consumption during the 
maturation phase, a stationary phase-like dormancy can be created71 due to nutrient 
depleted zones and/or enhanced metabolic metabolites in the depths of the biofilm. Con-
sequently this may encourage the emergence of persister cells29,72, which mediates antibi-
otic resistance in biofilm embedded bacteria. Therefore, limited penetration of nutri-
ents73,74 and starvation29, rather than restricted antibiotic diffusion75–78, may contribute to 
generalized resistance or tolerance to antibiotics18. The metabolically inactive cells are 
especially located in the deeper interior of the biofilm. Although the matrix may not inhibit 
the penetration of antibiotics into the biofilm altogether, it may retard the rate of penetra-
tion enough to induce the expression of a variety of genes within the biofilm that mediate 
resistance. This would lead to species or antibiotic resistance specific related processes 
such as the accumulation of antibiotic-degrading enzymes or the upregulation of efflux 
pumps17. Whereas planktonic cells are considered rather as a homogeneous population, 
biofilm cells are complex communities displaying structural, chemical and biological het-
erogeneity69. 
Bacteria in biofilm also coordinate behaviour by cell–to–cell communication using se-
creted chemical signals, often referred as quorum sensing18,79,80. Although most of the 
known quorum sensing signals are species specific, inter-species signalling has also been 
discovered81. The opposite, quorum quenching, a process in which bacteria secrete en-
zymes that degrade the quorum-sensing signals of heterologous species has been de-
scribed as well30,81. The S. aureus quorum-sensing system is encoded by the accessory gene 
regulator (agr) locus82 and the communication molecules that it produces and senses are 
autoinducing peptides (AIPs)83, also referred as autoinducers or pheromones14,34. AIPs are 
encoded by agrD and processed by agrB34,84. Upon reaching a critical concentration, AIPs 
activate the two-component agrA-agrC system. The response regulator of this system, 
agrA~P activates promoters P2 and P3 to transcribe RNAII encoding agrBDCA and the 
effector molecule RNAIII, respectively85. RNAIII inhibits the expression of genes encoding 
MSCRAMMs84,86, and stimulates the expression of genes encoding extracellular enzymes 
and toxins82, and as a consequence the activated agr system downregulates biofilm forma-
tion in general34. It is clear that RNAIII is an important determinant of virulence. Activation 
of the agr quorum sensing system is thought to be dependent on cell density84. Quorum 
sensing might be essential for aggregation and biofilm maturation87, involving processes 
as proliferation, accumulation and intercellular adhesion34. It definitely plays a crucial role 
during the final stage of the biofilm lifecycle. This phase involves the detachment of cells 
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via their own quorum sensing molecules initiated active dispersal56, which allows them to 
colonize new locations and to reinitiate the biofilm developmental process88. Dispersal is 
principally mediated via a functional and activated agr system34. Three distinct modes of 
biofilm dispersal have been discerned: erosing, sloughing or clumping and swarming or 
seeding dispersal56. Another form of shifting to a new habitat is ‘surface dispersal’, in which 
biofilm structures move across surfaces89. Furthermore, cell-division-mediated dispersal 
has been described56. Detachment can be caused by external perturbations, such as in-
creased fluid shear or by internal biofilm processes90. These processes occur in response to 
the release of AIPs and the transcription of RNAIII83,85 and include the release of detach-
ment factors such as glucosidases, (extracellular) proteases (ECP)91–93 and deoxyribonucle-
ases , which are endogenous enzymatic degradation factors. Independently of 56 agr, the 
staphylococcal accessory regulator (sarA) counteracts the production of ECPs (e.g. a metal-
loprotease aureolysin (aur), the two cysteine proteases staphopain A and B (sspB and scpA) 
and the V8 serine protease (sspA))83 and nucleases94,95. Since ECPs also seem to play a role 
in autolysis inhibition68,96, besides the suggested enhancement of MSCRAMM downregula-
tion92,96, the interplay between agr and sarA and its homologues is decisive for the switch 
between biofilm formation (the adhesive phenotype) and dispersal97. During activation of 
agr (the more invasive phenotype), toxin release is upregulated by RNAIII82 in conjunction 
with the influence of sarA98. Another dispersal approach which also depends on the AIPs is 
the release of surfactant-like molecules, the phenol soluble modulins (PSMs)34. The RNAIII 
encoded δ-hemolysin (PSMγ, hld)84 and the hla-encoded α-toxin (α-hemolysin)99 belong 
both to the PSMs and have strong surfactant properties100–102. Apart from that, like other 
secreted exotoxins such as Panton-Valentine leukocidin (PVL), the alpha-type PSMs are 
considered virulence determinants in the host-pathogen interrelationship. They induce 
pore formation-mediated cytolysis of neutrophils and cause an inflammatory mediator 
release103,104. Furthermore, it has been suggested that PSMα1–4 have a role in the interfer-
ence with competing colonizing pathogen105, contributing to the proposed competitive 
ecological advantage of community-associated MRSA (CA-MRSA) lineages like 
USA300106,107. 
Elucidating the physiologies of biofilm-associated bacteria is necessary for our under-
standing of pathogenesis and to clarify the recalcitrance of these bacteria compared with 
the resistance exhibited by their planktonic counterparts. 
Clinical manifestation and implications of bacterial biofilm 
Staphylococci are ubiquitous commensals of the skin and mucous membranes of humans. 
S. aureus and the coagulase-negative staphylococci (CoNSs), in particular S. epidermidis, are 
among the most leading causes of nosocomial infections108. Infections due to S. epidermidis 
typically are more subacute or even chronic and emerge particularly among predisposed 
or immunocompromised patients109. In contrast, the virulent pathogen S. aureus causes 
more acute infections associated with the colonization of tissue or bone (marrow), such as 
endocarditis or osteomyelitis, which may lead to sepsis. However, S. aureus is also a com-
mon cause of foreign-body-associated infections and, occasionally, S. epidermidis may 
cause native valve endocarditis110. Nevertheless, biofilm formation is now recognized as 
causing or exacerbating numerous chronic infections. It is estimated that approximately 
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80% of all bacterial infections are biofilm mediated66,75, with periodontitis, colitis, vaginitis, 
urethritis, conjunctivitis, chronic otitis media, chronic wound infections, recurrent urinary 
tract infections (UTI), recurrent tonsillitis, dental caries and cavities, chronic rhinosinusitis, 
cystic fibrosis associated pneumonia and device-related infections being just a summa-
rized list of common examples of biofilm-associated infections25,111. Difficulty in identifying 
in vivo biofilm infections has led to the formulation of diagnostic criteria, which are dis-
played in Box 1. 
 
Box 1. Diagnostic criteria for biofilm infections 
 criteria18,194 
 
  
(1) Pathogenic bacteria are associated* with a surface. 
(2) Direct examination of infected tissue demonstrates aggregated cells in cell clusters encased in a matrix, 
which may be of bacterial and host origin. 
(3) Infection is confined to a particular site in the host. 
(4) Recalcitrance to antibiotic treatment despite demonstrated susceptibility of planktonic bacteria** 
(5) Culture-negative result in spite of clinically documented high suspicion of infection (since localized 
bacteria in a biofilm may be missed in a conventional blood sample or aspirate). 
(6) Ineffective host clearance evidenced by the location of bacterial cell clusters (macrocolonies) in discrete 
areas in the host tissue associated with host inflammatory cells. 
  
* 
 
** 
The term ‘associated’ allows the inclusion of aggregates not necessarily firmly attached. 
 
Since antibiotic susceptibility of planktonic cultures can only be tested upon positive culture from a 
clinical specimen, it is suggested that in the absence of culture, recalcitrance to antibiotic therapy may be 
inferred from the presence of live bacterial cells in the biofilm from in situ viability staining or reverse 
transcription polymerase chain reaction (RT-PCR). 
  
 
From a mature biofilm, individual cells or aggregates can detach. Upon dispersal, bacteria 
disseminate via the blood stream, which is thought to lead to an extensive dissemination 
of bacteria. For this reason bacteraemia is frequently associated with metastatic spread of 
bacteria and particularly hard to treat circumstances. One of the measurements taken is 
often the removal of the offending device/ foreign body, especially in case of intravascular 
indwelling catheters. However, in case of implantable devices like hip or knee prostheses, 
pacemakers or heart valves, removal is complicated and therefore appropriate treatment 
options are greatly warranted. Various compounds ranging from chemical compounds like 
efflux pump inhibitors112,113, N-acetylcysteine114, biocides115 including triclosan116 and chito-
san117,118 to more natural substances such as traditional Chinese medicine119, honey (propo-
lis)120,121, 3’-5’-cyclic diguanylic acid or abbreviated c-di-GMP (a signalling molecule ob-
tained from other biofilm producing pathogens)90,122, vaccines directed against PNAG33,123 
or MSCRAMMs124, antibodies to quorum sensing molecules125, and maggot excretions126,127 
have been tested successfully in vitro against S. aureus biofilm. Yet, there is a lack of ran-
domized clinical trials to demonstrate the efficacy of these agents for biomaterial-related 
infections in vivo. In contrast to the absence of clinical trials for agents against biofilm-
contaminated devices, there is a wide variety of investigations going-on to search for the 
based on the modified Parsek–Singh
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most appropriate way to modify biomaterials128 in such a manner that biofilm formation 
could be prevented. 
Prevention of biofilm formation 
Biofilm formation can occur on natural tissue and on indwelling devices. Since biofilm 
starts with attachment to a (a)biotic surface, prevention of initial adherence is the most 
logical approach to prohibit biofilm formation. The ultimate goal is to obtain biomaterials 
with anti-biofouling features which are fully refractory to microbial adhesion129. Modifica-
tion of biomaterials involves, in most circumstances, impregnation, surface antifouling 
conditioning (by coating, e.g. through dipping, sputtering, spraying or solvent casting 
procedures130), physico-chemical surface modification, polymer-brushes131,132 or the utiliza-
tion of micro-nanotopologies133. Ideally, drug-eluting carriers, drug-delivery or leaching 
matrices with preferably controlled release should be manufactured134. Incorporation or 
attachment of antiseptics132,135,136, antibiotics135,137,138, precious pure metals132,139–142, hepa-
rin132,135,143,144 and/or antimicrobial peptides145,146 has been applied. For instance, a com-
monly used impregnation for central venous catheters (CVCs) in clinical practice with the 
intention to reduce bacterial colonization is the combination of chlorhexidine and silver-
sulfadiazine136,147,148. Prolonged application of CVCs and tip malpositioning are among risk 
factors associated with the occurrence of catheter-related bloodstream infections (CRBSIs) 
as a consequence of catheter colonization and/or exit-site contamination149,150. It is esti-
mated that almost 30–60% of all nosocomial bacteraemia originate from some sort of 
(intra)vascular access device2,151. The incidence of CRBSIs can be as high as two to seven 
episodes/cases per 1000 central line/catheter days in Western countries152, while the occur-
rence in developing countries is much higher (up to 40–60 episodes)153. In attempts to 
reduce the incidence of CRBSIs, antiseptic or antibiotic impregnated or external and/or 
lumen coated CVCs were introduced. Incorporation of antibiotics or antiseptics like chlor-
hexidine could be criticized since these might encourage the emergence of resistant mi-
cro-organisms137,154 or could induce anaphylaxis155. CRBSIs are related with (asymptomatic) 
thrombogenic occlusion150, which might result in serious complications such as embolisa-
tion. Thrombus formation starts by enclosure of the CVC with a fibrin sheath149,156, which 
promotes adherence of bacteria, concurrently150. Finally, these adhered bacteria might 
enhance the thrombogenic cascade and may become embedded by a partially self pro-
duced exopolysaccharide matrix (biofilm formation), and consequently become exceed-
ingly difficult to eradicate afterwards. 
Prevention of thrombotic complications by prescribing anticoagulant prophylaxis is 
currently not recommended157,158, since it is often contraindicated due to the risk of major 
bleeding in thrombocytopenic and renal impaired patients. Furthermore, there is absence 
of consensus due to limited evidence whether it exerts a beneficial effect at all. Strict fol-
lowing hygiene protocols, adherence to aseptic techniques and using sterile barrier pre-
cautions during insertion of CVCs are among the best available preventive measurements 
to reduce the number of CRBSIs150, but inadequate for full prevention. Also the application 
of lock (flush) solutions with (antibiotics, taurolidine159–161, chelators like citrate162 or 
EDTA163,164) or without (saline, heparin)165,166 antimicrobial substances has been advocated, 
although the latter one is surrounded by concerns about increased risk of bleeding, induc-
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tion of thrombocytopenia166,167 and promotion of biofilm generation168. It is evident that 
improvement in the biomaterial itself leads to better biocompatibility. In order to reduce 
the necessity for early removal of CVCs, the surfaces/interfaces should be practically non-
thrombogenic and must exhibit strong anti-adhesive or biocidal capacities simultaneously. 
Disintegration of the biofilm matrix 
Under circumstances where biofilm formation could not be prevented, biofilm have to be 
destructed. For this reason, other treatment modalities beside the prevention strategy of 
modification of biomaterials are greatly warranted to combat biofilm associated infections. 
It is believed that disintegrating agents to obtain passive dispersal should be combined 
with antimicrobial compounds to overcome the risk of colonization of new niches after 
chemically stimulated dispersal. Since no single mechanism of dispersal utilized by all 
bacteria exists, the development of a successful disintegrating agent is rather complex. 
Some classes of agents that may have clinical utility are: (i), biofilm-matrix-degrading or 
dispersing enzymes91,169–172; (ii), quorum-sensing interferants81,90,94,173–175 such as quorum 
quenching antibodies176; (iii), (bio)surfactants177,178; and (iv), small molecule inhibi-
tors90,125,179 of, for instance, bacterial diguanylate cyclases56. It remains to be seen whether 
any of these agents will have clinical applications. Probably, combinations are necessary to 
ensure significant reductions in biomass, since many agents act very specifically against 
only one matrix component, e.g. DNase I disrupts established biofilm due to digestion of 
eDNA57,180, while Dispersin B hydrolyzes PIA57,90. Intrapleural administered DNase is under 
clinical investigation in pleural biofilm-associated infections181. Aerosolized recombinant 
human DNase (dornase alfa) has already proven its value in cystic fibrosis (CF) patients182 
due to improvement of airway mucociliary clearance by reducing the viscosity and adhe-
siveness of infected bronchial secretions183,184. The only substances actually intravenously 
used in the clinical setting to date are antibiotics, in particular rifampicin185 combined with 
another agent. In relation to monotherapy, somehow paradoxically, adjuvant induced 
hyperthermia has been shown in vitro to enhance the antimicrobial effect of various anti-
biotics on staphylococcal biofilms186. Rifampicin could not be used as a single agent due to 
rapid resistance development as a consequence of commonly occurring point mutations 
in rpoB187. Although efficacy of rifampicin in combination therapy against clinically pre-
sumed biofilm infections has been reported188,189, the clinical outcome remains contradic-
tory190,191 and rifampicin resistant mutants have emerged during treatment as adjunctive 
agent192. Consequently, the biofilm was incompletely sterilized. So far, it is unclear whether 
these rifampicin induced resistant subpopulations would be responsible for persistant or 
on the long term reoccurring infections. It appeared that low-level rifampicin resistant 
mutants have a fitness advantage over their parental rifampicin susceptible strains in 
vivo193, which illustrates the risk of rifampicin exposure even more. 
The development of appropriate anti-biofilm approaches must take into account at 
least the following66: (i), unique accumulation molecules (e.g. proteinaceous vs. polysac-
charide); (ii), the development of persister cells, and (iii), the metabolic heterogeneity that 
is inherent to growth in a biofilm. 
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Outline of the thesis 
 
Research in the field of biofilm physiology, development and function has just started to 
begin. Extended knowledge of S. aureus resistance mechanisms and virulence factors 
involved in the capability to form biofilm, may contribute to the design and implementa-
tion of preventive strategies that could minimize the prevalence of biofilm-associated 
infections or could lead to novel ways to disassembly existing mature biofilm. 
Chapter 2 focuses on the genetic background of S. aureus in relation to the capability 
to produce biomass at different glucose concentrations on polystyrene surfaces. Recently, 
links were made to match strong biofilm producers with agr subtype195,196, methicillin 
susceptibility197, type of infection198, isolation site199 or pathogenic invasive potential of 
colonizing or commensal strains200. However, the genetic background was not taken into 
consideration. 
Currently, in daily clinical practice, there are no definitive methods for the diagnosis of 
a biofilm infection, except clinical suspicion and clinical presentation. When immediate 
removal (and replacement) of the infected indwelling device or implant is unwanted, ri-
fampicin is simply added to standard (empirically) initiated antibiotic treatment in concor-
dance with therapeutical guidelines and recommendations189,191,201,202. However, the ra-
tionale behind the supposed working mechanism remains obscure and rifampicin-
resistant subpopulations emerge during treatment192. Possibly, the use of rifampin as an 
adjunct in biofilm-associated infections is based on the ability to penetrate into biofilms 
and a presumed activity against dormant bacteria. 
It could be speculated that rifampicin-resistant isolates emerge inside the biofilm when 
the companion agent does not penetrate as quickly as rifampicin is expected to do. There-
fore, it is essential to know whether rifampicin is able to destruct the matrix of biofilm-
embedded rifampicin-resistant strains, e.g. through pore-formation. Chapter 3 deals with 
the efficacy of rifampicin against rifampin-susceptible and isogenic rifampin-resistant 
methicillin-susceptible S. aureus (MSSA) strains. The effects on the biofilm matrix and on 
viability were assessed with an in vitro static biofilm assay. 
Since there are still no compounds suitable for intravenous application on the market 
that effectively destruct preformed mature biofilm it is essential to prevent biofilm forma-
tion. This demands substantial improvements in biomaterials properties used for foreign 
bodies to hinder initial adherence of micro-organisms and/or substances from the envi-
ronment. It is known that bacterial adhesion and thrombus formation are interrelated150. 
For this reason we aimed to develop coatings for central venous catheters that are both 
anti-microbial, in the sense that they prohibit adhesion of bacteria, and anti-thrombogenic 
as well. The anti-thrombogenic features of the engineered new hydrophilic coating con-
taining sodium heparin and silver particles are essentially examined in chapter 4. The 
antimicrobial characteristics are further explored in chapter 5. In this chapter the silver 
content and the hydrophilicity of the coating were also taken into account. 
It is evident that multiple resistance mechanisms of micro-organisms are involved in 
their protection against environmental stresses and threats and thus their general survival 
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strategy. Bacterial cells embedded in biofilm are far more resistant to antimicrobial agents 
than their planktonic counterparts. It is questioned whether this could be solely attributed 
to the penetration barrier formed by the matrix. It is likely that the observed dormancy of 
bacteria in the deeper parts of the biofilm hinders the killing by antibiotics that require an 
active life-cycle turnover. Still, it is believed that both principles do not fully clarify the 
recalcitrance to eradication via the host immune system in combination with antibiotic 
therapy. It has been suggested that other conventional resistance mechanisms ultimately 
contribute to this phenomenon. A few of these mechanisms are scrutinized in the last 
experimental chapters. Enhanced extrusion of toxic substances from the cytosol via 
upregulation of efflux pumps has been suggested. Chapter 6 focuses on mutations in the 
(promoter region of the) norA gene, associated with the hyperexpression of the NorA efflux 
pump, in relation to the genetic background of S. aureus. Our findings that certain genetic 
backgrounds were strongly correlated with mutations associated with the capability to 
augment the expression of norA moved us to perform biofilm experiments with efflux 
pumps inhibitors directed against NorA transmembrane transporters among several dis-
tinct clonal lineages. Chapter 7 comprises this study that was undertaken to unravel the 
recent observation that efflux pump inhibitors like reserpine or thioridazine could prevent 
biomass formation by a single tested strain of S. aureus. According to recent suggestions, 
enhanced extrusion of wastes mediated via upregulation of efflux pumps could offer a 
survival advantage to the biofilm embedded bacterium17,112,203. It also had to be seen 
whether efflux pump inhibitors could have any influence on mature biofilm. 
Another observation is the entrapment and accumulation of beta-lactamases inside 
the biofilm matrix22,23. A subset of S. aureus strains that could be potentially more prone to 
beta-lactamase induction during penetration of a beta-lactam into the biofilm are the 
borderline oxacillin-resistant S. aureus (BORSA). These strains could not be differentiated 
from their fully susceptible counterparts by routine automatic susceptibility testing and 
will also not be isolated whenever screened for the mecA gene. Consequently they will be 
initially exposed to a beta-lactam antibiotic. 
In an attempt to unravel whether planktonic BORSA could be killed with a standard 
beta-lactam, such as oxacillin, various BORSA isolates were tested in a time-kill experiment. 
Alternatives like vancomycin, linezolid and daptomycin were also taken into account. 
Chapter 8 describes the pharmacodynamic analysis of all time-kill experiments comparing 
the EC50 and Emax values of the different antibiotics. Upon oxacillin exposure, the survival 
behaviour of pBORa53-like plasmid-containing BORSA204 was intentionally compared with 
non-methicillinase producing BORSA with oxacillin MICs ≥ 4 mg/L. 
Finally, a general discussion (chapter 9) is presented in which the findings of all studies 
are put into perspective and in which recommendations for further investigations are 
discussed. A brief overview of our findings regarding S. aureus biofilm formation, preven-
tion and disassembly can be found in the summary (chapter 10). 
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Abstract 
Background 
Since bacteria embedded in biofilms are far more difficult to eradicate than planktonic 
infections, it would be useful to know whether certain Staphylococcus aureus lineages are 
especially involved in strong biofilm formation. For this reason, in vitro biofilm formation of 
228 clinical S. aureus isolates of distinct clonal lineages was investigated. 
Results 
At 0.1% glucose, more than 60% of the S. aureus strains associated with multilocus se-
quence typing (MLST) clonal complex (CC)8 produced large amounts of biomass, com-
pared to 0–7% for various other clonal lineages. Additionally, S. aureus bloodstream iso-
lates associated with MLST CC8 and CC7 had similar biofilm forming capacities as their 
commensal counterparts. Furthermore, strong biofilm formation could not be attributed to 
a specific accessory gene regulator (agr) genotype, as suggested previously. The agr geno-
types were strictly associated with the clonal lineages. Moreover, strong biofilm formation 
was not related to slime formation. Congo red agar (CRA) screening is therefore not useful 
as a qualitative screening method for biofilm formation. 
Conclusion 
The adherence to polystyrene surfaces under physiologic glucose concentration (0.1%) 
was dependent on the clonal lineage. Strains associated with MLST CC8 were markedly 
more often classified as strong biofilm former at glucose concentrations of 0%, 0.1% and 
0.25%. 
The present study reveals that the MLST CC8 associated genetic background was a predis-
posing factor for strong biofilm formation in vitro, under all tested glucose concentrations. 
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Background 
 
One of the defense mechanisms of Staphylococcus aureus is the capacity to form biofilms. 
Bacteria embedded in biofilms are often difficult to eradicate with standard antibiotic 
regimens and inherently resistant to host immune responses1, 2. As a result, treatment of 
many chronic S. aureus biofilm related infections, including endocarditis, osteomyelitis and 
indwelling medical device infections is hindered3. Biofilm formation is a multistep process, 
starting with transient adherence to a surface. Subsequently, specific bacterial adhesins, 
referred to as microbial surface components recognizing adhesive matrix molecules (MS-
CRAMMS) promote the actual attachment4. Next, during the accumulation phase, bacteria 
stick to each other and production of extracellular polymeric substances (EPS) and/or 
incorporation of host derived components, such as platelets, takes place, resulting in a 
mature biofilm. In circumstances of nutrient deprivation, or under heavy shear forces, 
detachment of bacteria appears through autonomous formation of autoinducing peptides 
(AIP)5, with release and dispersal of bacteria as a consequence. It has been shown that 
expression of the accessory gene regulator (agr) locus, encoding a quorum-sensing sys-
tem, results in expression of surfactant-like molecules, such as δ-toxin6, contributing to the 
detachment. 
Essential for biofilm development in S. aureus is the regulatory genetic locus staphylo-
coccal accessory regulator (sarA), which controls the intracellular adhesin (ica) operon and 
agr regulated pathways7. It has been suggested that biofilm formation in methicillin-
resistant S. aureus (MRSA) is predominantly regulated by surface adhesins, which are re-
pressed under agr expression, while biofilm formation in methicillin-susceptible S. aureus 
(MSSA) is more dependent on cell to cell adhesion by the production of icaADBC-encoded 
polysaccharide intercellular adhesin (PIA), also referred as poly-N-acetylglucosamine 
(PNAG) or slime8. However a clear role for the ica locus of S. aureus is not as evident as that 
of Staphylococcus epidermidis9. 
In general, the presence of glucose represses the agr system through the generation of 
a low pH10, 11. So far, biofilm development in physiologic glucose-supplemented medium (1 
g/L), corresponding to normal blood glucose levels12, has not been investigated. Biofilm 
formation often occurs on medical devices, like catheters and heart valves, which are in 
direct contact with normal (floating) blood. Furthermore, since it has been shown that the 
regulatory pathways for biofilm formation vary between strains8, the question arose 
whether these strain-to-strain differences could be attributed to different clonal lineages. 
The aim of the present study was to examine the contribution of the genetic back-
ground of both MRSA and MSSA to biofilm formation under physiologic glucose concen-
tration. MRSA associated with the five major multilocus sequence typing (MLST) clonal 
complexes (CCs), i.e. CC5, CC8, CC22, CC30 and CC4513 and MSSA with the same MLST CCs, 
and also CC1, were included in this study, since it has been suggested that these lineages 
possess the ability to become MRSA14. The results were compared with those obtained 
with lineages normally not related to MRSA, i.e. CC7, CC12, CC15, CC25 and CC12115. Fur-
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thermore, the aim was to evaluate whether slime production is indicative for strong biofilm 
formation in S. aureus. 
 
Methods 
Bacterial strains 
S. aureus strains (72 MRSA and 156 MSSA) investigated were isolated during 2005 to 2008 
in the Maastricht University Medical Center, a tertiary 715-bed hospital, and originate from 
surveillance cultures (commensal flora) from individual patients, recovered from nasal 
swabs. MRSA and/or MSSA strains associated with MLST CC1, CC5, CC8, CC22, CC30, CC45, 
CC7, CC12, CC15, CC25 and CC121, were randomly selected from our institutional collec-
tion (Table 1). All MRSA strains were tested positive for the MRSA-specific mecA gene, by 
real-time PCR34. Additionally, 26 MSSA blood stream isolates from individual patients and 
associated with either MLST CC8 or CC7 were tested. These isolates were considered inva-
sive. 
Characterization of the genetic background 
Typing of the spa locus was carried out as described previously19. The spa types were as-
signed through the Ridom SpaServer (http://spaserver.ridom.de) and clustered into spa-
CCs using the algorithm based upon repeat pattern (BURP) with Ridom StaphType 1.4 
using the default settings35, 36. Although, spa typing alone sometimes lacks discriminatory 
power, due to related spa repeat patterns within different clonal lineages and the emer-
gence of homoplasies among spa sequences37, it has been shown that spa typing/BURP 
results are often in agreement with results obtained by MLST36, 38. Therefore, the associated 
MLST CCs were allocated through the SpaServer. To confirm the association between MLST 
and spa typing, in combination with BURP, MLST was performed on a representative set of 
16 strains of each major spa type and associated MLST CC39, 40. 
Phenotypic detection of slime producing ability onto Congo red agar 
MRSA (n=72), MSSA with MRSA associated MLST CCs (n=75), i.e. CC1, CC5, CC8, CC22, CC30 
and CC45, and MSSA with MSSA associated MLST CCs (n=81), i.e. CC7, CC12, CC15, CC25 
and CC121, were cultured on Congo red agar (CRA) plates, either consisting of trypticase 
soy or brain heart infusion agar (both from Becton Dickinson) with 0.8 g/L Congo red (Pro-
labo, Leuven, Belgium) and without or with 5% sucrose (Merck, Darmstadt, Germany). 
Colony morphology and color were evaluated after incubation at 37°C for 24 h. Colonies 
with a dry crystalline (rough) morphology were considered deviant and slime producing 
positive16, smooth round colonies were classified as low-slime producers. 
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Table 1. Distribution of spa types and associated MLST CCs among S. aureus strains included in this study 
 
 
associated 
MLST CC 
 
ST 
No. of 
MRSA 
strains 
No. of 
MSSA 
strains 
agr 
geno-
type 
spa types MRSA strains 
(No.) 
spa types MSSA strains 
(No.) 
       
1 ST1 NA# 16 III NA# t127 (15), t1787 
5 ST5/ST5 15 15 II t002 (4), t003, t041, t045, 
t447 (8) 
t002 (12), t179, t311, 
t2212 
8 ST8/ST1411a 26 15 I t008 (12), t052 (6), t064, 
t068 (5), t303, t622  
t008a (10), t190, t648, t701 
(2), t2041 
22 ST22/ST22 10 15 I t223 (10) t005 (9), t223, t474, t790, 
t1433, 
t1629, t2681 
30 ST36/ST714b 10 15 III t012 (7), t253 (2), t1820 t012 (2), t021b (4), t238, 
t300, t318 (2), t438, t1130, 
t1504, t2572, t2854 
45 ST45/ST45 11 15 I t038 (8), t445 (2), t740 t015 (2), t026, t050, t065, 
t102, t230 (3), t583, t589, 
t620 (2), 
t772 (2) 
7 ST7 - 15 I - t091 (15) 
12 ST12 - 10 II - t060, t156 (2), t160 (5), 
t213, t771 
15 ST15 - 15 II - t084 (11), t085, t491 (2), 
t1716 
25 ST25 - 10 I - t078 (4), t081, t087, t258, 
t353, 
t1671, t1898 
121 ST720c - 15 IV - t159 (2), t171c (4), t284, 
t408 (4), t645 (2), t659, 
t2213  
Total  72 156    
 
# not available 
Boldface indicates spa types on which multilocus sequence typing analysis was performed (ST, sequence type). 
a The strain spa typed as t008 had ST1411, a double locus variant of ST8 at the gmk and tpi locus. 
b The strain spa typed as t021 had ST714, a single locus variant of ST30 at the arcc locus. 
c The strain spa typed as t171 had ST720, a single locus variant of ST121 at the yqil locus. 
Detection of biofilm biomass with crystal violet staining 
The polystyrene crystal violet adherence assay was carried out as described previously41, 
with some modifications. Briefly, overnight cultures in Trypticase Soy Broth (TSB) without 
dextrose (Becton Dickinson, Le pont de Claix, France) were diluted until 108 CFU/mL in TSB 
containing 0%, 0.1%, 0.25% and 0.5% glucose. Individual wells of polystyrene, flat-
bottomed 96-well plates (Greiner Bio-One, Frickenhausen, Germany) were filled with 100-
μL aliquots of the cultures. As a negative control, uninoculated medium was used. S. aureus 
ATCC 25923 and one clinical S. aureus isolate from our collection, known to form fully es-
tablished biofilms (A590 values within the highest range and stable) as observed during a 
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pilot experiment, were added to each plate as reference standard17 and positive control, 
respectively. After 4 h of adhesion at 37°C on a rocking platform at 25 oscillations min-1, the 
medium containing non-adhered cells, was replaced by 100 μL fresh broth and the plates 
were further incubated for 24 h. Next, the wells were washed three times with 200 μL 0.9% 
NaCl. Biofilms were fixed at 60°C during 1 h. Subsequently, 100 μl crystal violet solution 
(0.3% wt/vol) was added to all wells. After 15 min., the excess crystal violet was rinsed off 
by placing the plates under running tap water. Finally, after drying the plates, bound crys-
tal violet was released by adding 100 μL 70% (vol/vol) ethanol with 10% isopropyl alcohol 
(vol/vol). Absorbance was measured spectrophotometrically at 590 nm (A590) and was 
proportional to biofilm biomass. All assays were performed in triplicate, and repeated on 
three occasions. The intra- and interday coefficients of variation for the assay were 14% 
and 23%, respectively. To obtain a threshold A590 value for which strong biofilm formation 
commences, the A590 values of all strains at the different glucose concentrations were 
sorted in ascending order and divided into quartiles. The distribution of A590 values in the 
lower three quartiles was similar at glucose concentrations of 0%, 0.1% and 0.25% and 
therefore used to determine the cut-off value (two standard deviations above the mean 
A590 value). The threshold A590 value was 0.374. Bacteria with A590 values above this value 
were considered strong biofilm formers. 
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Figure 1. Congo red agar screening of S. aureus isolates. CRA screening for S. aureus  with a dry crystalline 
colony morphology, which was considered indicative for slime formation. In the left panel (A), the black bar 
(not visible, 0%) represents MRSA (n=72), the dark grey bar represents MSSA with MRSA associated MLST 
CCs (n=75) and the light grey bar represents MSSA with MSSA associated MLST CCs (n=81). Asterisks denote 
statistically significant difference P < 0.01 (A) and statistically significant difference of individual CCs versus 
all other associated MLST CCs (B) P < 0.01. 
 
Determination of the agr type 
The agr types of all S. aureus isolates were determined by a real-time multiplex PCR assay, 
as described previously42. 
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Statistical analysis 
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. Chi-square 
analysis was used for comparison of the prevalence of strong biofilm formation or slime 
formation between the specified groups. Mann-Whitney U analysis was used to compare 
the A590 values between groups of strong biofilm formers. A P value of < 0.05 was consid-
ered to be statistically significant. 
 
%
 o
f s
tr
ai
ns
 o
f t
he
 s
pe
ci
fie
d 
gr
ou
p 
de
fin
ed
 a
s 
st
ro
ng
 b
io
fil
m
fo
rm
er
0
10
20
30
40
50
60
70
80
90
100
0% 0.1% 0.25% 0.5%        glucose
**
**
**
**
**
*
 
Figure 2. Quantification of strong biofilm formation in MSSA and MRSA. Quantification of strains of the 
specified group defined as strong biofilm former at different glucose concentrations. Black bars represent 
MRSA, dark grey bars represent MSSA with MRSA associated MLST CCs and light grey bars represent MSSA 
with MSSA associated MLST CCs. Asterisks denote statistically significant difference, (*) P < 0.05 and (**) P < 
0.01. 
 
Results 
Characterization of the genetic background 
The spa types and associated MLST CCs of all tested strains are shown in Table 1. The re-
sults of spa typing/BURP and MLST were in accordance for a representative set of 16 strains 
of each major spa type and associated MLST CC. 
Phenotypic detection of slime producing ability onto Congo red agar 
The different Congo red agar (CRA) screening methods described in the literature were 
evaluated16–18. The choice of the agar medium, either brain heart infusion or trypticase soy, 
did not influence the morphology. The majority of S. aureus strains (91%) displayed colo-
nies with a normal morphology (smooth round colonies), indicating that most strains were 
low-slime producers. Without sucrose, all colonies were colored (bright) red to bordeaux 
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red, irrespective of the agar medium used. Addition of sucrose to both agar media resulted 
in more dark colonies and made the dry crystalline morphology harder to recognize. With 
sucrose, all colonies on brain heart infusion agar with Congo red were colored red to bor-
deaux red, while strains on trypticase soy agar with Congo red displayed mostly purple to 
black colonies. Nuances in color were not corresponding to differences in morphology. 
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Figure 3. Biomass quantification of MSSA and MRSA. Absorbance (A590) of the crystal violet stained biofilm 
matrix for strong biofilm formers (with A590 above the threshold value of 0.374, represented by the 
horizontal dashed line) at different glucose concentrations. Boxplots at the left show MRSA, in the middle 
MSSA with MRSA associated MLST CCs and at the right MSSA with MSSA associated MLST CCs. The lower 
and higher boundary of the box indicates the 25th and 75th percentile, respectively. The line within the box 
marks the median. Whiskers above and below the box indicate the 90th and 10th percentiles. Open circles 
indicate the 95th and 5th percentiles. Asterisks denote statistically significant difference, (*) P < 0.05 and (**) 
P < 0.01. 
 
MSSA strains showed more often a deviant, dry crystalline (rough) morphology (slime 
producing positive) than MRSA isolates, 14% (22 of 156) and 0%, respectively. A significant 
distinction in slime formation was observed between MRSA and MSSA with MSSA associ-
ated MLST CCs, i.e. CC7, CC12, CC15, CC25 and CC121, and with MRSA associated MLST 
CCs, i.e. CC1, CC5, CC8, CC22, CC30 and CC45 (P < 0.01), as shown in Figure 1A. MSSA asso-
ciated with MLST CC121 had the highest prevalence of a deviant morphology, 67% (10 of 
15) (Figure 1B). 
Detection of biofilm biomass with crystal violet staining 
Under physiologic glucose (0.1%) concentration, 13% (n=30) of all strains formed a strong 
biofilm and all these strains were MRSA or had a MRSA associated MLST CC. MRSA and 
MSSA with MRSA associated MLST CCs, i.e. CC1, CC5, CC8, CC22, CC30 and CC45, were 
significantly more capable than MSSA with MSSA associated MLST CCs, i.e. CC7, CC12, 
CC15, CC25 and CC121, to form strong biofilms in the presence of 0.1% glucose (P < 0.01), 
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but not at glucose concentrations of 0.25% and 0.5% (Figure 2). The higher the glucose 
concentration, the more strains produced biofilm above the A590 threshold value and were 
consequently classified as strong biofilm former. At glucose concentrations of 0.25% and 
0.5%, the amount of biomass of the biofilms of strong biofilm forming strains was still 
significantly more for MRSA compared to MSSA irrespective of the MLST CCs (P < 0.01) 
(Figure 3). Of all strains classified as strong biofilm producers, MRSA and MSSA associated 
with MLST CC8 produced the most biomass under all tested glucose concentrations (Fig-
ure 4A and 4B). Strains defined as strong biofilm formers and associated with MLST CC5, 
CC25 and CC30 approached approximately the same level of biomass at the following 
glucose concentrations, i.e. CC5 at 0.25%, CC25 at 0.5% and CC30 at 0.5% glucose, respec-
tively. 
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Figure 4. Biomass formation related to the genetic background of S. aureus. Absorbance (A590) of the crystal 
violet stained biofilm matrix of strong biofilm forming S. aureus strains in relation to different associated 
MLST CCs (A) and of strong biofilm forming strains associated with MLST CC1, CC5, CC8, CC22, CC30 and 
CC45 (B). R in the legend represents MRSA and S represents MSSA. Quantification of strains of the specified 
genetic background defined as strong biofilm former at different glucose concentrations, (C) and (D). 
Asterisks denote statistically significant difference, (B) and (D), and statistical significant difference of 
individual CCs versus all other associated MLST CCs, (A) and (C), except #, (*) P < 0.05 and (**) P < 0.01. 
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The main contributors to the higher prevalence of MRSA and MSSA with MRSA associated 
MLST CCs to produce strong biofilms at 0.1% glucose were MLST CC8 isolates, approxi-
mately 60% (26 of 41), (Figure 4C), especially with a tendency towards MRSA (Figure 4D). 
Additionally, blood stream isolates of MSSA associated with MLST CC8 and MLST CC7 
were included in the study, to address the question whether the isolation site is an (addi-
tional) predisposing factor for strong biofilm formation. MSSA associated with MLST CC7 
are one of the main clonal lineages among blood stream isolates in our hospital19. No 
differences in the ability to produce strong biofilms were observed between bloodstream 
isolates and isolates of commensal origin among MSSA associated with MLST CC8 and CC7 
(Figure 5A and 5B). Furthermore, no significant differences in slime-forming ability were 
observed (Figure 5C). 
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Figure 5. Biofilm formation in Staphylococcus aureus isolates of bloodstream infections and commensal 
origin. Biofilm formation between S. aureus isolates of the same clonal lineage from blood stream infections 
(CC8 n=15, CC7 n=11) and of commensal origin (CC8 n=15, CC7 n=15), no significant differences were found 
(A). S in the legend represents MSSA, BSI represents bloodstream isolates and C represents commensal 
isolates. Number on each bar refers to number of isolates. Absorbance (A590) of the crystal violet stained 
biofilm matrix of strong biofilm formers at different glucose concentrations (B). CRA screening for colonies 
with a dry crystalline morphology (C). 
Correlation between slime formation and development of biofilm biomass 
In order to investigate whether slime production is indicative for strong biofilm formation, 
the correlation between these two characteristics was addressed. Phenotypic detection of 
slime production on CRA was not related to the quantitative detection of strong biofilms, 
measured by crystal violet staining, which was used as a gold standard. The sensitivity and 
specificity of the CRA method for S. aureus was approximately 9% and 90%, respectively 
(Table 2). Only a part of the slime producing strains surpassed the A590 threshold value for 
strong biofilm formation, namely 5%, 15%, 45% and 90% at 0%, 0.1%, 0.25 and 0.5% glu-
cose, respectively. 
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Table 2. Correlation between slime formation (Congo red agar screening) and development of biofilm 
biomass (crystal violet staining). 
 
Glucose Sensitivity Specificity PPV NPV 
CRA+ / 
CV+ 
CRA- / 
CV+ 
CRA+ / 
CV- 
CRA- / 
CV- 
(%) (%) (%) (%) (%) Number of S. aureus strains 
 
0 
 
6.3 91.0 5.0 92.8 1 15 19 193 
0.1 
 
9.7 91.3 15.0 86.5 3 28 17 180 
0.25 
 
11.6 93.0 45.0 63.5 11 76 9 132 
0.5 
 
8.3 80.0 90.0 3.9 18 200 2 8 
 
(PPV) positive predictive value, (NPV) negative predictive value, (CRA) Congo red agar screening, (CV) crystal violet 
staining 
 
Distribution of agr types 
Clonal lineages MLST CC7, CC8, CC22, CC25 and CC45 harbored agr-I, all CC5, CC12 and 
CC15 were characterized by agr-II, while all CC1 and CC30 were detected as agr-III. Fur-
thermore, CC121 isolates carried agr-IV (Table 1). No consistent relationship was found 
between agr genotype and the ability to produce biofilm. 
 
Discussion 
 
In vitro quantification of biofilm formation in distinct clonal lineages of S. aureus was per-
formed to investigate whether there were differences in the capacity to form fully estab-
lished biofilms. This study revealed that at 0.1% glucose, enhanced biofilm formation of S. 
aureus was strongly associated with MLST CC8 and observed in 60% of these isolates, while 
it varied between 0–7% for the other clonal lineages tested. 
A higher percentage of MSSA (14%) than MRSA (0%) was found positive for slime pro-
ducing ability, in concordance to the more important role of PIA/PNAG in MSSA than in 
MRSA biofilm development8. Addition of sucrose to CRA did not influence slime formation, 
suggesting that slime formation was carbohydrates independent. The results were consis-
tent with previous findings in MRSA and MSSA isolates of O’Neill et al. In MSSA isolates 
increased ica expression and PIA/PNAG production (as determined with PIA/PNAG im-
munoblot) was correlated with 4% NaCl-induced biofilm formation, but not with glucose-
induced biofilm production8. In addition, in MRSA, ica operon transcription was more 
potently activated by NaCl than by glucose, but did not result in PIA/PNAG formation8. 
Since it has recently been suggested that, in general, PIA/PNAG is a minor matrix compo-
nent of S. aureus biofilms5, 9, and thus possibly hardly detectable by CRA screening, a low 
prevalence of slime producing strains was expected. Knobloch et al. and Mathur et al. re-
Chapter 2 
 38 
ported a positive CRA assay result in only 4–5% of the S. aureus strains tested, in relative 
accordance with the results of this study, while Grinholc et al. mentioned 47% and 69% for 
MRSA and MSSA, respectively16–18. Jain et al. reported differences between blood stream 
isolates and commensal S. aureus isolates with regard to positive CRA screening, 75% and 
20%, respectively20. The variations could be due to differences in genetic backgrounds of 
the strains used, or to differences in interpretation of the colonies. The definition of slime-
forming strains used by Grinholc et al. and Jain et al. was based on the color of the colonies 
and not on the morphology. Furthermore, they both found a high consistency (96% and 
91%, respectively) between CRA screening and biofilm biomass crystal violet staining17, 20. 
In contrast, both in this study, as well in the studies by Knobloch et al., Rode et al., and 
Mathur et al.16, 18, 21, no correlation was found between slime producing MRSA and MSSA 
isolates and an enhanced tendency to form large amounts of biomass. These studies 
strongly suggest that CRA screening forms no alternative for crystal violet staining to de-
tect biofilm formation. Probably, the cell to cell adhesion, stimulated by the formation of 
PIA/PNAG, is less efficient than the expression of surface adhesins, in their contribution to 
produce more biomass. 
As described before, the agr genotypes were strictly associated with the clonal line-
ages22, 23. However, exceptions have been observed24–27 which might be due to interstrain 
recombination and intrastrain rearrangements28. The association between agr genotypes 
and the genetic background explains the absence of a relationship between the enhanced 
ability to form biofilm and specific agr genotype(s). Although, there was a tendency that 
the agr-I genotype was associated with an enhanced capacity to form strong biofilms (data 
not shown), this was a reflection of the biofilm-forming capacity of strains associated with 
MLST CC8. In contrast to our results, Cafiso et al. described a link between agr-II genotype 
and the capacity to form strong biofilms, since all strains with agr-II genotype were associ-
ated with strong biofilm formation at 0.25% glucose. However, the genetic background 
was not taken into consideration29. Our findings revealed that strains associated with MLST 
CC5, CC12 and CC15 (all harboring agr-II) were classified as strong biofilm formers in only 
21%, 9% and 53% of the cases at 0.25% glucose, respectively. Furthermore, the agr-II geno-
type encompass diverse strains, not including strains associated with MLST CC822, 23. 
Biofilm formation was induced by increasing glucose concentrations up to 0.5% in 
both MRSA and MSSA isolates, which is entirely consistent with previously reported data8, 
21. However, MRSA produced significantly more biomass than MSSA with MSSA associated 
MLST CCs, under all tested glucose conditions. Especially strains associated with MLST CC8 
contributed to this phenomenon. Furthermore, MSSA with MRSA associated MLST CCs 
were also capable to produce more biomass than MSSA with MSSA associated MLST CCs at 
0.1% glucose. Variations in biofilm forming capacities in clonal lineages of S. aureus could 
be explained by unique combinations of surface-associated and regulatory genes23 or by 
different expression levels of genes that regulate the different phases of biofilm formation. 
Since this study showed that the biofilm formation on polystyrene surfaces was the 
strongest for the MLST CC8 associated genetic background, further studies with other 
material or tissue are warranted. Recently, differences in adhesion to human airway epithe-
lial cells have been observed between strains belonging to MLST CC8 and CC5, the latter 
demonstrating a generally lower adherence in both representatives of MRSA and MSSA30. 
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An enhanced ability to adhere and invade these cells has also been shown for MRSA asso-
ciated with the Brazilian/Hungarian clone, which belongs to MLST CC815, compared to a 
population of MSSA with an unknown genetic background31. Furthermore, strains associ-
ated with the same clone were not included among our MLST CC8 isolates, but were pre-
viously classified as strong biofilm producers and designated superior in their ability to 
produce biofilm compared to isolates associated with the Pediatric clone (MLST CC5)32. 
To analyse possible other predisposing factors besides the MLST CC8 associated ge-
netic background, bloodstream and commensal isolates of the same clonal lineage were 
compared. The biofilm forming capacity between MSSA bloodstream and commensal 
isolates, associated with MLST CC8 and CC7, was similar and consistent with the findings of 
Smith et al., who compared the biofilm forming capacity of Scottish clinical S. aureus strains 
collected from different isolation sites33. In contrast, Jain et al. described more frequently 
strong biofilm formers among S. aureus bloodstream isolates than commensal20. A possible 
explanation might be that all bloodstream isolates came from patients with peripheral 
intravenous devices, while this was not an inclusion criterion in the study by Smith et al. . 
Peripheral or central line intraluminal colonization might be associated with strains that 
easily attach to (catheter) surfaces and as a consequence these strains could be dominant 
in leading to bloodstream infections. 
 
Conclusions 
 
In summary, the present study reveals that the MLST CC8 associated genetic background 
was a predisposing factor for strong biofilm formation in vitro, under all tested glucose 
concentrations, i.e. 0%, 0.1%, 0.25% and 0.5%. At physiologic glucose concentration (0.1%), 
0–7% of S. aureus from various clonal lineages were defined as strong biofilm former, com-
pared to 60% for the S. aureus associated MLST CC8. 
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Abstract 
 
The use of rifampicin as adjunct in biofilm-associated infections is based on the ability to 
penetrate into biofilms and a presumed activity against dormant bacteria. Yet, its efficacy 
remains contradictory and rifampicin-resistant strains frequently emerge during therapy. 
Therefore, the efficacy against rifampicin-susceptible and isogenic rifampicin-resistant 
methicillin-susceptible Staphylococcus aureus (MSSA) strains was evaluated. 
Biofilms were generated under static conditions using MSSA with various genetic 
backgrounds. Oxacillin alone or with rifampicin at various concentrations were subse-
quently added and after 24h biomass and viable cell counts were determined. 
Upon rifampicin addition, inter-strain variations in viable count change, ranging from a 
tendency towards antagonism to synergy, were observed among all strains tested, irre-
spective of the genetic backgrounds of the strains. Similar variations were observed in 
changes in biomass. The decrease in viable count upon rifampicin addition was negatively 
correlated to formation of large amounts of biomass, since strains embedded by more 
biomass showed a diminished reduction in viable count. 
Rifampicin (1 μg/mL) as adjunct to oxacillin achieved greater reductions in biomass 
produced by most rifampicin-susceptible isolates, ranging from 17 to 54% compared to 
4% for oxacillin alone. In contrast, rifampicin had no additional value in reduction of bio-
mass of isogenic rifampicin-resistant mutants. At subinhibitory concentrations of rifam-
picin (0.008 μg/mL), none of the strains tested yielded an extra reduction in biomass ≥ 
40%. 
In conclusion, the effect of rifampicin as adjunct on biomass and viable count was un-
predictable and the use of rifampicin against biofilm containing rifampicin-resistant strains 
seems unwarranted. 
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Introduction 
 
Bacteria embedded in biofilm are often hard to eradicate, which will often result in failure 
of antibiotic therapy. Biofilm can appear and persist on implanted or indwelling devices. 
Adherence to bone or natural tissue can also occur. As a consequence of biofilm formation, 
foreign body infections are a risk factor for persistent bacteremia1. 
Staphylococcus aureus biofilm infected devices often require removal in combination 
with antimicrobial therapy2. Even if an infection seems to be cured, a subset of bacteria can 
survive within the partly unremoved biofilm and remanifest after several years. These are 
the so-called low-grade infections3. The ideal antibiotic should be able to diffuse properly 
into biofilms, eradicate dormant bacteria and kill phagocytized S. aureus, since foreign-
body infections were associated with intracellular S. aureus4,5. Rifampicin meets these crite-
ria partially 6. Rifampicin penetrates biofilms adequately7 and improves the diffusion of a 
companion agent through the biofilm 8. It also reduces the adherence of bacteria to sur-
faces6. Furthermore, rifampicin addition eliminates intrinsic rifampicin-resistant Pseudomo-
nas aeruginosa (MIC 32 μg/mL) from biofilms9. Therefore, it could be hypothesized that the 
presence of rifampicin leads to biofilm matrix disintegration. However, rifampicin can not 
be used alone due to the rapid emergence of resistance10 and it is not as effective as pre-
sumed against slow growing bacteria7,11. An alternative approach for S. aureus biofilm-
associated infections is the addition of rifampicin to a companion drug. In clinical practice, 
rifampicin addition has occasionally demonstrated to be beneficial in terms of clinical or 
bacteriological cure rates12, especially for prosthetic device-related infections5,13,14. How-
ever, its effect remains poorly defined since the number of supporting human studies is 
limited and most of them are underpowered5,13–15. Moreover, recently performed in vitro 
studies have demonstrated antagonistic effects after addition of rifampicin in experimental 
foreign-body infection and endocarditis models16,17. 
Exposure to combination therapy including rifampicin frequently results in the emer-
gence of rifampicin-resistant subpopulations, which might hinder clearance of the infec-
tion18. This is probably due to the fact that the pharmacokinetics of the companion drug 
were different from that of rifampicin. Preferable, the companion drug needs to penetrate 
easily through diverse layers of a biofilm to prevent the development of rifampicin resis-
tance. But, although some antibiotics penetrate adequately through biofilms, bacteria may 
be protected from killing by thickening of the cell wall7. A high bacterial load is another 
causative reason for rapid resistance development19. To overcome the emergence of resis-
tance it is recommended that rifampicin should be initiated after the companion drug has 
been administered for 2 to 5 days, to reduce the high density of the initial burden20, or at 
least until a substantial reduction in bacterial load has been achieved18,21. 
Since inter-strain variability in response to rifampicin addition might be responsible for 
contradictory results obtained by various authors, the aim of the present study was to 
elucidate whether this variability does exist for strains between and within the S. aureus 
genetic backgrounds associated with multilocus sequence type (MLST) CC5, CC8 and 
CC30. Furthermore, since rifampicin-resistant mutants emerge during therapy and rifam-
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picin is used for a hypothesized destruction of the biofilm matrix, we evaluated whether 
continuation of exposure to rifampicin is useful against biofilms containing rifampicin-
resistant methicillin-susceptible S. aureus (MSSA). In addition, we examined whether a 
potential effect was also present at a subinhibitory concentration. 
 
Materials and methods 
Bacterial strains 
As part of an ongoing surveillance of S. aureus carriers, seventeen MSSA isolates from indi-
vidual patients, recovered from nasal swabs in the Maastricht University Medical Center, a 
tertiary 715-bed hospital, were evaluated. The isolates were randomly selected from a 
group of MSSA associated with MLST CC5 (n=6), CC8 (n=5) and CC30 (n=6) and a rifampicin 
MIC of 0.016 μg/mL (Table 1). All three lineages possess the ability to become methicillin-
resistant S. aureus (MRSA) by acquisition of a Staphylococcal Cassette Chromosome mec 
(SCCmec) element and belong to pandemic lineages, CC30 in Europe and CC8 in the USA22. 
This study was restricted to MSSA isolates, since the prevalence of MRSA is still low in the 
Netherlands23 and the Scandinavian countries24. 
 
Table 1. Characteristics of S. aureus strains and rifampicin-resistant mutants included in this study. 
 
associated 
MLST CC ST 
No. of 
isolates 
No. of 
mutants
Oxacillin 
MIC (μg/mL) 
Rifampicin MIC (μg/mL) 
/ Disk diffusion 
spa types 
(No.) 
  RSS RRM RSS RRM RSS RRM  
         
5 ST5 6 6 0.125 – 0.5 0.125 – 0.5 0.016 / S > 4 / R t002 (6) 
8 ST1411a 5 5 0.125 – 0.5 0.125 – 0.5 0.016 / S > 4 / R t008a (5) 
30 ST714b 6 6 0.125 – 0.5 0.125 – 0.5 0.016 / S > 4 / R t021b (2), t012 (2), 
t238 (1), t1130 (1) 
         
 
RSS, rifampicin susceptible strain ; RRM, rifampicin resistant mutant 
Boldface indicates spa types on which multilocus sequence typing analysis was performed (ST, sequence type). 
a The strain spa typed as t008 had ST1411, a double locus variant of ST8 at the gmk and tpi locus. 
b The strain spa typed as t021 had ST714, a single locus variant of ST30 at the arcC locus. 
 
Characterization of the genetic background 
Real-time amplification of the spa locus, followed by sequencing, was performed as de-
scribed before25. The spa types were assigned through the Ridom SpaServer 
(http://spaserver.ridom.de) and clustered into spa-CCs using the algorithm based upon 
repeat pattern (BURP) with Ridom StaphType 1.5 using the default settings26. Since it has 
been shown that spa typing/BURP, yields results consistent with typing results obtained by 
MLST26,27, the associated CCs, as determined with MLST, were allocated through the Ridom 
SpaServer. To confirm the association between MLST and spa typing, in combination with 
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BURP, MLST was performed on one isolate of each major spa type and associated MLST CC, 
as described previously25,28. 
Isolation of rifampicin-resistant mutants 
Selective rifampicin containing (16 μg/mL = 1000 × MIC) 5% sheep blood agar plates 
(Oxoid CM0331, Wesel, Germany) were seeded with 100 μL of a suspension of approxi-
mately 109 CFU/mL of MSSA and incubated overnight at 37°C. The colonies that appeared 
on these plates were picked, purified and cultured overnight on plates containing rifam-
picin (16 μg/mL). Afterwards, rifampicin-resistant mutants were kept frozen at -20°C, until 
further examination. Prior to each test, mutants were plated on non-antibiotic containing 
blood agar plates (Oxoid PB5039A, Basingstoke, UK). 
Susceptibility testing 
Susceptibility testing of the parent strains was performed using a micro-dilution technique 
according to the CLSI guidelines29. Prior and after each experiment, rifampicin resistance of 
the rifampicin-resistant mutants was confirmed using a disk diffusion method (Neo-
Sensitabs 30 μg, Rosco Diagnostica A/S, Taastrup, Denmark) on Mueller-Hinton II agar 
plates (Becton Dickinson Ref:221177, USA), according to the manufacturer’s recommenda-
tions and the CLSI breakpoints30. Rifampicin susceptibility of the rifampicin-susceptible 
isolates was likewise determined. 
Biofilm formation in microtiter plates and detection of biomass and viable count 
MSSA were allowed to establish biofilms during 24h in 96-well (biomass) and 24-well (vi-
able count) flat-bottomed non-tissue culture treated polystyrene microtiter plates (Greiner 
Bio-One, Frickenhausen, Germany and Becton Dickinson, Le Pont de Claix, France, respec-
tively) at 37°C on a rocking platform at 25 oscillations min-1. Individual wells were filled 
with 100 μL (biomass) and 800 μL (viable count) of an overnight culture which was diluted 
until 108 CFU/mL in Trypticase Soy Broth (TSB) without dextrose (Becton Dickinson, Le Pont 
de Claix, France), respectively, and supplemented with 0.1% glucose. After 24h biofilm 
formation, growth medium with planktonic cells was discarded and replaced by fresh 
broth containing antibiotics, except for controls, where medium was added only. Oxacillin 
(Sigma-Aldrich, Zwijndrecht, the Netherlands) was added at 2 and 4 × MIC (six replicates 
per concentration). Furthermore, rifampicin (Sigma-Aldrich) at ½ (0.008 μg/mL) and 62½ × 
MIC (1 μg/mL) was added to oxacillin. Oxacillin was also tested alone. The plates were 
incubated for an additional 24h. Subsequently, the wells were washed three times with 
200 μL (biomass) and 1.6 mL NaCl 0.9% (viable count), respectively. 
Similar concentrations of rifampicin were used when the rifampicin-resistant mutants 
were tested: a rifampicin concentration of 1 μg/mL was considered clinically achievable in 
serum. The subinhibitory concentration (½ × MIC) was used to reveal whether a low con-
centration affects the ability to form biomass and influences bacterial replication and/or 
killing. 
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Biomass formation in 96-well plates was quantified using the crystal violet adherence 
assay, carried out as described previously25 and performed in six fold. Biofilms grown in 24-
wells plates were dispersed with a disposable cell scraper, adjusted to 1 mL, diluted and 
plated on blood agar plates to determine the number of CFU per well. Viable count ex-
periments were repeated once. The intra- and interday coefficients of variation for the 
biomass assay were 10% and 15%, respectively. 
Synergy for the viable count measurements was defined as a decrease of ≥ 2-log10 CFU 
per well with a combination of two antimicrobials versus the most active single agent. 
Antagonism was defined as an increase of ≥ 1-log10 CFU per well with the combination 
compared with the least active single agent. 
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Figure 1. Categorization of the effect of rifampicin as adjunctive agent on S. aureus biofilm. Categorization 
of rifampicin-susceptible (RIF-S) isolates and rifampicin-resistant (RIF-R) mutants for viable count of biofilm-
embedded bacteria (A) and biomass (B) measurements. The effect was expressed as the difference between 
oxacillin alone and oxacillin in combination with rifampicin and subsequently categorized. The adjunctive 
use of rifampicin was evaluated at 0.008 μg/mL and 1 μg/mL, respectively. The number of strains tested are 
specified per category in each bar. An extra reduction of ≥ 1-log10 CFU per well (including synergism) upon 
rifampicin and oxacillin exposure was considered a positive outcome. Similarly, an extra decrease in 
biomass of > 20% in the presence of rifampicin, compared to oxacillin alone, was considered positive. All 
positive outcomes were clustered and are shown with slope striped patterns. Grey or white filled bars 
display a negative outcome and were clustered as well. 
 
Statistical analysis 
SPSS version 15.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. ANOVA with 
Bonferroni correction was used to compare individual runs of the biomass experiments. 
Chi-square analysis was used for comparison of the prevalence of defined categories be-
tween the specified groups. Mann-Whitney U analysis was used to compare biomass val-
ues and changes in viable count. A P value of ≤ 0.05 was considered to be statistically 
significant. 
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Figure 2. The effect of rifampicin as adjunctive agent on S. aureus biofilm per clonal lineage. Change in 
viable count (A) or biomass of biofilm-embedded bacteria (B) caused by oxacillin (OXA) combined with 
rifampicin (RIF) at 1 μg/mL, compared with control (dark grey filled bars). The effects of oxacillin alone at 2 × 
MIC are also shown (light grey filled bars). The results of the biomass experiments with BF35 were excluded, 
since BF35 showed a totally different outcome than the other isolates associated with MLST CC8. Error bars 
indicate standard error of the mean. The abbreviations RIF-S and RIF-R represent rifampicin-susceptible 
isolates and rifampicin-resistant mutants, respectively. 
 
 
Results 
Rifampicin as adjunct against rifampicin-susceptible isolates 
Following biofilm formation under static conditions, we examined the inter-strain variabil-
ity of rifampicin addition to oxacillin on biomass and viable count among genetically re-
lated biofilm-embedded MSSA strains. Rifampicin as an adjunctive agent at 1 μg/mL (62½ 
× MIC) reduced the viable count of these isolates and the amount of biomass formed gen-
erally more than oxacillin alone at 2 × MIC. Increased bacterial killing of ≥ 1 log10 CFU per 
well compared to oxacillin was observed in 10 out of 17 isolates, of which four demon-
strated synergism (Figure 1A). However, inter-strain variability in response to rifampicin 
was found since an increase in viable count was observed with four other isolates. Beside 
that, an additional decrease in biomass of 20% or more was noticed in 15 out of 17 isolates 
(Figure 1B), whereas one strain showed an increase in biomass. This isolate (BF35), associ-
ated with MLST CC8, demonstrated an increase of approximately 300% in biomass forma-
tion upon addition of rifampicin at 62½ × MIC to oxacillin (Figure 2B). This increase was 
accompanied by less effective killing of bacterial cells: –1.04 log10 versus an average of        
–2.69 log10 for the other rifampicin-susceptible isolates associated with MLST CC8 (Figure 
2A). Contrary to this observation, the relative change in biomass of the rifampicin-
susceptible isolates was independent on the genetic background (Figure 2B) when rifam-
picin was used as adjunctive agent at 62½ × MIC. However, rifampicin addition led to a 
smaller decline in CFU per well (–1.52 log10) against a few isolates associated with MLST 
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CC5 compared to CC8 (–2.69 log10) (except isolate BF35) and CC30 (–2.43 log10) (Figure 2A), 
but there was a tendency that the former were embedded by more biomass (Figure 3 and 
4C). 
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Figure 3. The additional change in viable count (Log10 CFU per well) of biofilm-embedded bacteria in the 
presence of rifampicin (1 μg/mL) as an adjunct to oxacillin (2 × MIC), compared to the change with oxacillin 
alone. The dashed horizontal line indicates the distinction between increase (upper panel) and decrease 
(lower panel) in viable count. The dotted line represents the threshold values for a synergistic effect of 
rifampicin. The amount of biomass (absorbance at 590 nm) of the controls is represented on the x-axis. The 
dashed vertical line indicates the previously defined threshold value for strong biomass formation. The 
symbol fillings of all tested strains associated with MLST CC8 (circles), CC5 (triangles downwards) and CC30 
(squares) represent the change in biomass upon addition of oxacillin in combination with rifampicin. 
Unfilled and filled symbols indicate an increase and decrease in biomass compared to control, respectively. 
The abbreviations S and R represent rifampicin-susceptible isolates and rifampicin-resistant mutants, 
respectively. 
 
 
To evaluate the concentration of the companion agent, we evaluated the effect on bio-
mass of 2 × MIC oxacillin compared with 4 × MIC oxacillin, both combined with rifampicin 
at 0.008 and 1 μg/mL. No differences in relative change in biomass were observed be-
tween these two oxacillin concentrations (data not shown). 
A subinhibitory concentration of rifampicin was tested to assess whether rifampicin 
augments biofilm formation, as described for various antibiotics against different bacterial 
species31,32. In general, compared to oxacillin alone, addition of rifampicin at 0.008 μg/mL 
(½ × MIC) to oxacillin neither triggered biomass formation, nor enhanced the reduction in 
biomass (Figure 1B). Moreover, compared to rifampicin at 1 μg/mL, the number of isolates 
without any effect on viable count increased from 3 to 8 out of 17 isolates (Figure 1A). 
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Rifampicin as adjunct against rifampicin-resistant mutants 
Besides a direct antimicrobial effect on RNA polymerase10, we hypothesized that rifampicin 
exercises an anti-biofilm effect by causing matrix degradation, thereby improving the 
diffusion of the companion agent. Therefore, we evaluated whether rifampicin was also 
able to destruct biofilms of rifampicin-resistant strains. Although we observed a synergistic 
bacterial killing effect for one isolate, when rifampicin was added at 1 μg/mL to oxacillin 
(Figure 1A), 7 out of 17 rifampicin-resistant mutants showed a slight increase in viable 
count (Figure 1A). Most rifampicin-resistant mutants (13 out of 17) showed indifference at 
0.008 μg/mL rifampicin. Although the viable count of some mutants associated with MLST 
CC5 and CC8 was reduced slightly more in the presence of rifampicin, compared with 
oxacillin alone (Figure 2A), the amount of biomass was rather unaltered (Figure 2B and 3). 
Overall, biomass was not affected by the presence of rifampicin in both concentrations: 15 
out of 17 rifampicin-resistant mutants showed an indifferent effect when rifampicin was 
added to oxacillin (Figure 1B). 
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Figure 4. The amount of biomass (absorbance at 590 nm) produced during 48h (A), the number of colony 
forming units (CFU) per biofilm (B) and the number of viable micro-organisms per biomass (C), per genetic 
background, in the absence of antibiotics. Error bars represent standard error of the mean. The 
abbreviations RIF-S and RIF-R represent rifampicin-susceptible isolates and rifampicin-resistant mutants, 
respectively. 
 
Effect of rifampicin in relation to biomass formation 
Some strains associated with MLST CC8 or CC5, including both rifampicin-susceptible 
isolates and rifampicin-resistant mutants, possessed an absorbance value above a previ-
ously defined threshold value of strong biomass formation at 0.1% glucose25 (Figure 3). 
When strong biomass formation was taken into account, the viable counts of both rifam-
picin-susceptible and rifampicin-resistant strains embedded by large amounts of biomass, 
were hardly affected by rifampicin addition to oxacillin. Additional changes in viable count 
were generally less than 1-log10 CFU per well (Figure 3). On the other hand, compared to 
strains with the highest amounts of biomass, half of all low biomass-producers (irrespec-
tive of the clonal lineage) showed a substantially larger additional reduction in viable 
count (up to 3-log10) upon rifampicin addition. However, mutants associated with MLST 
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CC30, which were also low biomass-producing strains, showed approximately 20% en-
hanced biomass formation in the presence of rifampicin (Figure 2B and 3). Consequently, 
these bacteria became more embedded upon rifampicin addition, resulting in rather no 
difference in effect on viable count, compared to oxacillin alone (Figure 2A and 3). 
 
Discussion 
 
Medical device associated infections such as orthopedic implant-related infections and 
prosthetic valve endocarditis or infections due to contaminated intravenous lines have 
been associated with bacteria embedded in biofilm12,13,15. In clinical practice, rifampicin is 
used as additional therapy in foreign body-related infections due to S. aureus2. Since con-
tradictory results of rifampicin as adjunctive agent for the treatment of S. aureus biofilm 
related infections have been reported5,13, we performed in vitro studies and demonstrated 
that eradication with rifampicin in combination with oxacillin displays inter-strain variabil-
ity, both for rifampicin-susceptible isolates and rifampicin-resistant mutants. 
Both the concentration of the adjunctive agent and the companion agent are essential 
for the outcome of the combination. A dose depending effect of the companion drug have 
been described for beta-lactams and fluoroquinolones16,33, but was not observed with 
oxacillin in our experiment. Similar results were obtained with oxacillin at 2 and 4× MIC. 
Furthermore, the reduction in the amount of biomass at 0.008 μg/mL of rifampicin added 
to oxacillin at 2× MIC was similar as for oxacillin alone, both for rifampicin-susceptible S. 
aureus isolates and rifampicin-resistant mutants. Apparently, subinhibitory concentrations 
of rifampicin were not sufficient to improve biofilm disintegration. In general, rifampicin at 
0.008 μg/mL did not induce biomass formation in contrast to what has been described for 
subinhibitory concentrations of certain antibiotics and various (subsets of) bacterial spe-
cies31,32. However, a possible inducible effect of a subinhibitory concentration of rifampicin 
could not be ruled out, since it was previously demonstrated that a particular subinhibitory 
concentration (range) could be responsible for induction31. To prevent exposure of bacte-
ria to subinhibitory concentrations of rifampicin, in clinical practice a high-dosage regimen 
(such as twice daily 600 mg) of rifampicin should be recommended, taking in considera-
tion the potential risks against the assumed benefits, which will be discussed below. 
When rifampicin at 1 μg/mL was used as an adjunct to oxacillin, an additional biomass 
reduction ≥ 20% was observed for 15 out of 17 rifampicin-susceptible S. aureus isolates , 
whereas only 10 out of 17 showed a reduction in viable count of more than 1-log10 CFU per 
well compared to the most active single agent. It is likely that the outer parts were mainly 
destructed by the antibiotics, resulting in a decrease in biomass, whereas the majority of 
bacteria located at the centre of the biofilm was less effected by rifampicin. 
Environmental triggers, including subinhibitory antibiotic concentrations, can specifi-
cally activate biomass formation of certain bacterial species, for example by influencing 
the production of exopolysaccharides or by disturbing the expression of signal transduc-
tion molecules that regulate cell surface adhesiveness31,32,34,35. Although the multiples of 
the MIC used for oxacillin and rifampicin were not subinhibitory for planktonic bacteria, 
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they might be the optimal subinhibitory concentration for bacteria embedded in biofilm 
to stimulate biomass formation. Due to the relatively strong biomass forming capacity of 
strain BF35 probably no high antibiotic levels inside the biofilm could be achieved, result-
ing in stimulation of biomass formation by oxacillin or rifampicin. It needs to be elucidated 
whether this observation is a rare example, or representative for other strong biomass 
producing strains. 
In contrast to the rifampicin-susceptible parent isolate of BF35, the rifampicin-resistant 
mutant did not induce biomass upon rifampicin exposure. For unknown reasons, the ri-
fampicin-resistant mutants of strains associated with CC30 showed the opposite, i.e. stimu-
lation of biomass formation by rifampicin, whereas this was not observed for the corre-
sponding rifampicin-susceptible isolates. Killing of embedded S. aureus was impaired in 
most cases in which biomass formation was stimulated by rifampicin or oxacillin. 
Inter-strain variability of responses to rifampicin addition might be clarified by differences 
in composition of biofilm matrices. Factors such as differences in expression of certain 
surface adhesins36 and dissimilarities in release of genomic DNA37,38, are the main causes of 
variations in composition. 
Overall, rifampicin was significantly less successful in achieving additional changes to 
the effect of oxacillin alone on biomass (P < 0.01) and viable count (P < 0.05) of biofilms of 
rifampicin-resistant mutants. After oxacillin and rifampicin exposure, no decrease in bio-
mass of these mutants was observed and only 3 out of 17 displayed (a tendency towards) a 
synergistic effect on reducing the viable count, while the opposite was found for 7 out of 
17 mutants. These results might suggest that continuation of rifampicin use in case of 
rifampicin-resistant mutants should not be recommended. Long-lasting persistent infec-
tions may be attributed to the emergence of resistant subpopulations, which unfortu-
nately could not always be detected by routine susceptibility testing. 
Beside the disadvantage of the emergence of rifampicin-resistant isolates and the un-
predictable outcome of the adjunctive use of rifampicin, it is necessary to take other disad-
vantages of the use of rifampicin into consideration, which include hepatotoxicity5 and 
drug-interactions18. A novel rifampicin derivate was developed to overcome poor clinical 
tolerance and important drug interactions due to induction of the cytochrome p450 sys-
tem, especially CYP3A and CYP2C39. However, this compound has not been extensively 
investigated and is not yet commercially available. Other compounds active against dor-
mant bacteria are under investigation11. 
In conclusion, based on current knowledge summarized in reviews5,12–14, adding rifam-
picin to standard antimicrobials warrants a careful risk-benefit assessment for the individ-
ual patient since its efficacy is uncertain, severe side effects and important drug-
interactions which can not be waved aside are known and rifampicin-resistant mutants can 
emerge. The unpredictable outcome of rifampicin tested in vitro against S. aureus biofilm 
emphasizes the need for controlled clinical trials of sufficient power to provide firm an-
swers. Furthermore, it seems prudent to omit rifampicin administration at the moment 
that resistant mutants are observed or suspected, since rifampicin demonstrated to be 
inefficacious against biofilms of rifampicin-resistant mutants in vitro. 
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Abstract 
 
Central venous catheters (CVCs) have become indispensable in the treatment of neonates 
and patients undergoing chemotherapy or hemodialysis. A CVC provides easy access to 
the patient’s circulation, thus enabling facile monitoring of hemodynamic parameters, 
nutritional support, or administration of (cytostatic) medication. However, complications 
with CVCs, such as bacterial bloodstream infection or thromboembolism, are common. 
Bloodstream infections, predominantly caused by Staphylococcus aureus, are notoriously 
difficult to prevent and treat. Furthermore, patients receiving infusion therapy through a 
CVC are at risk for deep-vein thrombosis, especially of the upper limbs. Several recent 
clinical trials have shown that prophylactic anticoagulation (low-molecular-weight heparin 
or vitamin K antagonists) is not effective. Here, we report on the systematic development 
of a new bifunctional coating concept that can –uniquely– be applied to make CVC sur-
faces antimicrobial and antithrombogenic at the same time. The novel coating consists of a 
moderately hydrophilic synthetic copolymer of N-vinylpyrrollidinone (NVP) and n-butyl 
methacrylate (BMA), containing embedded silver nanoparticles (AgNPs) and sodium hepa-
rin. The work demonstrates that the AgNPs strongly inhibit adhesion of S. aureus (reference 
strain and clinical isolates). Surprisingly, heparin not only rendered our surfaces practically 
non-thrombogenic, but also contributed synergistically to their biocidal activity. 
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Introduction 
 
Central venous catheters (CVCs) are used ubiquitously during treatment of critically ill 
cancer patients. According to recent estimates, more than 5 million cancer patients in the 
US require central venous access each year1. A similar estimate was made for Europe. CVCs 
offer important advantages, such as facile sustained administration of cytostatic or pain-
killing medication, infusion of stem cells, continuous measurement of hemodynamic pa-
rameters, or sustained nutritional support. However, application of CVCs is associated with 
a significant risk for adverse effects, particularly bloodstream infection2-5 and thromboem-
bolism6-10. In the US, approximately 80,000 CVC-related nosocomial bloodstream infections 
occur annually. The associated extra cost is in the range of $300 million to $2.3 billion per 
year, and the attributable mortality is around 20%. On an average, survivors usually remain 
one extra week in the intensive care unit, or 2–3 additional weeks in the hospital. 
Hence, prevention of CVC-related complications is of paramount importance. Regard-
ing infection, preventive strategies include the use of (i), a maximum sterile barrier during 
CVC insertion; (ii), innovative catheter hubs, and (iii), chlorhexidine-containing cutaneous 
antiseptics2-5,11. Moreover, strict adherence to evidence based protocols for hygiene and 
sterility proved highly successful11. Prevention of thrombotic complications is mostly at-
tempted through administration of anticoagulants during treatment6-10. Despite all efforts, 
it is evident that there is a need for improved biomaterials for the manufacture of safer 
catheters. Engineering into this direction must focus of the catheter’s surface, which must 
have broad-spectrum antimicrobial activity as well as excellent blood compatibility. We 
describe the systematic development of new bifunctional surface coatings that –uniquely– 
meet these requirements. 
 
Materials and methods 
Formulation 
Six different coating solutions were prepared as follows: (i), 600 mL of 10 % solution of the 
hydrophilic copolymer (SS) in NMP was equally divided over six 500-mL glass bottles. (ii), 
Sodium heparin (3 × 1.5 g, purchased from Celsus Laboratories, Cincinatti, OH, USA) was 
dissolved (mechanical stirring) in formamide (75 mL). The solution was split into three 
equal parts, and these were mixed with three of the SS solutions as indicated in Table 1. 
(iii), Silver nanoparticles, AgNPs, (Ag6V or Ag4E; 3.0 g, purchased from Metalor SA, Neuchâ-
tel, Switzerland; Ag6V and Ag4E differed with respect to the hydrophilic surface coating 
used for their stabilization) were dispersed in NMP and mixed with two of the SS solutions 
as follows: Coating #1 (SS): SS solution (100 mL) + NMP (50 mL). Coating #2 (SS-Hep): SS 
solution (100 mL) + NMP (25 mL) + 1.5 g heparin dissolved in formamide (25 mL). Coating 
#3 (SS-Ag6V): SS solution (100 mL) + NMP (50 mL) + nanosilver (1.5 g). Coating #4 (SS-
Ag6V-Hep): SS solution (100 mL) + NMP (25 mL) + nanosilver (1.5 g) + 1.5 g heparin dis-
solved in formamide (25 mL). Coating #5 (SS-Ag4E): SS solution (100 mL) + NMP (50 mL) + 
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nanosilver (1.5 g). Coating #6 (SS-Ag4E-Hep): SS solution (100 mL) + NMP (25 mL) + 
nanosilver (1.5 g) + 1.5 g heparin dissolved in formamide (25 mL). Coatings had a thickness 
of 3.0 μm, and differed only with respect to the embedded species. Fabrication of the 
specimens involved three consecutive steps: (i) formulation of coating suspensions 
through mixing of the NVP/BMA copolymer (designated SS) + AgNPs suspended in N-
methylpyrrolidone and/or sodium heparin dissolved in formamide; (ii) application of the 
coating onto a long (approximately 300 m) and thin (178 μm diameter) stainless steel wire 
in a continuous process; (iii), coiling of the coated wire around a rotating mandril of 600 
μm diameter12–14. 
 
Table 1. Atomic concentrations (percentages) measured by XPS. All data represent averages of two 
independent measurements 
 
Number Coating 
SS solution 
(mL) 
NMP 
(mL) 
Nanosilver 
(g) 
Formamide 
(mL) 
Sodium heparin 
(g) 
1 SS 100 50 - - - 
2 SS-Hep 100 25 - 25 1.5 
3 SS-Ag6V 100 50 1.5 - - 
4 SS-Ag6V-Hep 100 25 1.5 25 1.5 
5 SS-Ag4E 100 50 1.5 - - 
6 SS-Ag4E-Hep 100 25 1.5 25 1.5 
Methods and equipment 
The platelet-stabilizing anticoagulant mixture, citrate-theophilline-adenosine-dipyrida-
mole (CTAD) was purchased from Becton-Dickinson (Alphen a/d Rijn), the Netherlands). 
Brain Heart infusion broth and Mueller-Hinton agar were from Oxoid BV (Badhoevedorp, 
the Netherlands). The lactate dehydrogenase (LDH) assay was performed using the Cyto-
Tox 96 Non-Radioactive Cytotoxicity Assay from Promega Benelux BV (Leiden, the Nether-
lands). Platelet activation was quantified with the Assachrom ß-TG linked immunosorbent 
assay (ELISA), obtained from Roche Diagnostics Nederland BV (Almere, the Netherlands). 
Fluorescence tracings were recorded on a SpectraMax M2 spectrofluorometer (Molecular 
Devices, Sunnyvale, CA, USA). Absorbances were measured on an ELx808 Absorbance 
Microplate Reader (BioTek Instruments Inc., VT, USA). Sputter coating for electron micros-
copy was performed with a Sputter Coater 108/SE (Cressington Scientific Instruments Ltd., 
Watford, UK). Scanning electron microscopy was performed with a Philips XL30 instrument 
(Philips, Eindhoven, the Netherlands). X-ray Photoelectron Spectroscopy measurements 
were carried out in a Quantera SXM instrument from Ulvac-PHI (Q2). During the measure-
ments, the angle between the axis of the analyzer and the sample surface was 45o. The 
information depth is then appr. 6 nm. The measurements have been performed using 
monochromatic AlKα radiation in High Power mode (100 Watt, measuring spot 100 μm, 
scanned over 1400 μm x 500 μm). 
Experiments with bacteria 
Overnight cultures were prepared by inoculation of a bacterial colony into 10 mL growth 
medium (37 g/L heart infusion broth). From this culture, a bacterial suspension of 107 
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CFU/mL was prepared in 0.9 % NaCl. Coated coils (length 30 mm) were incubated at 37 oC 
for 60 min in 1.5 mL bacterial suspension, in a shaking incubator. The samples were subse-
quently transferred to a fresh volume of 1.5 mL 0.9 % NaCl, and vortexed for 1 s. Vortexing 
resulted in detachment of loosely adhered bacteria. Then, the samples were transferred 
again to fresh volumes of 1.5 mL of 0.9 % NaCl, and left for 4 h under continuous shaking. 
Subsequently, the catheter samples were carefully removed, washed in 0.9 % NaCl, and 
rolled over a Mueller-Hinton blood agar plate (38g/L Mueller-Hinton agar, 5 % defibrinated 
sheep blood). Plates were incubated overnight and photographed and evaluated on the 
next day. The six sample groups were subjected to these tests in three-fold. 
Thrombin generation experiments 
Freshly prepared human platelet-rich blood plasma (PRP) was used in the thrombin gen-
eration assays. There were two donor groups: a first group consisting of five healthy male 
volunteers (ages 22, 23, 24, 25, and 51 years), who were non-smokers and non-users of any 
drugs that could possibly influence hemostasis. The second group consisted of a cohort of 
nine patients who were under treatment in the Maastricht University Medical Center. 
These patients all received high-dose cytostatic medication through a central venous 
catheter; patient data are summarized in Table 2. 
 
Table 2. Data on patients and/or blood donors 
 
Informed consent was obtained in accordance with the Declaration of Helsinki, and the 
study was approved by the Maastricht University Medical Center ethical committee. The 
volunteers each donated approximately 40 mL blood through venipuncture. The collec-
tion tubes contained citrate for anticoagulation (end-concentration 0.013 M citrate). The 
patients donated 20 mL blood each. In these cases, Vacutainers containing citrate for anti-
coagulation were used. PRP was isolated through centrifugation (200g, 15 min, room tem-
perature). PRP was carefully transferred into new tubes and kept at 37 oC until further use. 
Patient Age 
(gender) 
Length (m) / 
mass (kg) 
Specified malignancy Thrombocyte 
counts 
(109/mL)† 
Leukocyte 
Counts 
(109/mL)‡ 
1 50 (f) 1.64 / 47 AML* 134 1.4 
2 61 (m) 1.72 / 64 Histiocytic sarcoma 52 0.2 
3 61 (f) 1.58 / 53 AML 145 3.0 
4 60 (m) 1.85 / 104 AML 51 1 
5 58 (f) 1.63 / 69 Amyloidosis 107 10.5 
6 66 (m) 1.83 / 65 MGUS + C1-esterase deficiency 281 4.5 
7 76 (m) 1.75 / 60 Mantle cell NHL** 120 0.8 
8 44 (m) 1.80 / 77 AML 252 6.2 
9 55 (m) 1.72 / 109 Multiple myeloma 27 1.5 
*AML = acute myeloid leukemia 
**NHL = non-Hodgkin’s lymphoma 
†Normal thrombocyte concentration: 150 – 450 x 109 / L 
‡Normal leukocyte concentration: 4.5 – 10 x 109 / L 
Patient #5 was the only patient receiving anticoagulant medication (low-molecular–weight heparin) at the time 
of blood sampling. 
 
Chapter 4 
 62 
Thrombin generation experiments were done according to a one-donor-on-one-day 
scheme. On such an experimental day, 30 thrombin generation curves were measured (6 
experimental coatings, each experiment in five-fold). The experiments were done in four 
consecutive steps: (i), Five pieces of 25 mm were cut out of each of the six different coils. 
Then, each piece was cut further into five approximately equal pieces, and these were 
transferred into one single well of a 96 well plate, (ii), The fluorogenic substrate for throm-
bin, Z-Gly-Gly-Arg-AMC (a product of Bachem Holding AG (Bubendorf, Switzerland; ref. I-
1140) was added to the citrated PRP to a final concentration of 400 μM. Then, the PRP was 
“recalcified” through adding CaCl2 stock solution (0.5 M) up to a final concentration of 20 
mM Ca2+. Consequently the mechanism for intrinsic (i.e. biomaterial-surface-induced) 
coagulation is no longer inhibited, (iii), The PRP was then rapidly distributed over the wells; 
200 μL was transferred into each well. All pieces of the coiled wire were submersed in PRP. 
Wells without coil-samples served as controls. (iv), Fluorescence tracings were recorded at 
37 oC. Wavelengths of excitation and measuring were 368 and 460 nm, respectively. Data 
were collected every 30 s; the plate was gently shaken for 2 s prior to each measurement. 
The fluorescence intensity was converted into nanomolar concentrations of thrombin. This 
technique resulted in a thrombin generation curve for each well. 
Statistical analysis 
Data were analyzed with a one-way analysis followed by a Bonferroni correction for de-
termining differences between groups. Differences were considered as statistically signifi-
cant with P < 0.05. 
 
Table 3. Atomic concentrations (percentages) measured by XPS. All data represent averages of two 
independent measurements. 
 
Entry Surface C1s N1s O1s Ag3d S2p (-SO3H) 
1 SS 79.7 4.6 14.4 - 0.21 
2 SS-Hep 78.6 4.3 14.5 - 0.43 
3 SS-Ag6V 80.4 4.2 12.6 0.22 0.21 
4 SS-Ag6V-Hep 79.2 5.0 14.2 0.11 0.42 
5 SS-Ag4E 79.3 6.6 13.0 0.15 0.24 
6 SS-Ag4e-Hep 78.9 5.3 14.6 0.19 0.35 
 
Results 
Samples and sample characterization 
The continuous coating process afforded a huge inventory of virtually identical specimens 
for every formulation. This approach distinguishes this study from other investigations on 
biomaterial surface coatings obtained through dipping or spraying, which are discontinu-
ous methods that generally introduce substantial noise in subsequent experimental data. 
Specimens were first studied with X-ray photoelectron spectroscopy (XPS). Figure 1B 
shows a representative wide-scan spectrum. Data were collected with a spot size of only 
100 μm at two positions per specimen, i.e., on the top of two individual windings. The 
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information depth was approximately 6 nm. Figure 1C shows narrow-scan XPS spectra of 
SS-Ag4E-Hep (sulfur and silver lines). The apparent atomic concentrations are compiled in 
Table 3. 
 
A 
 
B 
 
C 
 
 
Figure 1. XPS spectra of surface coating SS-Ag4E-Hep, containing silver nanoparticles and heparin. (A) 
Photograph of a typical specimen. Note the coiled structure. (B) Wide-scan XPS spectrum of the typical 
specimen SS-Hep-Ag4E. A small spot size (100 μm) was used, which enabled scanning on the top of one of 
the specimen’s windings. The signal intensity is reported in counts per second (CPS) (C) Narrow-scan X-ray 
photoelectron spectra of the outermost layer of the SS-Ag4E-Hep surface; left: Ag3d doublet due to surface-
exposed AgNPs, right: S2p peak due to the SO3H groups of heparin. 
 
 
All duplicate measurements were in good agreement. As expected, only specimens #3–#6 
expose silver at their surface. The specimens containing heparin (#2, #4 and #6) show 
clearly elevated concentrations of sulfur (-SO3H; 167.9 ± 0.1 eV) at their surfaces (0.43, 0.42 
and 0.35% respectively, vs. 0.21, 0.21 and 0.24% for specimens #1, #3, and #5). Hence, XPS 
confirms the presence of heparin at the surface of #2, #4 and #6. To the best of our knowl-
edge, this is the first example of the use of XPS to verify the presence of heparin in the 
outermost regions of biomaterial surface coatings. The presence of sulfur traces in speci-
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mens #1, #3, and #5 can be attributed to the binding layer of poly(ethersulfone), which is 
routinely used in the continuous coating procedure. 
Samples and sample characterization 
The system used for systematic comparison of the effects of embedded AgNPs and/or 
heparin is shown in Figure 1A. Fabrication of the specimens involved three consecutive 
steps: (i) formulation of coating suspensions through mixing of the NVP/BMA copolymer 
(designated SS) + AgNPs suspended in N-methylpyrrolidone and/or sodium heparin dis-
solved in formamide; (ii) application of the coating onto a long (approximately 300 m) and 
thin (178 μm diameter) stainless steel wire in a continuous process; (iii), coiling of the 
coated wire around a rotating mandril12–14. Note that the continuous coating process af-
forded a huge inventory of virtually identical specimens for every formulation. This ap-
proach distinguishes this study from other investigations on biomaterial surface coatings 
obtained through dipping or spraying, which are discontinuous methods that generally 
introduce substantial noise in subsequent experimental data. Note furthermore that two 
different types of AgNPs were used (designated Ag6V and Ag4E); these AgNPs differed 
with respect to the hydrophilic surface coating used for their stabilization. 
Biocidal activity 
The roll-plate method according to Maki et al.15 was used to assess adherence of the refer-
ence strain Staphylococcus aureus ATCC 29213 to the different coatings. This technique 
visualizes bacterial colonies on each roll track, provided that bacterial adhesion occurred 
during the incubation phase. Our cylindrical specimens were convenient to use in this 
assay, and data-reproducibility was excellent. Virtually no bacteria could be found on the 
agar plates for SS-Ag6V, SS-Ag6V-Hep, SS-Ag4E, and SS-Ag4E-Hep, whereas bacteria were 
abundantly present on the agar plates for SS and SS-Hep (Figure 2 and Figure 3A, B and C). 
These data confirm the strong antibacterial activity of the AgNPs Ag6V and Ag4E. Further-
more, it appeared that heparin exerts a pronounced antibacterial effect by itself (compare 
SS and SS-Hep). The antimicrobial effects of AgNPs and heparin are additive: it is clear that 
much less bacteria adhered to the SS-Ag6V-Hep surface than to SS-Ag6V alone. Analo-
gously, SS-Ag4E-Hep has less adhered bacteria (if any are present at all) than SS-Ag4E. At 
first sight, we were puzzled by this heparin effect; several recent papers pointed out that 
heparin per se has no antibacterial effects16, and even that heparin may promote biofilm 
formation, especially for S. aureus17,18. Interestingly, recent work of Schmidtchen et al. may 
explain our observations in terms of an indirect effect of heparin: proteins carrying struc-
tural characteristics that impart affinity for heparin (positive charges and consensus re-
gions such a the Cardin motif or the Weintraub motif), also have antimicrobial proper-
ties19,20. For example, heparin-binding plasma proteins such as fibronectin, vitronectin, 
protein-C inhibitor and von Willebrand factor are biocidal for Gram-positive and Gram-
negative bacteria. Thus, if incubation of our coatings in plasma first leads to adsorption of 
proteins with an affinity for heparin, then these proteins introduce biocidal activity at the 
coating’s surface in turn. 
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Figure 2. Bacterial colonies that developed on the sheep-blood columbia agar plates (roll-
plate method according to Maki et al.15). Experiments were done with six different coatings 
(one per column), and in four-fold (four rows). The specimens were carefully rolled from the 
right side to the left side of the dishes, thereby releasing bacteria that generated visible 
colonies afterwards. Note the presence of many colonies for the SS coating, compared to the 
SS-Hep coating. Bactericidal effects of the AgNPs are clearly visible. 
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Next to S. aureus ATCC 29213, we studied two clinical isolates (MRSA BF110 and MSSA 
BF45), i.e., S. aureus bacteria that were isolated from patients with a catheter-associated 
bloodstream infection. The biocidal effects of our materials on the clinical isolates (BF110 
and BF145) were, in fact, stronger than those found for the reference strain (Figure 3D). 
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Figure 3. Roll-plate analysis carried out in agar-covered Petri dishes. In each dish, two identical specimens 
were rolled horizontally from one end of the Petri dish to the other end. Colonies were allowed to grow for 
24 h. Specimens were not removed. (A) Enlarged view of the abundant growth of bacterial colonies that 
were transferred from the SS specimen to the agar. (B) Same experiment, carried out with SS-Hep. 
Compared to SS, less colonies are found, showing that heparin exerts a significant biocidal effect by itself. 
(C) Same experiment with SS-Ag4E-Hep, showing the combined antimicrobial effect of heparin and AgNPs. 
Note the presence of the specimens at the top of A, B, and C. (D) Quantitative data of the roll-plate analysis. 
Data are expressed as mean ± SE. *P < 0.05, **P < 0.01, ***P < 0.001 SS-Ag4E-Hep or SS-Ag6V-Hep versus SS-
Ag4E or SS-Ag6V without heparin, respectively; #P < 0.001 SS-Hep versus SS only. 
 
In vitro assessment of blood compatibility: the thrombin generation assay 
The six different surfaces were subjected to a thrombin generation assay12,13. Platelet-rich 
blood plasma (PRP) was used from five healthy volunteer donors and from nine patients 
undergoing high-dose chemotherapy against a hematological malignancy in the Maas-
tricht University Medical Center (Table 2). We measured so-called thrombin generation 
curves ([thrombin] vs. time) in six-fold for every specimen-PRP combination. Thrombin lag 
times, i.e. time elapsing between the moment of recalcification and the moment at which 
[thrombin] becomes > 2 nM, were abstracted from all curves12,13. Note that the assay 
measures intrinsic activation of the coagulation system: the biomateral’s surface is the only 
trigger for thrombin formation (i.e., the assay uses no tissue factor or any other procoagu-
lant agent). As we advocated previously, the thrombin lag time is a valuable measure of 
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the thrombogenicity of the biomaterial under investigation12,13. The longer the lag time, 
the higher the level of blood compatibility in vitro. Figure 4A compiles lag times measured 
for our heparin-free specimens in contact with PRP from volunteer donors and patients. 
 
Thrombin lag time (min)
0 4 8 12 16 20 24
D1
D2
D3
D4
D5
P1
P2
P3
P4
P5
P6
P7
P8
P9
SS
SS-Ag6V
SS-Ag4E 
A
Thrombocyte count (109 / L)
0 50 100 150 200 250 300
Th
ro
m
bi
n 
la
g 
tim
e 
(m
in
)
6
8
10
12
14
16
18
20
22
SS
SS-Ag6V
SS-Ag4E
B
 
 
Figure 4. Thrombin generation in PRP from nine patients (abbreviated as P) on high-dose chemotherapy 
against a hematological malignancy and from five healthy volunteer donors (abbreviated as D) Thrombin 
lag times measured for coatings SS (black, lower bars), SS-Ag6V (light grey, middle bars), and SS-Ag4E (dark 
grey, upper bars) (A). Averaged thrombin lag times for the nine patients (viz. Figure 4A) plotted vs. 
thrombocyte counts. Thrombin lag times were measured for SS (black dots), SS-Ag6V (white triangles), and 
SS-Ag4E (black squares) (B). 
 
 
The volunteer data show a clear donor-dependency, which is in agreement with previous 
findings12. All heparin-containing specimens, for volunteer donor PRP and patient-derived 
PRP, had lag times > 60 min, revealing that the anticoagulant activity of heparin is by no 
means neutralized or significantly compromised by the AgNPs. The thrombin lag times 
measure for the patients also show considerable spreading. Data measured for patients #3, 
#6, #7 and #8 compare well with those of the volunteers, others were somewhat longer 
with appr. 20 min max. Taken together, all thrombin generation lag times are grossly simi-
lar, despite the fact that most patients show clear leukopenia and/or thrombocytopenia 
(Table 2). This reflects, albeit from an unusual point of view, that the regulation mechanism 
of the blood coagulation system manages to maintain hemostatic balance, even under 
conditions of severe illness and high-dose chemotherapy. Closer inspection of the patient 
data showed that one of the patients (#5) received low-molecular-weight heparin at the 
time of blood sampling. For the other eight patients, the thrombin lag times appeared to 
correlate inversely with the thrombocyte counts (r2 = 0.76; Figure 4B). A similar but weaker 
correlation (r2 = 0.45) was found between the thrombin lag times and the leukocyte counts 
of these patients. This may point out that patients with normal or close-to-normal platelet 
(and leukocyte) concentrations are likely to be at the largest risk for catheter-associated 
thrombus formation. Clinical testing of this hypothesis falls outside the scope of this study 
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but is certainly worthwhile: if true, then simple thrombocyte counting would provide an 
indication whether or not to provide prophylactic anticoagulation during the catheter-
based treatment period (e.g. through (subcutaneous) administration of low-molecular-
weight heparin). 
In vitro assessment of blood compatibility: thrombocyte adherence 
Adhesion of blood platelets to the six experimental coatings was studied further with PRP 
from healthy donors #2 and #3. The SS surface had the largest density of adherent platelets 
(LDH assay, appr. 20,000/cm coil). Inclusion of heparin (SS-Hep) or AgNPs (SS-Ag6V) re-
duced this number to appr. 6,000/cm coil and 5,000/cm coil, respectively. The combination 
of heparin and AgNPs (Ag6V) reduced the density of adhered platelets further (down to 
appr. 2,000/ cm coil). Remarkably, the use of Ag4E nanoparticles per se (SS-Ag4E) already 
reduced the density of adhered platelets to approximately 2,000/cm coil. No further effect 
due to inclusion of heparin (SS-Hep-Ag4E) could be observed. 
Scanning electron microscopy showed that platelets on the SS surface were mostly dis-
crete with partly spread morphology. Small pseudopodia by which they attach to the 
surface were observed. It was very difficult to discern platelets on the three heparin-
containing surfaces. On the other hand, adherent platelets could be found easily on the 
two coatings that contain merely AgNPs (SS-Ag6V and SS-Ag4E). These platelets were 
mostly associated with distorted morphologies as was observed previously12,21,22. 
 
Discussion 
 
Hydrophilic surface coatings for medical devices have drawn widespread attention during 
the last years. Adherent hydrophilic coatings provide catheters and guidewires with a 
“slippery-when-wet” lubricious surface, and this is extremely important for indwelling 
catheters, but also for delicate interventional procedures, such as percutaneous translu-
minal coronary angioplasty (PTCA) and super-precise embolization of solid tumors. New 
developments are focused on embedding of active components in hydrophilic surface 
coatings. This principle can lead to controlled release of active agents from the device’s 
surface, and/or to exposure of active molecules at the device’s surface. The combination of 
hydrophilic coatings with heparin can lead to anticoagulant and lubricious surfaces. 
Research on drug-containing hydrophilic surface coatings requires a highly accurate 
and reproducible coating protocol. Obviously, variations of the coating quality (thickness, 
adherence, etc.) would generate substantial experimental noise, which could easily ob-
scure effects of active constituents of the coating. Our extrusion-like coating procedure to 
apply NVP/BMA copolymers as uniform thin layers on thin metallic wires generates a plat-
form of precisely defined experimental coatings. These can be used in detailed compara-
tive studies. For instance, the hydrophilic nature of the materials can be tuned through the 
composition: the molar ratio NVP (hydrophilic):BMA (hydrophobic) determines parameters 
like contact angle, aqueous swelling ratio, etc. NVP/BMA coatings can be engineered such 
that the bio-active compound is either slowly released upon immersion in an aqueous 
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medium, or remains immobilized at the coating’s surface. This principle has already led to 
the development of, e.g., new devices for controlled delivery of drugs to the tear film of the 
eye, and heparin releasing/exposing guidewires for intravascular use featuring an excellent 
level of blood compatibility 13,24,25. 
Here, we studied NVP/BMA coating formulations in which silver nanoparticles and so-
dium heparin were co-embedded, with the aim to develop coatings for medical devices 
that effectively combine antimicrobial AND antithrombogenic features. Our data reveal 
that AgNPS and heparin can be combined effectively. Interestingly, synergetic effects of 
heparin and nanosilver were observed: (i), heparin enhances the biocidal activity of the 
AgNPs, and (ii), no lysis of contacting thrombocytes occurs.; rupture of platelets was ob-
served previously with NVP/BMA coatings that merely contain embedded AgNPs23. In 
addition, it is clear that our methodology can readily be scaled-up and transformed into an 
industrial procedure. We anticipate that this work can provide the basis for the develop-
ment of safer central venous catheters. There is a clear unmet need for biomaterials and 
surfaces that combine excellent biocidal properties with zero or close-to-zero throm-
bogenicity in vivo. Improved CVCs will, next to other measures to prevent infection and 
thromboembolism, help to improve treatment of many critically ill patients, and to reduce 
health care cost, especially when prolonged hospitalization can be prevented indeed. 
 
Conclusion 
 
Copolymers of NVP and BMA generate a platform of biocompatible coatings for medical 
devices. The hydrophilic nature of these materials can be tuned through the composition; 
the molar ratio NVP (hydrophilic): BMA (hydrophobic) determines parameters like contact 
angle, aqueous swelling ratio, etc. Furthermore, it has been established that the hydro-
phobic constituent is responsible for the adherence of the coating to the underlying sub-
strate (polyethersulfone). 
The NVP/BMA coatings offer number of interesting options. Firstly, they can be applied 
onto long wires or tubes in a precisely controlled extrusion-type procedure. Secondly, 
biologically active species can be embedded in the coatings. The NVP/BMA coatings can 
be engineered such that the bio-active compound is either slowly released upon immer-
sion in an aqueous medium, or remains immobilized at the coating’s surface. This principle 
has led to the development of, e.g., new devices for controlled delivery of drugs to the tear 
film of the eye, and heparin releasing/exposing guidewires for intravascular use featuring 
an excellent level of blood-compatibility. 
Now, we have identified NVP/BMA coating formulations that effectively combine bio-
cidal and anticoagulant features. This combination of bioactivities was obtained after 
embedding both silver nanoparticles and sodium heparin in the NVP/BMA coatings. Silver 
nanoparticles are known to have a strong biocidal effect against a wide range of microor-
ganisms. Noteworthy, the presence of heparin in the coating has two very beneficial ef-
fects: (i), heparin enhances the biocidal activity of the AgNPs, and (ii), no lysis of contacting 
thrombocytes occurs (this was observed previously with NVP/BMA coatings that merely 
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contain embedded AgNPs). To the best of our knowledge, no other biocompatible coat-
ings that feature both biocidal and non-thrombogenic behavior have been described so 
far. In addition, it is clear that our methodology can readily be scaled-up and transformed 
into an industrial procedure. 
We anticipate that this work can potentially provide the basis for the development of 
safer central venous catheters. Regarding CVCs, there is a clear unmet need for biomate-
rials and surfaces that combine excellent biocidal properties with zero or close-to-zero 
thrombogenicity in vivo. Improvement of CVCs is a particularly important objective, since 
complications due to infection and thrombosis are common and hazardous for many 
patients. Improved CVCs will, next to other measures to prevent infection and throm-
boembolism, help to improve treatment of many critically ill patients and to reduce health 
care cost, especially when prolonged hospitalization can indeed be prevented. 
 
Hydrophilic surface coatings for medical devices featuring both biocidal and non-
thrombogenic behavior can be prepared. The methodology as described in this work can 
be scaled-up and transformed into an industrial procedure. This work may help to realize 
the goal of manufacturing catheters and other medical devices that combine excellent 
biocidal properties with zero or close-to-zero thrombogenicity in vivo. 
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Abstract 
 
Percutaneous (skin-penetrating) catheters such as central venous catheters (CVCs), are 
used ubiquitously in the treatment of critically ill patients, although it is known that the 
risks for serious complications, particularly bloodstream infection and thromboembolism, 
are high. Materials science and engineering offer important new perspectives regarding 
further improvement of CVCs. A promising approach is the use of synthetic biocompatible 
hydrogel coatings with both silver particles and heparin embedded therein. Such formula-
tions combine the well-known broad-spectrum antimicrobial features of silver with the 
anticoagulant activity of immobilized heparin. Previous work revealed that heparin aug-
ments antimicrobial activity of silver, while maintaining its anticoagulant function. This 
study set out to investigate the synergy of heparin and silver in more detail. Exit-challenge 
tests, experiments on bacterial killing and adherence, as well as in vitro challenge tests with 
three S. aureus strains (one reference strain, and two clinical isolates) consistently showed 
the synergistic effect. In addition, the impact of changing the coating’s hydrophilicity, and 
changing the silver concentration in the coatings, were examined. The experimental re-
sults, taken together and combined with data from the literature, point out that synergy of 
heparin and silver is best explained by binding of Ag+ ions to heparin within the swollen 
coating, followed by release of heparin-Ag+ complexes upon immersion of the coatings in 
an aqueous environment such as blood. Possible implications of this work regarding the 
development of improved/safer CVCs are briefly discussed. 
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Introduction 
 
Central venous catheters (CVCs) play a key-role in the treatment of critically ill patients. For 
example, CVCs are commonly applied for intravenous delivery of cytostatic agents, blood 
transfusion, hemodialysis, blood sampling, parenteral nutrition or plasmapheresis. Yet, the 
use of CVCs is associated with a high incidence of serious complications, particularly blood 
stream infection1–6. Especially indigenous microorganisms such as coagulase-negative 
staphylococci (CoNSs) and the more virulent Stahylococcus aureus are involved7, 8. Infec-
tions mostly occur from the port of entry along the CVCs surface8. Another important 
source of complications with CVCs is thromboembolism4, 9–11, due to imperfect blood-
compatibility of the blood-contacting interface of the CVC12, 13. 
Biomaterials science and engineering can contribute to further technical improve-
ments of CVCs. Evidently, such endeavors must concentrate on the CVC surface. Ideally, the 
surface should inhibit bacterial adhesion and feature perfect or near-perfect hemocom-
patibility. In our previous work, we have reported on new synthetic hydrophilic biomate-
rials with both silver particles and heparin embedded therein14. These materials were ap-
plied as thin surface coatings, with the obvious aim to exploit both the broad-spectrum 
antimicrobial activity of silver15–17 and heparin’s inhibitory effect on the intrinsic coagula-
tion pathway. Our experiments revealed an unexpected synergistic effect: coatings con-
taining both silver particles and heparin were much more effective in preventing bacterial 
adhesion, compared to coatings containing merely silver or heparin. 
The objective of the present study was to further explore this synergy by: (i), examining 
different Staphylococcus aureus strains, including clinical isolates; (ii), studying the effect of 
silver particles and heparin on bacterial killing, and by performing exit-site and in vitro 
challenge tests; (iii), studying the effect of the hydrophilicity of the coating matrix; (iv), 
studying the effect of the silver content of the coating. 
 
Materials and Methods 
Materials 
Hydrophilic SlipSkin® (SS) coating biomaterials were purchased from INterface BIOmate-
rials BV (Geleen, the Netherlands). Two versions were used: copolymer SS90:10, prepared 
from N-vinyl-2-pyrrolidinone (NVP) and n-butylmethacrylate (BMA) in a molar ratio 90:10, 
and the less hydrophilic copolymer SS70:30, prepared from NVP and BMA in a molar ratio 
70:30. Sodium heparin was supplied by Celsus Laboratories (Cincinatti, OH, USA). Silver 
particles were purchased from Metalor SA (Neuchâtel, Switzerland). Two different types 
were used: Ag4E (stabilized by polyethylene glycol, PEG), and Ag6V (stabilized with polyvi-
nylpyrrolidone, PVP). All experiments were done with Ag4E, in some cases parallel experi-
ments with Ag6V were done as well. Data on Ag6V are described in the Supporting Infor-
mation. Commercial silver-impregnated catheters were purchased from Vygon BV (Valken-
swaard, the Netherlands). The Vygon® Multicath Expert 2 lumen catheter (ref. 8157.207) 
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was used throughout this work for benchmark referencing. The active antimicrobial con-
stituent is the silver-based agent AgION, which is not just a surface coating, but is incorpo-
rated into the material from which the tube is made. 
 
 
Table 1. Composition of the seven solutions that were used in the preparation of the specimens for this 
study. Ag, refers to Ag4E silver particles 
 
No. 
 
Coating 
 
SS90:10 / SS70:30 
[mL] 
Ag 
[g] 
NMP 
[mL] 
Sodium-Heparin 
[g] 
Formamide 
[mL] 
       
1 SS90:10 100 - 50 - - 
2 SS90:10-Hep 100 - 25 1.5 25 
3 SS90:10-Ag 100 1.5 50 - - 
4 SS90:10-Ag-Hep 100 1.5 25 1.5 25 
5 SS70:30-Ag 100 1.5 50 - - 
6 SS70:30-Ag-Hep 100 1.5 25 1.5 25 
7 SS70:30-Ag2×-Hep 100 3.0 25 1.5 25 
       
 
Formulation 
Seven different coating solutions were prepared as is compiled in Table 1. First, 400 mL of a 
10% solution of SS90:10 in N-methylpyrrolidone (NMP) was prepared. This solution was 
split into four equal parts. Secondly, 300 mL of a 10 % solution of SS70:30 in NMP was 
prepared; this solution was split into three equal parts. Thirdly, sodium heparin (6.00 g) was 
dissolved in 100 mL of formamide. This solution was split into four equal parts and these 
were mixed with two of the SS90:10 solutions (#s 2 and 4, Table 1) and two of the SS70:30 
solutions (#s 6 and 7, Table 1). Fourthly, Ag4E silver particles (3.00 g) were dispersed in 
NMP (100 mL) through mechanical stirring, split into two equal parts, and combined with 
SS90:10 solution #3 and SS70:30 solution #5. Analogously, 3.00 g silver was dispersed in 
NMP (50 mL), split into two equal parts and combined with SS90:10 solution #4 and 
SS70:30 solution #6. Finally, silver (3.00 g) was dispersed in NMP (25 mL) and combined 
with SS70:30 solution #7. Note that in this case a double content of silver was achieved.  
Analogously to the procedure described above for the Ag4E silver particles, two differ-
ent coating solutions were prepared with Ag6V silver particles (with and without sodium 
heparin), as is compiled in Table 2.  
All coating solutions were used in MCTec BV’s procedure for the continuous and pre-
cisely controlled application of thin adherent polymer coatings on long metallic wires, as 
described previously18. Stainless steel wires with a diameter of 178 μm were used. The 
thickness of the coatings was 3–4 μm. Coated wires were coiled, using a rotating mandril 
of 600 μm diameter. 
 
 
Hydrophilic surface coating with silver and sodium heparin 
 77 
Table 2. Composition of the two solutions with Ag6V silver particles (with or without heparin) that were used 
in the preparation of the specimens for this study. 
 
No. 
 
Coating 
 
SS90:10 
[mL] 
Ag6V 
[g] 
NMP 
[mL] 
Sodium-Heparin 
[g] 
Formamide 
[mL] 
       
1 SS90:10-Ag 100 1.5 50 - - 
2 SS90:10-Ag-Hep 100 1.5 25 1.5 25 
       
 
Bacterial strains 
The Staphylococcus aureus reference strain ATCC 29213, and two clinical S. aureus isolates 
(coined BF110 and D107) were tested. BF110 (meticillin-resistant, MRSA), previously shown 
to be a strong biomass producer19, with the genetic background associated with multilo-
cus sequence typing (MLST) clonal complex (CC)8. D107 (meticillin-susceptible, MSSA), was 
obtained from a patient with a CVC-related bloodstream-infection. 
Exit site challenge 
An in vitro method was adopted that determines the ability of antimicrobial coatings to 
prevent migration of bacteria along the external surface of a CVC after cutaneous coloniza-
tion and invasion of the insertion site. Coils (30 mm length) were inserted half into 35-mm 
thick solidified 28 g/L nutrient (Oxoid) agar, which was in advance poured into containers 
(4 cm diameter). Afterwards, the surrounding surface of the insertion site was inoculated 
with S. aureus ATCC 29213, 106 CFU/mL using a swab, mimicking the circumstances in 
which an insertion site on the skin is adequately disinfected before entrance of a CVC and 
the cutaneous port of entry later becomes re-colonized. To mimic not properly disinfected 
skin surface, coils were also inserted after inoculation of the agar surface, as described 
previously.20 Migration of bacteria down the coils along the abluminal coating surface was 
assessed visually for up to seven days during incubation at 37°C. 
Bacterial killing 
Coils were segmented into 30-mm long test-samples by cutting under aseptic conditions. 
The length of the Vygon® catheter pieces was corrected for external and internal surface 
area. The specimen parts were added separately to 10-mL NaCl 0.9% tubes containing a 
bacterial inoculum of 106 CFU/mL and incubated at 37°C. At t = 0, 2, 4, 8, 12, 24, 48 and 72 h 
samples of 100 μL were drawn to count viable bacteria. The lower limit of detection was 
2.73 log10 CFU/mL, using a spiralplater (Eddy Jet; IUL Instruments, Barcelona, Spain) as part 
of the enumeration procedure. 
Bacterial adherence 
Specimen pieces of 30 mm were separately exposed to bacterial suspensions to assess 
adherence of ATCC 29213, BF110 and D107 to the different coating surfaces. The length of 
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the Vygon® catheter pieces was corrected for external surface area. To mimic infusion 
through and/or flushing of CVC prior to colonization or infection, a part of the specimens 
was pre-washed in Milli-Q water or plasma (Sanquin, Amsterdam, the Netherlands). The 
duration of pre-wash varied between 0 and 72 h. The bacterial exposure time (105, 106 or 
107 CFU/mL in 1.5 mL NaCl 0.9%) varied between 1 and 8 h at 37°C. The inoculum was 
maintained at the same level by replacement of the inoculum each hour and was checked 
before and after each replacement. 
Non-adhered bacteria were removed by vortexing each specimen for 1 s in fresh 1.5 
mL NaCl 0.9% and transferring it to another tube with 1.5 mL NaCl 0.9%, which was kept in 
a shaking incubator at 37°C for 4h. Subsequently, specimens were rolled over Mueller-
Hinton agar plates containing 5% defibrinated sheep blood, according to a roll-plate assay 
described previously.21 After overnight incubation at 37°C, the numbers of CFU per cm2 of 
each roll track (33 cm2) were determined. 
In vitro challenge 
In order to determine which coating provided the best anti-adhesive properties over a 
prolonged period of time, a repeating set-up of the adherence assay was used in which 
exposure to S. aureus ATCC 29213 (105 CFU/mL NaCl 0.9% at 37°C) was alternated with roll-
plate assessment.21 The series was terminated after 25 challenges. 
Statistical analysis 
SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analyses. Independ-
ent t-tests were used to compare bacterial adherence data. A P value of ≤ 0.05 was consid-
ered to be statistically significant. 
 
 
 
 
Figure 1. Scanning electron micrograph of a typical specimen, showed the coiled structure. 
 
Results 
Specimens 
Preparation of the coiled specimens proceeded smoothly; Figure 1 shows a typical exam-
ple. The advantage of this procedure is that numerous identical specimens can be pro-
duced. Reproducibility is an important issue, especially in comparative studies of surface 
coatings. 
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Figures 2A and B show scanning electron micrographs of the silver particles (Ag4E). Note 
that these particles are microparticles rather than nanoparticles, since their smallest di-
mension is appr. 1 μm. Figures 2C – F show light-microscopic images of our wires prior to 
coiling: SS90:10 (C), SS90:10-Hep (D), SS90:10-Ag (E), and SS90:10-Ag-Hep (F). Note the 
alignment of the rod-shaped silver particles at the wire’s surface (E and F). 
 
 
 
  
  
  
 
 
Figure 2. Scanning electron micrographs of the silver particles Ag4E, which were used throughout this work 
(A,B). Light-microscopic images of the coated wires SS90:10 (C), SS90:10-Hep (D), SS90:10-Ag (E), and 
SS90:10-Ag-Hep (F). Note that (i), the wires in C-F were photographed prior to coiling; (ii), the extrusion-like 
coating procedure results in some alignment of the silver particles in the direction of the wire (E,F). 
 
 
A B
C 
E F
D
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Figure 3. Exit site challenge. First signs of ATCC 29213 migration extending along the coating surfaces of 
SS90:10 (A) and SS90:10-Hep (B), observed 24 h after inoculation of the surrounding agar surface at the 
insertion site, respectively. (C) No migration of ATCC 29213 along the coating surface (existing of SS90:10-
Ag-Hep) was observed over 168 h. (D) Growth of inserted bacteria at the surface of SS90:10. (E) Vertical 
movement and/or growth of bacteria directed away from the coating surface (SS90:10-Ag-Hep) through the 
agar, when specimens were inserted after inoculation of the insertion site. 
 
Exit site challenge 
The set-up of this test essentially mimics the situation in which the insertion site on the 
skin is first disinfected, and later becomes invaded by bacteria after cutaneous recoloniza-
tion. For the SS90:10 and SS90:10-Hep coatings, clear bacterial migration along the speci-
mens was observed after 24 h (Figure 3A,B). Growth extended further down the coiled 
wires within 72 h. Coatings SS90:10-Ag and SS90:10-Ag-Hep did not show bacterial migra-
tion under the same conditions, indicating that the silver particles effectively inhibit 
movement and growth of bacteria. Still no bacterial invasion was noticed after 168 h of 
incubation (Figure 3C). Changing the matrix into the less hydrophilic version (SS70:30) 
influenced the outcome of the test. The surfaces SS70:30-Ag and SS70:30-Ag-Hep pre-
vented bacterial migration within 48 h, but some signs of migration were observed after 72 
h. The test was also performed in such a way that the agar surface was first inoculated with 
S. aureus ATCC 29213, as described previously.20 Essentially, this would mimic the situation 
in which the skin surface was not properly disinfected before insertion. 
For all specimens, it was observed that bacteria were transferred with the specimen 
into the agar. Subsequently, bacterial growth occurred in all cases, but there was a clear 
distinction between the reference coatings (SS90:10 and SS90:10-Hep) on one hand, and 
the silver-containing coatings on the other hand. The reference coatings showed bacterial 
growth along their surfaces (Figure 3D), whereas the silver-containing coatings directed 
  A                      B                         C                        D                         E
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bacterial growth more away from the specimens, i.e. perpendicular to their surfaces (Figure 
3E). 
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Figure 4. 
Antibacterial activity of different coating compositions (containing Ag4E silver particles and/or heparin) 
over time against inocula of 106 CFU/mL S. aureus (A) ATCC 29213, (B) BF110 and (C) D107. Error bars 
indicate standard errors (SE). 
 
Bacterial killing 
Figure 4 shows data on survival of bacteria of the S. aureus reference strain ATCC 29213 
(Figure 4A), and the clinical isolates BF110 and D107 (Figure 4B,C) upon incubation with 
the different test coatings, up to 72 h. Figure 4A reveals that SS90:10 and SS90:10-Hep did 
not influence the survival of ATCC 29213. Incorporation of silver (SS90:10-Ag) resulted in 
killing of a substantial portion of the bacteria, such that the number of bacteria dropped 
with 2–3 orders of magnitude. Embedding the same amount of silver in the less hydro-
philic matrix (SS70:30) did not introduce a major difference. Strikingly, introduction of 
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silver and heparin led to almost complete killing of ATCC 29213 within 72 h. This effect was 
independent of the coating’s hydrophilicity (SS90:10 vs. SS70:30). Doubling of the amount 
of silver (in SS70:30-Ag2x-Hep) reduced the viable count similarly. Noteworthy, the com-
mercial Vygon® catheter, which is claimed to have an antibacterial surface22, had no impact 
on the survival of ATCC 29213 within 72 h. 
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Figure 4-S. Antibacterial activity of different coating compositions (containing Ag6V silver particles and/or 
heparin) over time against inocula of 106 CFU/mL S. aureus (A) ATCC 29213, (B) BF110 and (C) D107. Error 
bars indicate standard errors (SE). 
 
 
The experiments with the S. aureus clinical isolates BF110 and D107 led to highly similar 
bacterial time-kill curves. Again, no variation in bacterial counts occurred upon incubation 
with SS90:10 or SS90:10-Hep. Furthermore, combining silver particles and heparin 
(SS90:10-Ag-Hep) substantially improved the bactericidal activities, achieving practically 
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complete kill (99.99%) within 24–48 h. Although eradication of the reference strain seemed 
independent of the amount of embedded silver and the coating hydrophilicity, substantial 
differences were seen regarding the clinical isolates BF110 and D107. Compared to 
SS90:10-Ag-Hep, SS70:30-Ag-Hep reduced the viable count of these isolates more slowly. 
However, whenever a double amount of silver particles was incorporated in the less hy-
drophilic coating (SS70:30-Ag2x-Hep), similar reductions in viable count of BF110 were 
obtained as with SS90:10-Ag-Hep. Moreover, the fastest killing of D107 was observed with 
SS70:30-Ag2x-Hep, which exceeded even the eradication time of SS90:10-Ag-Hep. No bac-
tericidal effect was noticed when testing the Vygon® catheter pieces. 
As shown in Figure 4-S, highly similar antimicrobial effects were realized for the PVP-
stabilized silver particles. Generally, the biocidal effects of PEG-stabilized silver particles 
were slightly stronger than those of their PVP-stabilized counterparts. 
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Figure 5. Adherence of S. aureus ATCC 29213 to different specimens during incubation for 1–8 h in 105 
CFU/mL (A). The same data expressed as normalized effect score (B). Adherence was assessed by roll-plate 
analysis. Asterisks denote statistically significant difference, (*) P < 0.05 and (**) P < 0.01. 
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Figure 6. Adherence of S. aureus ATCC 29213 to different specimens during incubation for 1 h in 106 
CFU/mL after pre-wash of the specimens with milliQ water (MQ) for 12–72 h (A). The same data expressed as 
normalized effect score (B). Adherence was assessed by roll-plate analysis. Asterisks denote statistically 
significant difference, (*) P < 0.05 and (**) P < 0.01. 
 
Bacterial adherence 
Adherence to different specimens was examined after various washing periods and incu-
bation times. Figure 5A shows data on the adherence of ATCC 29213 to different speci-
mens after incubation in a constant inoculum of 105 CFU/mL for 1, 2, 4 or 8 h. The adher-
ence to the SS90:10-coating was influenced by the incubation time; the longer the expo-
sure the more adherence of ATCC 29213 was seen. Considerably more bacteria adhered to 
this coating compared to the other ones, which occurred already from on-set. Initial ad-
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herence was much lower for coatings containing both (Ag4E) silver particles and heparin 
compared to silver particles alone. There was also a difference in initial adherence when 
the hydrophilicity of the coating was taken into account. The more hydrophilic coatings 
SS90:10-Ag and SS90:10-Ag-Hep adhered less bacteria compared to SS70:30-Ag and 
SS70:30-Ag-Hep, respectively. Especially the difference in initial adherence between the 
SS90:10-Ag and SS70:30-Ag coatings is noteworthy. 
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Figure 7. Adherence of S. aureus ATCC 29213 to different specimens during incubation for 1 h in 107 
CFU/mL after pre-wash of the specimens with milliQ water (MQ) for 1–12 h or with human plasma (HP) for 
1–12 h (A). The same data expressed as normalized effect score (B). Adherence was quantified by roll-plate 
analysis. Asterisks denote statistically significant difference, (*) P < 0.05 and (**) P < 0.01. Asterisks between 
brackets denote statistically significant difference of individual conditions versus all other circumstances 
(except SS90:10). 
 
 
However, there was a tendency that the anti-adhesive effects on bacteria of the SS90:10-
silver containing coatings deteriorated more quickly than their counterparts. The quicker 
reduction in anti-adhesive efficacy of the more hydrophilic coatings became more obvious 
when the data was presented as a normalized effect score, whereby the adherence within 
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1 h was set to an arbitrary value of 1.0 (Figure 5B). Although this relative increase was more 
pronounced for the more hydrophilic matrixes, absolute adherence was sustained at a 
slightly lower level for SS90:10-Ag-Hep compared to SS70:30-Ag-Hep. No influence of 
more embedded silver was observed since adherence to SS70:30-Ag-Hep and SS70:30-
Ag2x-Hep was maintained at a similar level. 
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Figure 8. In vitro challenge results of all specimens with Ag4E silver particles. The roll-plate assay was used 
to assess adherence (CFU/cm2) of ATCC 29213 after each challenge, consisting of incubation in 105 CFU/mL 
during 1 h at 37°C and removement of non-adhered bacteria afterwards. Error bars indicate standard errors 
(SE). The detection limit was approximately 80–100 CFU/cm2. 
 
 
Bacterial adhesion to the different matrixes was also assessed after preceding washing 
periods. This essentially mimics the situation whereby a CVC is routinely used for a certain 
period of time and later becomes contaminated with bacteria. As shown in Figure 6A, even 
after 72 h pre-wash, adherence of ATCC 29213 was more pronounced when only silver 
particles (without heparin) were incorporated in the coating. Pre-wash with milliQ water 
seemed to have no effect on the adherence of ATCC 29213 to the less hydrophilic coatings 
SS70:30-Ag and SS70:30-Ag-Hep. On the other hand, the anti-adhesive features of the 
coatings SS90:10–Ag and SS90:10-Ag-Hep declined when pre-wash was extended (Figure 
6B). Remarkably, while the effect of pre-washing was negligible for the coatings having 
SS70:30 as the matrix, SS70:30-Ag2x-Hep displayed a tendency towards more adherence of 
ATCC 29213 when a longer pre-wash program was applied. 
To explore whether fouling a (thin) film of human plasma proteins would influence 
bacterial adherence to the specimens, milliQ water as a washing fluid was replaced by 
drug-free human plasma from healthy volunteer blood donors. It appeared that plasma 
incubated specimens containing heparin in its coating layer, i.e. SS90:10-Hep and SS90:10-
Ag-Hep, displayed increased adherence of ATCC 29213 (Figure 7A,B). Still, adherence with 
SS90:10-Ag-Hep was far below the level achieved with the reference coatings SS90:10 and 
at the same level as the coating containing silver particles alone, SS90:10-Ag. The coatings 
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without heparin, i.e. SS90:10-Ag, lost repulsion activity when pre-washed during 12 h with 
milliQ water in the same order as when plasma was used. Surprisingly, there was a ten-
dency for these specimens that pre-wash in plasma during 12 h resulted in less adherence 
of ATCC 29213 in comparison with 1 h pre-wash in plasma. 
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Figure 8-S. In vitro challenge results of all specimens with Ag6V silver particles. The roll-plate assay was 
used to assess adherence (CFU/cm2) of ATCC 29213 after each challenge, consisting of incubation in 105 
CFU/mL during 1 h at 37°C and removementy of non-adhered bacteria afterwards. Error bars indicate 
standard errors (SE). The detection limit was approximately 80–100 CFU/cm2. 
 
In vitro challenge 
Upon multiple challenges, bacterial adherence to all specimens containing silver particles 
gradually increased over time, but remained relatively low, especially for the ones with 
heparin (Figure 8). In contrast, soon after the first few challenges, roll-plate analysis of 
SS90:10 and SS90:10-Hep displayed a strong rise in the number of adhered bacteria. Al-
ready after 4–5 challenges the limit of detection, i.e. 100 CFU/cm2, was exceeded (Figure 
8A). After eight challenges it was estimated that specimens SS90:10 and SS90:10-Hep 
achieved a maximum of adhered cells of approximately 230 CFU/cm2 (data not shown). 
However, it has to be noticed that during the first four challenges it was clear that speci-
mens containing heparin alone, SS90:10-Hep, demonstrated anti-adhesive properties on 
interaction with ATCC 29213. From the beginning, bacterial adherence to the Vygon® 
catheter segments was excessive compared to all silver-containing specimens. After the 
last challenge, adherence to the Vygon® segments was approximately six times more 
compared to all silver-containing specimens. Whereas SS90:10-Ag and SS90:10-Ag-Hep 
demonstrated low adherence from the on-set, SS70:30-Ag and Vygon® catheter segments 
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showed initially a higher adherence, while its anti-adhesive capacities improved soon 
thereafter (Figure 8B). 
Compared to matrixes with both heparin and silver particles in them, adherence to sil-
ver-containing specimens remained slightly higher over multiple challenges. This observa-
tion was independent of the coating’s hydrophilicity. The less hydrophilic coating with the 
double amount of silver particles, SS70:30-Ag2x-Hep, displayed more decline in its anti-
adhesive capacities than the one with the reference content, SS70:30-Ag-Hep. 
 
Discussion 
 
Our experimental data confirm that embedding of silver particles in hydrophilic surface 
coatings is a feasible strategy toward biocidal surfaces for medical devices such as cathe-
ters23. The experiments on bacterial killing and adhesion showed strong synergistic effects, 
if silver particles and heparin were co-embedded in the coating. This is the key message of 
this work. The effect was found with three different S. aureus strains: a reference strain 
(ATCC 29213) and two clinical isolates. 
The observed more-than-additive effect of silver particles and heparin on bacterial kill-
ing and adhesion clearly asks for an explanation. First, it is important to consider the 
mechanistic background of the antimicrobial activity of surfaces containing silver. It is well-
known that silver particles expose Ag+ ions at their periphery24. Furthermore, it is essential 
to realize that all our media contained chloride ions, and that the solubility of AgCl in aque-
ous media is extremely low. Hence, dissolution of Ag+ ions from the silver particles does –
most probably– not play a major role in the observed biocidal effects. In our earlier work 
(see chapter 4), we have corroborated this through a series of titration experiments, using 
the soluble silver salt AgNO3. We found that dissolved Ag+ ions only start to become bio-
cidal if their concentration exceeds 100 nM25. We hypothesized, therefore, that antimicro-
bial effects of our silver-containing surfaces can be attributed to collisions of bacteria with 
the surface. During such a collision, transfer of Ag+ ions can occur from the silver particles 
surface to the bacterium’s membrane, e.g. by binding to negatively charged phospatidyl 
serine moieties. These membrane-bound Ag+ ions can subsequently induce rupture of the 
bacterial wall, eventually killing the bacterium. In essence, this mechanism is heterogene-
ous, as the critical step is collision between suspended bacteria and a solid surface that 
exposes Ag+ ions at its surface. 
The question now is how this mechanism will change if heparin is introduced in the 
surface coating, next to the silver particles. Clearly, collisions and transfer of Ag+ ions as 
described above can still occur. But in addition, there is release of heparin molecules from 
the coating’s surface occurring, especially if the matrix is hydrophilic26. Heparin molecules, 
escaping from the coating can drag silver ions with them; affinity of heparin for monova-
lent cations is well documented27. So, in essence there is now a second mechanism by 
which Ag+ ions can reach the bacterium, based on dissolved heparin molecules working as 
a carrier for Ag+ ions. This second mechanism is homogeneous, and heparin/Ag+ complexes 
could bind to the outer surface of bacteria, or be internalized. 
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The present experimental data can not be used to prove our hypothesis right or wrong, 
but it is obvious that most of our observations are in line with it. Bacterial killing with the 
coatings SS90:10-Ag-Hep, SS70:30-Ag-Hep and SS70:30-Ag2x-Hep against inocula of S. 
aureus was much stronger, in comparison with counterpart coatings that contained only 
silver particles or heparin (Figure 4). Analogously, adherence of S. aureus ATCC 29213 was 
much lower for the coatings containing both silver particles and heparin (Figure 5); pre-
washing with MQ water or with human blood plasma did not change this picture (Figures. 
6, 7). The in vitro challenge tests also pointed out that the coatings SS90:10-Ag-Hep, 
SS70:30-Ag-Hep and SS70:30-Ag2x-Hep outperformed their counterparts containing either 
silver particles or heparin. Interestingly, the adherence tests allowed us to compare the 
long term effects between SS90:10-Ag-Hep and SS70:30-Ag-Hep coatings (up to 72 h pre-
wash). These coatings differ only regarding the hydrophilicity of the matrix. The less hy-
drophilic material SS70:30 is expected to have slower release of embedded heparin (and 
consequently augmented co-transport of silver particles), and –hence– a more sustained 
antimicrobial effect. This is exactly what is seen in Figure 6. 
 
Conclusions 
 
In summary, we found that embedding of silver particles in SlipSkin (NVP/BMA) hydrophilic 
surface coatings leads to pronounced antimicrobial effects in experiments with three 
strains of S. aureus (one reference strain and two clinical isolates). Heparin potentiates the 
biocidal activity of the silver particles. A tentative explanation for this effect of heparin is 
based on two premises: (i) the observed biocidal effects of silver per se relate to a collision 
mechanism, and (ii) silver ions are transported by heparin molecules that are released from 
the coating’s surface. This works shows for the first time that it is possible to design surface 
coatings with strong antimicrobial and antithrombogenic features. Most probably, rational 
design of such coatings becomes possible if the mechanistic details are explored further. 
We expect that this work will open a new route to safer (percutaneous) blood-contacting 
medical devices such as CVCs, which have become indispensable in the treatment of criti-
cally ill patients. 
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Large-scale evaluation of mutations in norA gene and its 
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Introduction 
 
To date, at least seven genes have been described in the chromosome of Staphylococcus 
aureus which encode multidrug efflux pumps (EPs): i.e. mdeA, mepA, norA, norB, norC, sdrM 
and sepA1, 2, 3, 4, 5, 6. In addition, many other efflux pumps located on plasmids have been 
described as well, such as qacA/B, qacC, qacD and qacG7, 8, 9. NorA has been one of the most 
well described EPs in S. aureus. Studies have shown that NorA is a protein containing 
twelve transmembrane segments, that uses proton motive force to export diverse drugs 
such as ethidium bromide, quaternary ammonium compounds and hydrophilic fluoroqui-
nolones such as norfloxacin and ciprofloxacin3, 10, 11, 12. Mutations in the promoter and the 
norA gene itself as well as mutations in mgrA, encoding a regulatory gene, are known to 
affect the expression of norA11, 13. An increase in expression is linked to an increased resis-
tance to its substrates such as ciprofloxacin3. NorA-related fluoroquinolone resistance is 
however low as compared to resistance caused by mutations in topoisomerase or gyrase 
genes, but there is evidence suggesting that norA mediated low-level resistance predis-
poses to development of high-level resistance14. 
Several studies have been published describing different mutations which were asso-
ciated with an increased expression of norA. Noguchi et al. published an overview of se-
quences of norA and its promoter of 20 strains, including five reference strains11. The au-
thors discerned three main alleles: norA wt, norA1199 and norAII3, 15. Most publications 
however, only investigated a limited number of strains, often providing even more limited 
or no gene expression data and to our knowledge, no studies have been performed look-
ing at the link between the sequence of norA (and linked to that, overexpression of norA) 
and the genetic background of S. aureus. The goal of this study was to investigate a large 
group of S. aureus isolates, with different genetic backgrounds, both methicillin suscepti-
ble S. aureus (MSSA) and methicillin resistant S. aureus (MRSA), with respect to sequence 
and expression of norA. 
 
Materials and Methods 
Bacterial strains 
The S. aureus strains (72 MRSA and 156 MSSA) investigated were isolated during 2005 to 
2008 in the Maastricht University Medical Center, a tertiary 715-bed hospital, and originate 
from surveillance cultures (commensal flora) from individual patients, recovered from nasal 
swabs16. MRSA and/or MSSA strains associated with MLST CC1, CC5, CC8, CC22, CC30, 
CC45, CC7, CC12, CC15, CC25 and CC121, were randomly selected from our institutional 
collection. All MRSA strains were tested positive for the MRSA-specific mecA gene, by real-
time PCR17. Antibiotic susceptibility data for an extensive panel of antibiotics including a.o. 
methicillin, oxacillin, ciprofloxacin, moxifloxacin, gentamicin, clindamycin, linezolid and 
vancomycin for the different strains was obtained by routine broth micro dilution suscep-
tibility testing, according to CLSI guidelines. 
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Table 1. Primers used for sequencing of (promoter) norA, grlA and gyrA. 
 
Primer Sequence Tm (°C) 
   
NorAF4 GTCCGCTAAAAGTTTCATATGATTG 63 
NorAF2 CAAATGTAGCAATGTTGTGAATAC 55 
NorAF3 TTCACCAAGCCATCAAAAGC 53 
NorAR2 TGGCATACGATGTGAAACTTC 55 
NorAR3 TTGCAATTCATGCTAAATATCC 51 
NorAR4 TTAATGAATTAGGTATGTGGATTGC 61 
   
NorA LongF AGCGAGATGTCCGCTAAAAG 55 
NorA LongR TAACGCACCTGCGATTAAAG 53 
   
GyrF TCGTGCATTGCCAGATGTTCG 59 
GyrR TCGAGCAGGTAAGACTGACGG 61 
   
GrlF TGCCAGATGTTCGTTCGTGATGGT 67 
GrlR TCGAGCAGGTAAGACTGACGG 61 
   
Characterization of the genetic background 
Typing of the spa locus was carried out as described previously18. The spa types were as-
signed through the Ridom SpaServer http://spaserver.ridom.de and clustered into spa-CCs 
using the algorithm based upon repeat pattern (BURP) with Ridom StaphType 1.4 using 
the default settings19, 20. Although, spa typing alone sometimes lacks discriminatory power, 
due to related spa repeat patterns within different clonal lineages and the emergence of 
homoplasies among spa sequences21, it has been shown that spa typing/BURP results are 
often in agreement with results obtained by MLST20, 22. Therefore, the associated MLST CCs 
were allocated through the SpaServer. To confirm the association between MLST and spa 
typing, in combination with BURP, MLST was performed on a representative set of 16 
strains of each major spa type and associated MLST CC23, 24. 
norA, grlA and gyrA sequencing 
For norA sequencing purposes, a number of PCRs were implemented. A dedicated PCR 
developed by Couto et al., was used for sequencing of the norA promoter and the start of 
the norA coding region25. A PCR amplifying a 1500bp amplicon covering most of the pro-
moter and the norA gene was developed as part of this study. Within this amplicon, addi-
tional primers were developed for sequencing of internal regions (Table 1). 
Briefly, the procedure was comprised of suspension of one colony picked from a blood 
agar plate in 100 μL of ultrapure water. Of this 1 μL was added to the PCR mixture. This 
mixture contained 0.4 μM of each primer, 0.2 units HotStarTaq Plus DNA polymerase (Qia-
gen, Venlo, the Netherlands) 1× accompanying reaction buffer and 100 μM of each dNTP. 
The PCR protocol consisted of an initial denaturation step of 5 min. at 95°C, followed by 40 
cycles of 30sec. at 95°C, 30sec. at 50°C and 2 min. at 72°C. After PCR, amplicons were puri-
fied using PCRapace spin columns (Invitek GmbH, Berlin, Germany). Subsequently se-
quence reactions were performed using 0.1 μM of each primer, 1 μL of 1.1 BigDye Termina-
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tor reaction mix (Applied Biosystems, Carlsbad, CA, USA), 1.5 μL accompanying sequencing 
buffer and 1 μL of purified amplicon (in a final volume of 10 μL). Readout of the sequences 
was performed on a 3730 DNA sequencer (Applied Biosystems). 
Ultimately, the different norA promoter sequences were aligned and compared to the 
three previously described norA alleles: norA wt33, norA119914 and norAII21. Afterwards, the 
different sequences were grouped, with each group carrying an identical norA promoter, 
and named after the most resembling allele. 
 
Table 2. Overview of 24 strains which have been further investigated regarding norA expression of different 
promotor sequence groups and mutations in gyrase and topoisomerase. 
 
S. 
aureus 
strain 
Relative 
norA 
expression
CC 
Sequence 
norA 
promotor 
norA promoter – 
10 region 
MIC 
cipro 
(mg/L) 
(CLSI) 
Topo-
isomerase 
(GrlA    
codon 80) 
Topo-
isomerase 
(GrlA    
codon 84) 
DNA gyrase 
(GyrA   
codon 84) 
DNA gyrase 
(GyrA   
codon 88) 
          
3 1 5 A (WT) ataCAATata 0.25 TCC(Ser) GAA (Glu) TCA (ser) GAA (Glu) 
137 0.5 5 A (WT) ataCAATata 0.25 TCC(Ser) GAA (Glu) TCA (ser) GAA (Glu) 
140 0.9 5 A (WT) ataCAATata 0.25 TCC(Ser) GAA (Glu) TCA (ser) GAA (Glu) 
29 11.8 5 B ataCAATataG(Δ11bp) 16 TTC (Phe) GAA (Glu) GCA (Glu) GAA (Glu) 
11 1.5 22 C ataCAATata 0.25 TCC(Ser) GAA (Glu) TCA (ser) GAA (Glu) 
55 1.7 22 C ataCAATata 0.25 TCC(Ser) GAA (Glu) TCA (ser) GAA (Glu) 
135 14.6 5 D ataCAAT(CAAT)ata 256 TAC (Tyr) GGA (Gly) TTA (Leu) AAA (Lys) 
139 32.1 5 D ataCAAT(CAAT)ata 256 TAC (Tyr) GGA (Gly) TTA (Leu) AAA (Lys) 
82 2.2 8 F ataCAATata 128 TTC (Phe) AAA (Lys) GTA (Val) GAA (Glu) 
69 1.9 45 I ataCAATata 0.25 TCC(Ser) GAA (Glu) TCA (ser) GAA (Glu) 
108 3.0 8 I ataCAATata 0.25 TCC(Ser) GAA (Glu) TCA (ser) GAA (Glu) 
95 5.0 45 K ataCAATataGAAG 256 TTC (Phe) GAA (Glu) TTA (Leu) GAA (Glu) 
100 37.6 45 K ataCAATataGAAG 256 TTC (Phe) GAA (Glu) TTA (Leu) GAA (Glu) 
101 46.0 45 K ataCAATataGAAG 256 TTC (Phe) GAA (Glu) TTA (Leu) GAA (Glu) 
102 23.6 45 L ataCAATataGAAG 512 TTC (Phe) GAA (Glu) TTA (Leu) GAA (Glu) 
16 43.0 30 N ataCAAT(ATCAAT)ata 128 TTC (Phe) GAA (Glu) TTA (Leu) GAA (Glu) 
17 56.1 30 N ataCAAT(ATCAAT)ata 128 TTC (Phe) GAA (Glu) TTA (Leu) GAA (Glu) 
90 81.2 30 N ataCAAT(ATCAAT)ata 128 TTC (Phe) GAA (Glu) TTA (Leu) GAA (Glu) 
158 2.4 30 O ataCAATata 0.25 TCC(Ser) GAA (Glu) TCA (ser) GAA (Glu) 
160 2.2 30 O ataCAATata 0.5 TCC(Ser) GAA (Glu) TCA (ser) GAA (Glu) 
179 13.5 30 P ataCAATata 0.5 TCC(Ser) GAA (Glu) TCA (ser) GAA (Glu) 
207 1.1 121 Q ataCAATata 0.25 TCC(Ser) GAA (Glu) TCA (ser) GAA (Glu) 
212 2.2 121 Q ataCAATata 0.25 TCC(Ser) GAA (Glu) TCA (ser) GAA (Glu) 
209 1.3 121 R ataCAATataGAAG 0.5 TCC(Ser) GAA (Glu) TCA (ser) GAA (Glu) 
          
norA expression studies 
Saturated overnight cultures of S. aureus strains (n=24) were diluted 1:20 in Mueller-Hinton 
(MH) and incubated for 1 hour at 37°C with constant shaking. 100 μL culture of each sam-
ple was pelleted (in triplicate) by centrifugation, the pellet was resuspended in 40 μL of cell 
suspension buffer (50 mM Tris, 50 mM EDTA; pH 8), 2 μL of RNase-inhibitor (Applied Biosys-
tems) and 10 μL lysosthaphin solution (1 mg/mL) (Sigma) were added, mixed and incu-
bated at 37°C until visible lysis of the cells (typically 5–10 min.) occurred. The lysate was 
extracted twice with phenol/CHCl3 (1:1) and once with CHCl3. Nucleic acids were ethanol 
precipitated, air-dried dissolved in DEPC treated water. Genomic DNA was removed by 
incubating the sample with 1–2 units of DNaseI (Fermentas GmbH) for 30 min. After DNase 
I digestion, the sample was extracted with phenol/CHCl3, precipitated and dissolved in 50 
μL DEPC treated water. 
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Quantitative RT-PCR was performed using the Bio-Rad iScriptTM One-Step RT-PCR kit 
according to the supplier’s instruction with primers NorAF3 and NorAR2 (Table 1) and 
primers for 16S rDNA, which was used as a housekeeping reference gene25. In summary, 
the template was diluted 1:100 for norA detection and 1:10000 for the endogenous control 
(16S rDNA). Amplification conditions were as follow: cDNA was synthesised at 42°C for 20 
min. After a denaturing step at 95°C for 5 min., DNA was amplified in 42 cycles (95°C for 30 
sec.; 50°C for 30 sec.; 72°C for 30 sec.) followed by a melting curve analysis (MyiQTM Single-
Color Real-Time detection system, Bio-rad). Negative controls and controls for genomic 
DNA contamination were included. Quantification (comparative Ct method26) was per-
formed using strain 3 as a reference strain (wild type for norA, grlA and gyrA genes). 
 
Results 
norA expression of different norA promotor sequence groups 
After sequencing of the norA promoter of 228 S. aureus isolates, the promoter sequences 
were aligned and 18 sequence groups, named A-R, could be differentiated (Figure 1, Table 
2). Each group consisted of strains with identical sequences; i.e. when a point mutation was 
found, a new sequence group was designated. The sequences were compared to three 
reference sequences of the three known norA alleles as described by Noguchi et al.11. The 
results show that sequence groups resembling all three known alleles were present in our 
collection. From the different promotor sequence groups A-R, 21 strains were selected for 
further investigation (Table 2). The selection of these strains was based on two points: i) 
from each sequence group consisting of > two strains, two strains were investigated, and 
ii) from each group containing mutations within the region -15 to +7, at least one strain 
was investigated. From each of the 21 strains, the expression of norA was monitored. Simi-
lar to earlier studies, a change of expression of ≥ 4-fold was considered to be a significant 
change27. Table 2 shows that representatives from six groups (B, D, K, L and N and P) dem-
onstrated an increased expression of norA up to maximally ~80-fold. Representatives from 
all other groups showed an expression similar to a randomly chosen reference wt strain 
(i.e. strain 3). Interestingly, norA overexpression was seen within each of the three norA 
alleles (Figure 2). 
For further analysis, all samples in each sequence group were assumed to have a simi-
lar expression profile. This assumption was tested by random choice of three more repre-
sentative strains of respectively group A, K and N (in italics in Table 2). The norA expression 
of these strains confirmed our previous findings. 
As high-level resistance to fluoroquinolones is traditionally a result of mutations in gyrase 
and topoisomerase, mutations in gyrA and grlA were monitored as part of this study. The 
results revealed that 22 of the 23 strains which were further investigated and representing 
groups B, D, K, L and N also showed mutations in these genes which are known to lead to 
resistance to fluoroquinolones (Table 2). Only the single strain representing group P 
showed mutations in group norA and no mutations in grlA and gyrA. 
 
Chapter 6 
 98 
A TTCTCCTTTTTCCAACACTAGTAGTATAGTATGATTACTTTTTTGCAATTTCATATGATC 
B ------------------------------------------------------------ 
C ---G--------T----------------------------------------------- 
D --------------*--------------------------------------------- 
E --------------*--------------------------------------------- 
F --------------*--------------------------------------------- 
G --------------*--------------------------------------------- 
H ---G--------T-*--------------------------------------------- 
I ---G--------T----------------------------------------------- 
J ---G--------T----------------------------------------------- 
K ---G--------T----------------------------------------------- 
L ---G--------T----------------------------------------------- 
M ---G--------T-*--------------------------------------------- 
N ------------T----------------------------------------------- 
O ------------T----------------------------------------------- 
P ------------T----------------------------------------------- 
Q ------------T----------------------------------------------- 
R ------------T----------------------------------------------- 
 
A AATCCCCTTTATTTTAATATGTCATTAATTATACAATTAAA-TGGAAAATAGTGATAATT 
B ------------------------------------------------------------ 
C ------------------------------------------------------------ 
D ------------------------------------------------------------ 
E -----------C------------------------------------------------ 
F ------------------------------------------------------------ 
G -----------------------------------------A------------------ 
H ------------------------------------------------------------ 
I ------------------------------------------------------------ 
J ------------------------------------------------------------ 
K ------------------------------------------------------------ 
L ------------------------------------------------------------ 
M ------------------------------------------------------------ 
N ------------------------------------------------------------ 
O ------------------------------------------------------------ 
P ------------------------------------------------------------ 
Q ------------------------------------------------------------ 
R ------------------------------------------------------------ 
 
                     -35                -10     ↓ 
A ACAAAGAAAAAA-TATTGTCAAATGTAGCAATGTTGTAATACAA------TATAGAAACT 
B -------------------------------------------------------***** 
C ------------------------------------------------------------ 
D --------------------------------------------TCAA------------ 
E ------------------------------------------------------------ 
F ------------------------------------------------------------ 
G ------------------------------------------------------------ 
H ------------------------------------------------------------ 
I --------------------------------A--------------------------- 
J --------------------------------A--------------------------- 
K --------------------------------A------------------------G-- 
L --------------------------------A--------T---------------G-- 
M --------------------------------A--------------------------- 
N ------------A-------------------------------TATCAA---------- 
O ------------A----------------------------------------------- 
P ------------A------------------------G---------------------- 
Q ------------A---------T---------A--------------------------- 
R ------------A---------T---------A------------------------G-- 
 
Figure 1: to be continued on the next page 
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A TTTTACGAATATTTAGCATGAATTGCAATCTGTCGTGGAAAAGAAGAATAACAGCTTTAA 
B ******------------------------------------------------------ 
C ------------------------------------------------------------ 
D ------------------------------------------------------------ 
E ------------------------------------------------------------ 
F A----------------------------------------------------------- 
G ------------------------------------------------------------ 
H ------------------------------------------------------------ 
I ---------------------------------------------A-----------G-- 
J ---------------------------------------------A-----------G-- 
K ---------------------------------------------A-----------G-- 
L ---------------------------------------------A-----------G-- 
M ---------------------------------------------A-----------G-- 
N -----------------------------T------------------------A----- 
O -----------------------------T------------------------A----- 
P -----------------------------T------------------------A----- 
Q ---------------------------------------------A-------------- 
R ---------------------------------------------A-------------- 
 
    Start 
A GCATGACATGGAGAAAAAA-GAGGTGAGCATATGAATAAACAGATTTTTGTCTTATATTTT 
B ------------------------------------------------------------- 
C ------------------------------------------------------------- 
D ------------------------------------------------------------- 
E ------------------------------------------------------------- 
F ------------------------------------------------------------- 
G ------------------------------------------------------------- 
H ------------------------------------------------------------- 
I -AG-----A-T-------------------A-----------------G--A--------- 
J -AG-----A-T-------------------A-----------------G--A--------- 
K -AG-----A-T-------------------A-----------------G--A--------- 
L -AG-----A-T-------------------A-----------------G--A--------- 
M -AG-----A-T-------------------A-----------------G--A--------- 
N -A----------------------------------------------------------- 
O -A----------------------------------------------------------- 
P -A-----*----------------------------------------------------- 
Q -AG-----A-T-------------------A-----------------G--T--------- 
R -AG-----A-T-------------------A-----------------G--T--------- 
 
A AATATTTTCTTGATTTTTTTAGGTATCGGTTTAGTAATACCAGTCTTGCCTGTTTATTTA 
B ------------------------------------------------------------ 
C ------------------------------------------------------------ 
D ------------------------------------------------------------ 
E ------------------------------------------------------------ 
F ------------------------------------------------------------ 
G ------------------------------------------------------------ 
H ------------------------------------------------------------ 
I -----------A------------------C----G-----------A------------ 
J -----------A-----------A------C----G-----------A------------ 
K -----------A------------------C----G-----------A------------ 
L -----------A------------------C----G-----------A------------ 
M -----------A------------------C----G-----------A------------ 
N ------------------------------------------------------------ 
O ------------------------------------------------------------ 
P ------------------------------------------------------------ 
Q -----------A--A---------------C----G-----------A------------ 
R -----------A--A---------------C----G-----------A------------ 
 
Figure 1: to be continued on the next page 
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A AAAGATTTGGGATTAACTGGTAGTGATTTAGGGTTACTTG 
B ---------------------------------------- 
C ---------------------------------------- 
D ---------------------------------------- 
E ---------------------------------------- 
F ---------------------------------------- 
G ---------------------------------------- 
H ---------------------------------------- 
I -----------G---------------------------- 
J -----------G---------------------------- 
K -----------G---------------------------- 
L -----------G---------------------------- 
M -----------G---------------------------- 
N ---------------------------------------- 
O ---------------------------------------- 
P ---------------------------------------- 
Q -----------G---------------------------- 
R -----------G---------------------------- 
 
 
Figure 1. Alignment of part of norA and its promoter. 18 different groups can be distinguished (A-R; norA 
overexpressing types as in bold and underlined). The -35 and -10 regions are marked and underlined. The 
transcription initiation site is marked with an arrow. 
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Figure 2. Distribution of the norA overexpressing S. aureus strains per norA allele. 
 
Antibiotic susceptibility and norA overexpression 
Of all 228 strains, resistance to the fluoroquinolones ciprofloxacin and moxifloxacin as well 
as to methicillin was investigated in relation to overexpression of norA. The results showed 
that there was a 95% correlation between strains in the norA overexpressing sequence 
groups (B, D, K, L, N and P) (n=20) also showing resistance to methicillin and ciprofloxacin. 
Only strain 179 in sequence group P was susceptible to both methicillin and ciprofloxacin. 
Regarding moxifloxacin, three overexpression strains were still susceptible to moxifloxacin, 
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but the other 84% was shown to be resistant to this antibiotic. For other antibiotics (such 
as vancomycin, gentamycin, clindamycin, linezolid, imipenem and rifampicin) no correla-
tion with norA overexpression was found (data not shown). 
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Figure 3. (A) Distribution of the different MLST associated clonal complexes (CCs) per norA allele of the 
different examined S. aureus isolates. (B) The distribution of norA overexpressing strains per associated 
MLST-CC. 
 
norA sequence and genetic background 
All strains were spa-typed after which associated MLST clonal complexes (CC’s) were de-
termined. Figure 3A shows the distribution of the different norA alleles within the different 
clonal lineages. Results show that with a maximum exception of one strain, the different 
CC’s all contain only 1 norA allele. Figure 3B shows the distribution of the norA overex-
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pressing strains over the different CC’s. From the results, it is clear that norA overexpressing 
strains are only found in MLST associated CC’s 5, 30 and 45. Specifically, these strains had 
spa-types t002 and t311 (CC5), t012 and t2854 (CC30) and t038 and t740 (CC45). 
 
Discussion 
 
Initial studies have shown that overexpression of the chromosomally encoded efflux pump 
NorA leads to resistance to a.o. fluoroquinolones, ethidium bromide and various biocides3. 
In several studies mutations in the norA gene and its promoter were presented, which are 
suspected to lead to overexpression of norA11, 25, 28, 29, 30. However, most studies describe 
incidental findings of these mutations, with often a limited number of investigated strains 
or isolates. In this study we investigated a collection of 228 S. aureus strains, for mutations 
in the promoter of norA. Results showed that all three described alleles of norA were found 
within our collection. Notably, the norA allele was strongly correlated with the genetic 
background of S. aureus: i.e. all MLST associated CC30 strains except one contained a norAII 
allele, whereas CC45 and CC121 had the norA1199 allele. All other CC’s within the collec-
tion (CC1, 5, 7, 8, 12, 15, 22 and 25), except one exception in CC5, all contained the wt norA 
allele. To our knowledge, the norA allele has not been linked to the genetic background of 
S. aureus before. However, for example reference strain JCM2413 which was analysed by 
Noguchi et al. and shown to contain norAII, belongs to CC30, which is in agreement with 
our findings11. 
Looking at the norA sequences in more detail, we showed that within our collection, 16 
different sequences could be distinguished. These sequences contained several previously 
described mutations, such as the T388→A mutation30 and the insertions downstream of 
the -10 region in groups D and N31, but also new mutations such as the A→G mutation at 
the site of the start of transcription. Notably, the previously reported flqB mutation was not 
found in any of the 228 strains28, 32, 33. In spite of the respectable number of studies report-
ing data regarding the sequence of norA and its promoter, only few studies combine this 
with data on the actual expression of the norA gene. In our study, we showed that strains 
with six norA sequence types demonstrated an increased expression of norA up to maxi-
mally ~80-fold. Both sequence types D and N showed an insert immediately downstream 
of the -10 region. Our overexpression data (between 15 and 80-fold) for those groups were 
in agreement with those previously reported by DeMarco et al. (4.8–50.6 fold) for strains 
with AAT or CAAT insertions downstream of the -10 region27 and by Kosmidis et al. with an 
~19-fold increase of expression for strains with an ATCAAT insertion at the same locus31. 
Our expression data were however markedly higher than for example the 4–5-fold increase 
in expression measured for strain TS69 with an TACAAT insert downstream of the -10 re-
gion11. This is likely due to the difference in technique used for gene expression measure-
ments, but could also be contributed to growth conditions at the time of expression 
measurements. As recommended by Kaatz et al., we performed our experiments at mid-
exponential phase34. Sequence types K and L also showed norA overexpression (on aver-
age ~30-fold). Interestingly, the difference between for example group I, which expresses 
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norA at a wt level, and K is only one bp in the entire investigated area: i.e. A→G mutation at 
the site of the start of transcription. However, as the strain in group R contained this muta-
tion and expressed norA at a wt level, future studies will have to reveal what the exact 
impact of this mutation on norA expression is. norA expression is known to be also regu-
lated by mgrA and norG13, 32, 35. Finally, group P (consisting of only one strain) showed an 
increased norA expression of around 13-fold. This strain was very similar to strains in group 
O, however the strain in group P contained a.o. a A→G mutation 2 bp upstream of the -10 
region. To our knowledge this mutation has not been described before and similar to the 
mutation at the transcription start site, future studies will have to determine the impact of 
this mutation on the norA expression. 
Our study clearly showed that overexpression of norA was associated with sequence 
types of all three known norA alleles. But, the overexpressing strains were limited to a few 
clonal lineages, and within the MLST associated clonal complexes to a few spa-types (spa-
types between brackets): i.e. 5 (t002 and t311), 30 (t012 and t2854) and 45 (t038 and t740). 
These MLST associated clonal complexes are known to be associated with methicillin resis-
tant S. aureus (MRSA)36, and coincidentally, all the overexpressing strains, except for strain 
179 in group P, found in our study were found to be resistant to methicillin. This is mostly 
in agreement with earlier results from DeMarco et al., showing that the majority of the 
clinical isolates with efflux-related resistance in that study were MRSAs37. A potential limita-
tion of our study was that all strains were collected in one geographical region/center 
(although spread over a period of three years) and thus a relatively large homogeneity 
between the strains in a clonal complex can be expected. Future studies will have to in-
clude strains collected from a larger geographical area. 
NorA has long been associated with low-level resistance to hydrophilic fluoroqui-
nolones3. In addition, high-level resistance to fluoroquinolones is caused by mutations in 
the genes encoding gyrase and topoisomerase (reviewed in37) and it has been suggested 
that low-level norA-mediated resistance predisposes to high-level resistance14. In our 
study, all but one strain (strain 179, group P) overexpressing norA showed high-level resis-
tance but also contained known mutations in the genes encoding gyrase and topoisom-
erase leading to this high-level expression. Strain 179 was the only norA overexpressing 
strain that was not resistant to fluoroquinoles with a ciprofloxacin MIC of 0.5 mg/L. How-
ever, previous studies demonstrated that strains overexpressing norA showed an increase 
in substrate MICs (amongst which fluoroquinolones) between 2 and 16-fold25, 38. As from 
our data it cannot be excluded that the ciprofloxacin MIC of strain 179 has been raised 
slightly, more work will have to be performed to further clarify the impact of norA overex-
pression on fluoroquinolone MIC. Consequently, future work will also have to confirm 
expression data on a protein level. 
In conclusion, our study has for the first time indicated that there seems to be a rela-
tion between the genetic background of S. aureus and the norA allele. Analysing 228 
MSSA/MRSA strains from different genetic backgrounds revealed 16 different norA se-
quence types related to all three known norA alleles. Within the three norA alleles, six se-
quence types were associated with norA overexpression. Within the norA overexpressing 
strains, several novel mutations were found, especially in the -10 promoter region. These 
norA overexpressing strains were in this study in 95% found in MRSA strains from distinct 
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genetic backgrounds. All but one of the overexpressing strains were resistant to the 
fluoroquinolone ciprofloxacin, but all of these strains also contained mutations in genes 
encoding gyrase and topoisomerase, which are known to lead to fluoroquinolone resis-
tance. Understanding the relationship between the genetic background of S. aureus, norA 
evolution, its overexpression and its contribution to resistance to its substrates such as 
hydrophilic fluoroquinolones, will ultimately contribute to the control of the emergence of 
antimicrobial resistant strains. 
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Abstract 
 
Biofilm-embedded bacteria are often causative for persistent infections. Recently, inhibi-
tion of efflux pumps was considered as a manner to influence biomass formation of 
Staphylococcus aureus. The impact of efflux pump inhibitors (EPIs) was more pronounced 
to prevent biofilm formation than to reduce pre-existing mature biomass. The ineffective-
ness of EPIs against the latter might be due to a penetration barrier of EPIs into the biofilm 
layers. 
We exposed different clonal lineages to EPIs in the presence of 0.1% or 1% glucose to 
determine the effect on mature biofilm and biomass prevention. Our data confirm that at 
0.1% glucose the EPI thioridazine effectively prevented biomass formation of strains par-
ticularly associated with multilocus sequence typing (MLST) clonal complex (CC)8, while at 
1% glucose comparable results were obtained with strains associated with MLST CC30 and 
CC45. Reserpine was inferior to thioridazine in prevention of biomass accumulation. Re-
markably, MLST CC8-associated strains elevated biomass production upon exposure to 
both EPIs at 1% glucose. We presume that EPIs have a non-specific affinity for a variety of 
transporters, including nutrient-importers. Blocking these importers at 0.1% glucose would 
result in suppression of biomass formation, especially among strains with a high carbohy-
drate uptake capacity. Conversion of abundantly imported amounts of carbohydrates, at 
1% glucose, to acetate, would theoretically result in intracellular acidification. Concerning 
strains associated with MLST CC8 we hypothesized that blocking the efflux of acidic me-
tabolites promotes – instead of prevents – biomass formation, while influx of glucose is not 
much affected. 
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Introduction 
 
The native functions of trans-membrane transporters, such as efflux pumps, of bacteria like 
Staphylococcus aureus have not been fully unravelled yet. For multi drug resistance (MDR) 
pumps, extrusion of excessive amounts of (toxic) substances as part of intracellular waste 
management, is probably the most likely one1, 2. These substances are often acidic by-
products, originated from decomposition of metabolic pathways3, 4. Another function 
includes the protection against toxic substances from the environment, which were in-
fluxed or diffused across the permeable cell wall. Besides the efflux mechanisms, trans-
membrane transporters are also necessary to facilitate import of essential nutrients as 
glucose and amino acids3, 5, 6 or to maintain electrolyte and pH homeostasis 2–4, 7. 
The expression of various trans-membrane transporters is positively (AbcA) or nega-
tively (NorA, NorC and Tet38) regulated by the multiple gene regulator (mgrA)8–11, except 
that of the NorB efflux pump, which is repressed by phosphorylated mgrA11. Besides, mgrA 
is involved in the repression of biofilm formation12. On one hand, this is the resultant of 
mgrA-induced upregulation of the accessory gene regulator (agr)12, consequently ending 
up in (i) hindering microbial surface components recognizing adhesive matrix molecules 
(MSCRAMM) expression and (ii) improving the release of detachment factors or surfactant-
like molecules such as phenol-soluble modulins (PSM) and hla-encoded α-toxin (α-
hemolysin)13. On the other hand, mgrA inhibits cidA-related cell lysis triggered extracellular 
DNA (eDNA) release and stimulates the repression of autolysis by lrgAB12. 
From several points of view it has been postulated that efflux pumps are up-regulated 
during the transition from planktonic cells into sessile encapsulated ones1, 14. First, the 
principle behind the well-known (remaining) recalcitrance of biofilm to normal concentra-
tion of antibiotics might be partly attributed to enhanced extrusion mechanisms1, 15. Sec-
ond, due to the cramped conditions in a biofilm, cells inside a biofilm need to exploit an 
efficient efflux system for endogenous waste products2. Third, cell autolysis and thus eDNA 
release is affected by AbcA transporters16. Another ATP-binding cassette (ABC) transporter, 
the graRS-regulated vraFG efflux pump, is required for citrate-stimulated cell-to-cell inter-
actions17. Finally, involvement of transporters in quorum sensing related extrusion of sig-
nalling molecules, also referred as autoinducers, has also been mentioned2, 15, 18. 
Although efflux pumps might play a vital role during biofilm development, their sug-
gested overexpression does not fit with the mgrA repressor function of biomass formation 
and the opposite regulation on different efflux pumps, depending on the phosphorylation 
state of mgrA. Presumably, other regulators, such as arlRS, sigB, rsbU, graRS and norG, con-
tribute in a crucial manner to the expression of efflux pumps10, 11, 15, 17. Nevertheless, it has 
been recently demonstrated that efflux pump inhibitors (EPI) were effective in the preven-
tion of biomass development1. However, so far, EPIs were only tested against a limited 
number of strains and the effects of EPIs on mature S. aureus biofilms were unexplored. 
Therefore, we conducted a study in which we exposed mature biofilm of methicillin-
susceptible S. aureus (MSSA) (n=9) and methicillin-resistant S. aureus (MRSA) (n=15) of 
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different clonal lineages to the EPIs thioridazine and reserpine. In addition, we assessed the 
capacity of the EPIs to prevent biomass formation of the same isolates. 
 
Materials and Methods 
Bacterial strains 
As part of an ongoing surveillance of S. aureus nasal carriers, nine MSSA and fifteen MRSA 
strains from individual patients in the Maastricht University Medical Center, a tertiary 715-
bed hospital, were evaluated (Table 1). The isolates were randomly selected from a group 
of MSSA and MRSA with distinct globally disseminated genetic backgrounds. The selected 
isolates were associated with multilocus sequence typing (MLST) clonal complex (CC)8, 
CC22, CC30 and CC45. 
Characterization of the genetic background 
Real-time amplification of the spa-locus, followed by sequencing, was performed as de-
scribed earlier19. The spa-types were assigned through the Ridom SpaServer 
(http://spaserver.ridom.de) and clustered into spa-CCs using the algorithm based upon 
repeat pattern (BURP) with Ridom StaphType 1.5 using default settings20. As spa-
typing/BURP yields results consistent with typing outcomes obtained by MLST20, 21, the 
associated MLST CCs were allocated through the Ridom SpaServer. To confirm the associa-
tion between MLST and spa typing, in combination with BURP, MLST was performed on 
one isolate of each major spa type or associated MLST CC, as described previously19, 22. 
Susceptibility testing efflux pump inhibitors 
The susceptibility of the strains to the EPIs was tested using a micro-dilution technique23. In 
the biofilm experiments, the concentrations of EPIs used were between one-quarter and 
one-half the MICs in planktonic cultures. Thioridazine and reserpine (Sigma Aldrich, 
Zwijndrecht, the Netherlands) were used as EPIs24–26. Reserpine is often used as benchmark 
compound during the development of novel EPIs15, 27, 28. The highest final concentration of 
organic solvent for the EPIs, dimethyl sulphoxide (DMSO), which caused no inhibition of 
bacterial growth was <1% v/v. 
Biofilm formation 
To find out the effect of EPIs on the destruction of mature biofilms, the S. aureus strains 
were allowed to establish biofilms during 24 h in 96-well flat-bottomed non-tissue culture 
treated polystyrene microtiter plates (Greiner Bio-One, Frickenhausen, Germany) at 37°C 
on a rocking platform at 25 oscillations min-1. Individual wells were filled with 100 μL of an 
overnight culture (108 CFU/mL in Trypticase Soy Broth (TSB) without dextrose) (Becton 
Dickinson, Le Pont de Claix, France), and supplemented with 0.1% or 1% glucose. After 24 
h biomass formation, growth medium with planktonic cells was discarded and replaced by 
fresh broth containing EPIs at ¼ - ½ × planktonic MIC, except for controls, where medium 
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and/or organic solvent (DMSO) were added only. The plates were incubated for an addi-
tional 24 h. Subsequently, the wells were washed three times with 200 μL NaCl 0.9%, and 
the amount of biomass was quantified. 
 
Table 1. Overview of S. aureus strains included in this study. 
 
     
S. aureus 
strain 
associated 
MLST CC 
spa type MSSA (S) or 
MRSA (R) 
mecA 
     
     
BF82 8 t008 R + 
BF106 8 t052 R + 
BF109 8 t052 R + 
BF110 8 t052 R + 
BF111 8 t052 R + 
BF143 8 t008 R + 
BF144 8 t008 R + 
BF11 22 t223 R + 
BF55 22 t005 S - 
BF151 22 t223 R + 
BF153 22 t223 R + 
BF236 22 t1433 S - 
BF237 22 t005 S - 
BF238 22 t005 S - 
BF244 22 t005 S - 
BF87 30 t012 R + 
BF88 30 t012 R + 
BF246 30 t483 S - 
BF254 30 t021 S - 
BF92 45 t445 S - 
BF94 45 t038 R + 
BF98 45 t038 R + 
BF256 45 t230 S - 
BF265 45 t772 R + 
     
 
 
In order to examine prevention of biomass formation by the EPIs, the experiments were 
carried out by adding the EPIs from onset to the growth medium. After 24 h of biomass 
formation in the presence of EPIs, planktonic cells were removed and the amount of bio-
mass was determined. 
Biomass formation was quantified using the crystal violet adherence assay19 and per-
formed in six fold. Influence of EPIs on biofilm formation was calculated as follows: 
 
100%
A
AA
control
590
DMSO
590
DMSO   EPI
590 ×⎟⎟⎠
⎞
⎜⎜⎝
⎛ −+
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Statistical analysis 
SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) was used for statistical analysis. After verify-
ing that the assumption of normality was met, a paired two-tailed sampled t test for the 
independent experiments was used. P < 0.05 was considered statistically significant. 
 
Results 
Prevention of biomass formation 
Biofilm formation was prevented when S. aureus strains associated with MLST CC8 were 
grown in the presence of 0.1% glucose plus thioridazine (0–24 h) from onset. Similar results 
were obtained with reserpine (Figure 1). However, at 1% glucose the opposite was noticed 
with both compounds separately, i.e. enhanced biomass formation compared to control 
(Figure 1 and 2A). 
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Figure 1. Prevention of biomass formation by strains associated with MLST CC8 upon exposure to the efflux 
pump inhibitors thioridazine (T) and reserpine (R) at 0.1% and 1% glucose. 
 
In addition, S. aureus strains from other clonal lineages were tested. Both at 0.1% and 1% 
glucose concentration, reserpine exposure from 0–24 h did not prevent biomass formation 
by strains associated with MLST CC22, CC30 and CC45. Moreover, it promoted biomass 
formation at 1% glucose (CC22 and CC45). In contrast to strains associated with MLST CC8, 
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thioridazine (0–24 h) inhibited biomass formation similarly (CC45) or slightly more (CC30 
and CC22) at a glucose concentration of 1% instead of at 0.1% (Figure 2B, C and D). 
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Figure 2. Influence of thioridazine and reserpine on biofilm formation by S. aureus strains associated with 
MLST (A) CC8, (B) CC22, (C) CC30 and (D) CC45, displayed as bar plots. Indicated above each bar plot is the 
percentage of glucose present in the growth medium, the period of exposure to the efflux pump inhibitors 
(EPIs) and the time frame of biomass formation (A590). EPIs were added from onset (0–24h) when prevention 
of biomass formation was examined, while exposure started later on (24–48h) during monitoring of mature 
biofilm destruction. The A590 values of the controls in the absence of EPIs and/or solvents, which are directly 
proportional to the amount of biomass produced, are also shown (line plots with symbols: •). Asterisks denote 
statistically significant difference (**) P < 0.01, (*) P < 0.05, as determined by a paired two-tailed t-test for the 
independent experiments). 
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Destruction of existing (mature) biofilm matrix 
Addition of reserpine during 24–48 h to a 24 h pre-developed biofilm did not reduce the 
amount of biomass produced, but augmented biomass formation of several strains, inde-
pendent of the tested clonal lineages and especially at 0.1% glucose. Compared to reser-
pine, thioridazine was somewhat more successful in destruction of mature biofilms. 
Against mature biofilms of strains associated with MLST CC8, thioridazine added during 
24–48 h achieved a reduction (~ 12%) at 0.1%, but not at 1% glucose (Figure 2A).  
However, this reduction in biomass was far beyond the level achieved by thioridazine 
when testing prevention of biomass accumulation (~ 39%). Thioridazine did not have the 
capability to destruct mature biofilms at 0.1% glucose of the other clonal lineages (associ-
ated with MLST CC22, CC30 and CC45). However, in contrast to our observations with 
strains associated with CC8, the other clonal lineages showed more pronounced reduc-
tions in biomass at 1% glucose (Figure 2B, C and D). 
The amount of biomass formed by strains associated with MLST CC8 increased more 
quickly at 0.1% glucose compared to the other clonal lineages, as could be deduced from 
the higher A590-values: 0.78 vs. an average of 0.46 during 0–48 h (Figure 2). At 1% glucose 
within 24 h, strains associated with CC30 and CC45 demonstrated a considerable increase 
in the amount of biomass produced (A590-values of 3.52 and 2.03 after 24 h, respectively). 
After 48 h the amount of biomass produced by strains associated with MLST CC22 was 
(still) the lowest (A590-value of 1.97 vs. an average of 2.79). Linked to the impression that 
biofilm maturation was the fastest for CC8 and the slowest for CC22, it was noticeable that 
thioridazine was able to prevent biomass formation at 0.1% glucose of the former and 
could destruct pre-formed biomass at 1% glucose of the latter. 
 
Discussion 
 
Various serious persistent infections have been associated with biofilm embedded micro-
organisms attached to indwelling devices. Eradication of biofilm by antibiotics is difficult 
and leads often to surgical removal of the foreign body. Attempts to prevent biofilm for-
mation, such as by anti-adhesive coatings or catheter lock solutions are under broad-
scaled investigation29, 30. Still, under particular circumstances biofilm formation could so far 
not be prevented. Therefore, an innovative concept for the development of a new class of 
agents to prevent biomass formation and eradicate existing biofilm is of paramount im-
portance. 
This study demonstrated that the EPIs thioridazine and reserpine did not fully meet this 
criterion, especially regarding the inefficient destruction of mature biofilms. We observed 
that the glucose availability was important for the effects of EPIs on the prevention of 
biomass formation. At 0.1% glucose thioridazine was only able to reduce biomass forma-
tion of strains associated with MLST CC8, while at 1% glucose it only partly diminished 
biomass formation of the other clonal lineages CC22, CC30 and CC45. Differences in the 
genetic background may have accounted for these divergent results. Taken together, 
Inhibition of membrane transporters during Staphylococcus aureus biofilm growth 
 115 
thioridazine prevented biomass formation more effectively than reserpine, independent of 
the glucose availability. 
Based on the assumption that various efflux pumps might be overexpressed during 
the biofilm mode of growth, EPIs were put forward as potential anti-biofilm agents1. In-
deed, we observed that both thioridazine and reserpine were able to prevent biomass 
formation at 0.1% glucose of strains associated with MLST CC8, as shown earlier for S. 
aureus 8325–4 (spa-type t211, MLST CC8)1. However, the opposite was observed when the 
glucose concentration was raised to 1%, to simulate circumstances with large amounts of 
nutrients. The inability to prevent biomass formation at 1% glucose, with even stimulation 
of biomass formation as a consequence, suggest that glucose availability and/or metabo-
lism influences the outcome. Based on data from the literature we propose the following 
model for biofilm-associated pathways (Figure 3), which enabled us to obtain premises to 
support our observations. 
When rapidly catabolizable carbon sources are abundantly present (as is in the pres-
ence of 1% glucose), it is known that the tricarboxylic acid (TCA) cycle is repressed31. As a 
consequence this is followed by the accumulation of acetate and/or lactate. As proposed 
in Figure 3, increasing concentrations of acetate and lactate enhance (by intracellular pH 
lowering) the catabolite control protein A (ccpA) triggered polysaccharide intracellular 
adhesin (PIA) formation and cidA related eDNA release3. Thus, blocking the efflux of acetate 
might stimulate biofilm formation of strains associated with MLST CC8, as observed at 1% 
glucose concentration. The reduction in biomass formation by EPIs at a lower glucose (~ 
0.1 – 0.3%) concentration has previously been attributed to the accumulation of waste 
products1, resulting in toxification. However, this does not clarify our results at 1% glucose. 
Another explanation for the observations at 0.1% might be that EPIs have affinity for other 
membrane-based transporters, besides efflux pumps. Inhibition of glucose-influx by EPIs 
might prohibit biomass accumulation. A deficiency in intracellular amount of glucose 
would lead to TCA cycle activation, enhancement of TCA cycle intermediates c.q. metabo-
lites and consequently inhibition of icaABCD and upregulation of the mgrA biofilm-
repressor function12 via activated graRS (Figure 3). Although graRS might also upregulate 
rot32, which acts as a negative transcription regulator of α-toxin and protease expression 
and as a positive regulator on certain MSCRAMMs33, we expect that graRS exerts a stronger 
effect on mgrA than rot. This expectation is based on a transcriptome analysis32 and a de-
scribed negative feedback on rot via mgrA and agr34 and is in agreement with the pre-
sented data as well. We presume that due to an excessive amount of glucose at 1%, more 
competition exist for the transporter, resulting in an incomplete inhibition of the glucose 
importer function by the EPI. 
Furthermore, we observed that the EPIs in the presence of 0.1% glucose were less ef-
fective in destruction of pre-existing established biofilms, compared to prevention of bio-
mass production. This could be clarified by different assumptions. First, the recalcitrance to 
antibiotics is explained by a penetration barrier caused by the densely adherent biofilm 
matrix35, consisting of proteins, eDNA and/or PIA. It is plausible that such a diffusion prob-
lem also exist for EPIs, resulting in subinhibitory concentrations locally present inside the 
biofilm. Such concentrations are then below the minimum biofilm eradication concentra-
tion (MBEC). Subinhibitory concentrations of certain antibiotics and probably also other 
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compounds were able to augment biomass formation of all different types of bacteria36, 37. 
Additionally, it has been shown that after a shift to (semi)-anaerobic conditions, the 
amount of lactate accumulates since the conversion of pyruvate into acetyl-CoA requires 
oxygen31. As shown in Figure 3, (partially) blocking lactate extrusion would improve acidifi-
cation leading to increased ccpA expression and thus biomass expansion. Cells inside ma-
ture biofilms surrounded by a nutrient depleted environment might also start to produce 
autoinducing peptides (AIP), as part of quorum sensing intercellular communication2. 
Reducing the extrusion of AIP by EPIs would prohibit dispersal and result in the conserva-
tion of biomass, with consequently more biomass compared to control. 
 
 
 
 
Figure 3. Simplified overview of (postulated) biofilm related pathways in S. aureus. It is clearly noticeable 
that the multiple gene regulator mgrA plays a central role as a regulator of transmembrane transporters, 
capsular polysaccharide formation and biomass formation. Abbreviations – agr: accessory gene regulator; 
ccpA: catabolite control protein A; ECP: extracellular proteases; eDNA: extracellular DNA; MSCRAMMs: 
microbial surface components recognizing adhesive matrix molecules; PIA: polysaccharide intracellular 
adhesin; PSM: phenol-soluble modulin; sarA: staphylococcal accessory regulator; spoVG: stage V sporulation 
protein G; rot: repressor of toxins. 
 
 
Interestingly, at 1% glucose, differences between prevention of biofilm formation and 
destruction of established biofilms by EPIs were also observed. Compared to the elevated 
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biomass forming capacity of strains associated with MLST CC8 provoked by the EPIs during 
the prevention period (0–24 h), the inducible effect of EPIs (24–48 h) on mature biofilms 
was less pronounced (Figure 2A). Probably, after 24h of biomass formation in the presence 
of high glucose concentration, the cells are trying to counteract the produced large 
amounts of lactic acid, acetic acid and formic acid by upregulating urease activity (Figure 
3). This would result in ammonium and/or ammonia formation8, 38. Excess of ammonia is 
normally expelled since it is toxic for bacterial cells. Thus, blocking the extrusion of ammo-
nia would break down biomass. In addition, at the post-exponential biofilm phase, (intra-
cellular) glucose is almost completely consumed and oxygen becomes limited in the dee-
per layers of the biofilm39, 40. As a survival strategy, (some) TCA cycle enzymes could get 
upregulated due to oxygen limitation and/or a too-high acidification to permit better 
metabolism and/or consumption of excreted fermentation products7, 17, 31, 39. Thus blocking 
the influx of previously excreted fermentation products like acetate31 would reduce the 
intracellular acetate concentration more quickly in order to create more TCA intermedia-
tes, and consequently depletes biomass. 
The influence of thioridazine and reserpine on biomass was slightly different for strains 
belonging to the clonal lineages associated with MLST CC22, CC30 and CC45, which were 
not previously tested1. These variations might be attributed to other biomass-related 
metabolic changes or different expression levels of membrane-based transporters. We 
confirmed that the amount of biomass produced during a certain time period depends on 
the genetic backgrounds19, indicating that nutrient import capacities are variable as also 
the rate of metabolic alterations. However, the effects of EPIs on biomass of strains associ-
ated with the related MLST lineages CC30 and CC4541 were practically similar. 
In general, the glucose and oxygen availability within microbial biofilm communities is 
changing over time, which concomitantly modifies the TCA cycle activity of the embedded 
bacteria. As a result, based on fluctuations in indirect mgrA stimulation by TCA cycle inter-
mediates17, 32, the expression of efflux pumps and other trans-membrane transporters of 
these bacteria changes. Therefore, it was not surprising that inhibition of trans-membrane 
transporters by EPIs as a tool to hinder biofilm formation was only effective under certain 
circumstances, depending on the environmental glucose availability and the already pre-
existing amount of biomass. Since the latter differed per clonal lineage and variations 
among their trans-membrane transporters are likely, the genetic background of the strain 
is of importance in whether an EPI could be a valuable tool to prevent biomass formation 
or to eradicate mature biofilm. 
In summary, we demonstrated with in vitro experiments that at 0.1% glucose the EPIs 
thioridazine and reserpine were predominantly able to prevent biomass accumulation of 
strains associated with MLST CC8, while at 1% glucose almost the same was achieved with 
thioridazine only for strains associated with MLST CC30 and CC45. Destruction of mature 
biofilms was in general ineffective. Only biofilm produced by strains associated with MLST 
CC22 were slightly affected. Based on biofilm-related pathways described in the literature, 
we discussed our findings regarding the inconsistent and inefficient anti S. aureus biofilm 
characteristics of EPIs. 
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Abstract 
 
Since it is unknown whether β-lactam antimicrobial agents can be used effectively against 
borderline oxacillin-resistant Staphylococcus aureus (BORSA) with oxacillin MIC ≥ 4 mg/L, 
the in vitro bactericidal activity and pharmacodynamic effect of oxacillin against clinical 
BORSA isolates was evaluated. Time-kill experiments with oxacillin were performed and 
compared with those of vancomycin, daptomycin and linezolid against BORSA with oxacil-
lin MIC ≥ 4 mg/L and BORSA with oxacillin MIC ≤ 2 mg/L. Furthermore, the effect of β-
lactamase production and plasmid profile analysis were used to clarify responses to oxacil-
lin. 
The oxacillin killing activity was attenuated against BORSA compared to ATCC 29213, 
since the pharmacodynamic parameters revealed that the potency of oxacillin was mark-
edly reduced (approximately 10×) against BORSA with oxacillin MIC ≥ 4 mg/L. pBORa53-
like plasmid containing BORSA with oxacillin MIC ≤ 2 mg/L showed markedly more re-
growth. 
In conclusion, oxacillin displayed non-effective eradication of either (i) BORSA that pos-
sesses oxacillin MIC ≥ 4 mg/L or (ii) β-lactamase hyperproducing BORSA (MIC ≤ 2 mg/L). 
Further investigation into β-lactam dosing strategies against different BORSA strains is 
warranted in order to avoid putative therapy failure. 
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Introduction 
 
In addition to methicillin-sensitive (MSSA) and -resistant S. aureus (MRSA), borderline ox-
acillin-resistant S. aureus (BORSA) have been described. BORSA strains exhibit oxacillin MIC 
values enclosing the European Committee on Antimicrobial Susceptibility Testing (EU-
CAST) oxacillin break-point of >2 mg/L, since BORSA strains with oxacillin MIC below or 
above the break-point have been described1, 2. BORSA strains lack the MRSA-specific mecA 
gene on the Staphylococcal Cassette Chromosome mec (SCCmec), and, consequently, do 
not express the low-affinity penicillin-binding protein (PBP)2a or 2’. The borderline pheno-
type has been attributed to (i) the hyperproduction of blaZ-encoded penicillinase and/or 
(ii) the production of an inducible, plasmid-mediated, membrane-bound methicillinase2–5 
and/or (iii) different modifications in the PBPs 1, 2 and 4 genes, due to spontaneous amino 
acid substitutions in the transpeptidase domain2, 6, 7. Unfortunately, a single trait that dif-
ferentiates BORSA strains from susceptible or resistant S. aureus isolates has not yet been 
identified. Outbreaks of BORSA infections were reported at an estimated incidence of 5%8, 
9. Treatment of early experimental endocarditis and in vitro data suggest efficacy of β-
lactamase-resistant penicillins against BORSA strains with oxacillin MIC of 2 mg/L by en-
hancement of the dosage10, 11. Whether BORSA with higher oxacillin MIC (≥ 4 mg/L) can be 
treated effectively with β-lactamase-resistant penicillins is unknown. 
The aim of the present study was to examine the antibacterial activity of oxacillin com-
pared to vancomycin, daptomycin and linezolid, against three mecA-negative BORSA iso-
lates, M002, M008 and M015, with oxacillin MIC ≥ 4 mg/L and compared with two BORSA, 
M007 and VU94, with oxacillin MIC ≤ 2 mg/L, using time-kill analysis. 
 
Materials and methods 
Bacterial strains 
S. aureus ATCC 29213 and VU94 were used as MSSA and BORSA reference strain, respec-
tively4, 12. BORSA M015, which was investigated in more detail, was a clinical isolate from a 
patient admitted to the Maastricht University Medical Center. Fourteen other BORSA iso-
lates, including M002, M007 and M008, were isolates from general practice patients. 
VU94 and M007 were BORSA with oxacillin MIC ≤ 2 mg/L and M002, M008 and M015 
were BORSA with oxacillin MIC ≥ 4 mg/L. The S. aureus protein A (spa) types were t3033, 
t078, t127, t002 and t091, respectively, associated with multilocus sequence typing (MLST) 
clonal complexes (CC)25, CC25, CC1, CC5 and CC7. The remaining eleven strains were 
subjected only to susceptibility testing, using the Phoenix system as well as a microdilution 
technique. All BORSA strains were tested positive for the S. aureus-specific femA gene and 
negative for the MRSA-specific mecA gene13. ATCC 29213 and 25923 served as positive and 
negative β-lactamase producing controls, respectively14, 15. 
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Antibiotics 
Daptomycin and linezolid were kindly supplied by the manufacturers (Novartis, Basel, 
Switzerland and Pfizer, Groton, CT, respectively). Oxacillin and vancomycin were purchased 
(Sigma-Aldrich, Zwijndrecht, the Netherlands). Prior to each experiment stock solutions 
were prepared. 
Susceptibility testing 
Susceptibility testing was performed by microdilution techniques according to CLSI guide-
line16. Daptomycin MICs were determined using E-test-strips (AB Biodisk, Solna, Sweden). 
Additionally, oxacillin MICs were determined using the Phoenix system (Becton Dickinson, 
Sparks, MD). Tolerance was defined as a MBC/MIC ratio ≥ 3217. 
Time-Kill experiments 
Time-Kill studies were done according to Isenberg’s guidelines18 and performed in Brain 
Heart Infusion (BHI) broth (Oxoid, Basingstoke, Hampshire, England). When testing dapto-
mycin, Mueller-Hinton broth II (BBLTM, Becton Dickinson, Le pont de Claix, France) was 
supplemented with calcium (50 mg/L)19. Bacteria from an overnight culture were grown 
until late logarithmic phase and diluted to 1×106 CFU/mL. Antibiotics were added (100 μL 
per 10 mL medium) to obtain concentrations of ½, 1, 2, 4 and 8× MIC. Samples were taken 
at t=0, 2, 4, 6, 8, 10, 24 and 48 h of incubation at 37°C, serially diluted (10–1 to 10–6) to mini-
mize carryover effects, plated (37.3 μL) using a spiralplater (Eddy Jet, IUL instruments, 
Barcelona, Spain) and incubated at 37°C for 18–24 h. CFU were counted with a colony 
counter (Flash & Go, IUL instruments). The lower limit of detection was 2.73 log10 CFU/mL. 
Experiments with M015 and ATCC 29213 were carried out in duplicate to eightfold to test 
reproducibility. Bactericidal activity (99.9% kill) was defined as a ≥ 3-log10 CFU/mL decrease 
in colony count at 24 h compared to the initial inoculum. 
Isolation and restriction of plasmid DNA 
To analyse the presence of β-lactamase encoding plasmids, such as pBORa53, plasmid 
DNA was isolated and digested with HindIII, essentially as described previously20. 
Beta-lactamase quantitation 
The crude β-lactamase was prepared as described previously21. Oxacillin was used as the 
inducer at a concentration of 0.375 mg/L. Uninduced cultures were also included. ATCC 
29213 and 25923 were induced with 0.125 and 0.0625 mg/L oxacillin (½× MIC), respec-
tively. The specific activity was calculated by dividing the total activity by the protein con-
tent. 
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Statistical analysis 
Differences between concentration profiles in log10 CFU/mL at 24 h were assessed by 
analysis of variance with Tukey’s test for multiple comparisons, using SPSS 14.0. A P value 
of < 0.05 was considered statistically significant. 
Determination of pharmacodynamic parameters 
An uncomplicated εmax-model can describe the change in CFU over time during the initial 
phase of cell killing, using the growth rate constant (λ) in the absence of antibiotic pressure 
and on the concentration depending kill rate constant (ε), as shown in Equation 1. 
 
N
CC
C
dt
dN ×⎟⎟⎠
⎞
⎜⎜⎝
⎛
+−= γγ
γ
ε
ελ
50
max
                                            (1) 
 
The maximum kill rate constants εmax (h-1) and concentration necessary to achieve half of 
the maximum kill rate εC50 (mg/L) were obtained as described previously22. 
However, this model can be inaccurate to estimate pharmacodynamic parameters 
since effect-time profiles are often not log-linear over a longer period of time. In order to 
cover the overall effect over 24 h, the log difference viable count was used as the differ-
ence between growth in the presence and absence of an antibiotic. For each concentra-
tion, the effect (E) was defined as the area under the curve (AUC0–24) of the log difference 
curves (Equation 2), equal to the area between the curves (ABC0–24), and calculated via the 
trapezoidal rule method in Prism 4.0 (GraphPad Inc) . 
 
( ) ( )[ ]
2401010 −− antibioticrolgrowthcont CFULogCFULogAUC                                (2) 
 
The maximum effect (Emax) was determined by fitting the data to the Hill equation. To carry 
out a parellel line assay23, the logarithms of E/Emax-E were plotted against the logarithm of 
the concentration (mg/L) according to the Hill plot (Equation 3)24. 
 
( )[ ] [ ] KCLogEEELog +=− γmax/                                          (3) 
 
The EC50 represents the concentration at which 50% of the maximum effect is obtained and 
is therefore considered as a potency marker. The EC50 is equal to 10-K/γ. 
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Results 
Susceptibility testing 
Similar MICs of daptomycin and vancomycin were observed for BORSA with a MIC oxacillin 
≥ 4 mg/L (M002, M008 and M015) or ≤ 2 mg/L (M007 and VU94) (Table 1). Tolerance to 
oxacillin was noted for M002 and M00817. Persisters were observed when determining the 
MBC of M01525. All BORSA, including eight isolates with oxacillin MICs of 4 and 8 mg/L, 
tested on the Phoenix system were classified as susceptible for oxacillin (as shown for five 
strains in Table 1). 
 
 
Table 1. In vitro activity and pharmacodynamic parameters of oxacillin, vancomycin, daptomycin and 
linezolid against BORSA. 
 
MIC 
(mg/L) 
MIC b 
(mg/L) 
MBC 
(mg/L) 
Time to 99.9% kill 
(h) 
Emax γ 
EC50 
(mg/L) 
γ΄ c  
εmax,o/i d 
(h-1) 
εC50 
(mg/L) 
γ Bacterial 
strains and 
antibiotics a    
2¯ 
MIC 
4¯ 
MIC 
8¯ 
MIC 
I e  II e 
29213 OXA 0.25 ND 0.5 21.36 18.31 15.09 121.03 2.28 0.20  0.94 / 2.00 0.19 1.66 
M015 OXA 4 2 8† 26.61 27.38 25.59 95.88 1.85 2.01 
2.20 
 0.52 / 1.50 2.22 2.59 
M008 OXA 4 0.5 >64 44.32 47.96 44.30 80.22 2.29 1.89   0.75 / 1.93 1.58 2.05 
M002 OXA 8 2 >64 NA NA NA 89.04 1.57 1.92   0.74 / 1.88 1.89 2.60 
VU94 OXA 0.75 0.5 1 NA NA NA 100.40 1.67 0.42   1.06 / 2.05 0.31 2.03 
M007 OXA 2 0.5 4 NA NA 18.89 75.02 2.07 0.61   0.75 / 1.67 0.49 2.94 
29213 DAP 1 ND ND 4.92 3.63 2.10 176.52 0.85 0.66  2.05 / 2.82 0.57 0.88 
M015 DAP 0.5 ND ND 9.15 6.82 6.10 131.47 1.64 0.26 
1.05 
 1.18 / 1.82 0.14 1.55 
M008 DAP 0.5 ND ND 7.42 5.21 4.39 147.40 1.09 0.21   1.28 / 2.02 0.24 1.42 
M002 DAP 0.75 ND ND 4.03 4.88 3.48 147.80 1.03 0.08   1.27 / 2.10 0.29 1.36 
VU94 DAP 0.75 ND ND 5.76 5.73 5.39 147.90 1.40 0.33   1.39 / 2.09 0.49 1.47 
M007 DAP 0.75 ND ND 5.61 5.12 4.64 142.80 1.79 0.41   1.04 / 1.89 0.28 1.40 
29213 LZD 4 ND ND NA NA NA 82.54 5.36 1.79  0.53 / 1.59 1.32 3.27 
M015 LZD 1 ND ND NA 32.49 27.63 99.68 1.98 0.73 
2.16 
 0.71 / 1.69 0.80 1.02 
29213 VAN 1 ND ND NA 24.36 24.24 98.82 4.31 1.48  0.66 / 1.72 0.57 6.51 
M015 VAN 1 ND ND NA 22.01 22.20 100.07 3.58 1.60 
4.13 
 0.56 / 1.54 0.62 5.82 
M008 VAN 1 ND ND NA 22.52 29.18 97.45 4.37 1.37   0.83 / 2.01 0.95 6.58 
M002 VAN 1 ND ND NA 17.24 16.12 114.80 3.98 1.28   1.01 / 2.16 0.87 3.04 
VU94 VAN 1 ND ND NA 21.97 20.00 102.20 2.83 1.34   0.84 / 1.84 0.63 5.85 
M007 VAN 1 ND ND NA 20.85 17.24 103.90 4.14 1.83   0.77 / 1.69 1.27 3.92 
 
a DAP, daptomycin; LZD, linezolid; OXA, oxacillin; VAN, vancomycin 
b MIC values determined with the Phoenix system 
c common sigmoidicity coefficients for strains ATCC 29213 and BORSA M015 when concentration-effect lines were 
forced to be in parallel 
d observed (o) and intrinsic (i) maximum kill rate constants (εmax,i = εmax,o + λ); the generation times (gt = t / ((log2)-1 × 
log (Nt/N0)) and λ = ln2/gt) were in BHI or CAMHB (DAP): 0.70 and 0.90; 0.70 and 0.99; 0.65 and 1.08; 0.61 and 0.83; 
0.75 and 0.81 and 0.58 and 0.93 (h) for respectively ATCC 29213, VU94, M015, M002, M007 and M008. 
e method I, effect expressed as the ABC0–24; method II, effect expressed as the kill rate (ε) 
† persisters detected up to 64 mg/L 
ND, not determined 
NA, not achieved within 48 h 
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Time-Kill experiments 
ATCC 29213 and all BORSA showed similar growth characteristics: there were no conside-
rable differences in the effects of vancomycin, linezolid and daptomycin (Figure 1, Table 1). 
The EC50 and εC50 were in the same size of order, except for vancomycin. Regrowth was 
especially observed with vancomycin, even at 2× MIC for all strains. 
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Figure 1. The pharmacodynamic effect, expressed as the difference in log viable count over a time period of 
24 h, and denoted by the area between the curves (ABC0–24), versus the concentration in mg/L for (A) 
oxacillin, (B) vancomycin and (C) daptomycin against BORSA strains M002, M007, M008, M015 and VU94 
and MSSA ATCC 29213. 
 
 
Oxacillin was significant less effective at 4 and 8× MIC against M015, compared to ATCC 
29213, in reducing the bacterial viable counts over 24 h (P < 0.05 and P < 0.001), as was the 
time to achieve 99.9% killing at 2, 4 and 8× MIC (5–10 h longer) (Table 1). This was consis-
tent with the lower εmax. Both, M002, M008 and M015 did not achieve 99.9% kill within 24 
h, even not at 8× MIC. The maximum effect of oxacillin was considerably reduced for all 
BORSA compared to ATCC 29213 (Figure 1A). Furthermore, markedly regrowth at 2 and 4× 
MIC was observed with BORSA M007 and VU 94 (oxacillin MIC ≤ 2 mg/L), while no re-
growth was seen with BORSA with oxacillin MIC ≥ 4 mg/L (M002, M008 and M015) (Figure 
2). 
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Figure 2. Antibacterial activity of oxacillin (OXA) against (A) S. aureus ATCC 29213 (white symbols and dotted 
lines) versus the average data of BORSA strains M002, M008 and M015 (MIC OXA ≥ 4 mg/L) (black symbols 
and straight lines) and (B) S. aureus ATCC 29213 (white symbols and dotted lines) versus the average data of 
BORSA strains M007 and VU94 (MIC OXA ≤ 2 mg/L) (black symbols and straight lines) at concentrations 
corresponding to ½× (circles), 1× (triangles downwards), 2× (squares), 4× (diamonds) and 8×MIC (triangles 
upwards) in comparison to growth controls (hexagon). Error bars represent standard errors of the mean. 
 
Beta-lactamase activity and plasmid profile analysis 
The β-lactamase activity and plasmid profile analysis were performed to clarify the diffe-
rences in regrowth observed with oxacillin between BORSA M007 and VU94, and BORSA 
M002, M008 and M015, at the same multiples of the MIC. Although, BORSA M015, M008 
and M002, with oxacillin MIC ≥ 4 mg/L, showed a twice as high induction ratio than BORSA 
M007 and VU94, with oxacillin MIC ≤ 2 mg/L, the latter produced considerably higher 
amounts of β-lactamase after induction (Figure 3A). The four plasmid DNA fragments of 
BORSA M007 and VU94 were similar in size to that of plasmid pBORa53 (Figure 3B), pre-
viously described as a pBW15-like β-lactamase plasmid26. In the other BORSA, pMW2-like 
plasmids were identified, a penicillinase-encoding plasmid27. 
Pharmacodynamic comparison 
For each antibiotic a potency ratio was calculated between ATCC 29213 and M015, using 
the parellel line assay23. The difference in potency is visualized by the horizontal shift of the 
concentration-effect curve (Figure 4). Oxacillin was approximately 10× more potent 
against ATCC 29213 than against M015. The same result was found for the other BORSA, 
M002 and M008 with oxacillin MIC ≥ 4 mg/L. These strains showed similar concentration – 
effect profiles (Figure 1A), resulting in consistent EC50. On the other hand, the potency 
estimates for ATCC 29213 versus M007 and VU94 were 2× and 3×, respectively. 
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Figure 3. (A) The effect of β-lactamase induction by oxacillin on the nitrocefin-hydrolyzing activities of BORSA 
strains. (B) BORSA M007 and VU94, contain a BORSA-related, pBORa53-like plasmid. The image shows an 
ethidium bromide-stained agarose gel containing HindIII-digested plasmids from M007 (lane 1), VU94 (lane 
2), M002 (lane 3), M008 (lane 4) and M015 (lane 5). The HindIII-digested DNA fragment sizes predicted from 
the plasmids pBORa53 (GenBank Accession Nr. AY917098) and pMW2 (Genbank Accession Nr. AP004832) are 
indicated on the left- and right-hand side, respectively. 
 
 
Discussion 
 
This study revealed that oxacillin was not effective to eradicate, in vitro, neither BORSA with 
MIC oxacillin ≥ 4 mg/L, nor BORSA with MIC oxacillin ≤ 2 mg/L. Actual concentrations of 
oxacillin to eradicate in vitro BORSA with oxacillin MIC ≥ 4 mg/L (M002, M008 and M015) 
were notably higher than can be attained with normal dosing strategies, while M007 and 
VU94 (MIC oxacillin ≤ 2 mg/L), showed early regrowth with oxacillin, possibly due to a 
pBORa53-like plasmid related hyperproduction of β-lactamases. 
The change in killing rate over time is a reflection of the influence of (i) degradation of 
antibiotics, (ii) adaptation and (iii) heterogeneous subpopulations28. Consequently, re-
growth can occur. Furthermore, the growth rate is not constant over time, since the repli-
cation of microorganisms is influenced by the amount of nutrients in the medium. There-
fore, an alternative method, which incorporates all available time-kill data, was used to 
obtain concentration-effect parameters. In contrast to the method of Tsuji et al.29, who 
used the log ratio based on the proportion between growth or killing in the absence and 
presence of an antibiotic, our method is based on the absolute difference between these 
characteristics. 
Because the kill rates were obtained from the log linear initial phase of the survival 
curve, εmax was affected only minimally by regrowth. In contrast, the reduced efficacy as a 
result of regrowth was manifested in Emax, since the variation of the survival curve over a 
longer period of time was taken into account. This might clarify the discrepancy between 
EC50 and εC50 values (Table 1). The vancomycin effect is overestimated by the εC50. 
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Figure 4. The logarithm of (E/Emax-E) versus the logarithm of the concentration in mg/L for S. aureus ATCC 
29213 (solid lines) and BORSA M015 (dashed lines). The corresponding EC50 were determinated from the 
points where the dotted horizontal line (y = 0) intersects the different concentration-effect curves. The 
differences in potency are visualized by the left or right shift of the curves. The corresponding Hill 
coefficients (γ΄) are equal to the slopes of the curves. The dotted vertical lines indicate the MIC of the 
represented antibiotics. The abbreviations DAP, OXA, LZD and VAN represent daptomycin and oxacillin, 
linezolid and vancomycin, respectively. 
 
 
The decreased EC50 for oxacillin against BORSA with oxacillin MIC ≥ 4 mg/L (M002, M008 
and M015) is accompanied by a reduction in Emax. Usually, target site alterations are reflec-
ted by a reduced Emax. BORSA resistance mechanisms have been related, among others, to 
target site alterations, such as amino acid substitutions in PBP2, which might explain the 
reduced Emax2, 6. Upregulation of β-lactamases could be responsible for the increased EC50. 
However, the production of β-lactamases by these strains was only slightly enhanced after 
induction, compared to ATCC 29213 (Figure 3A). Although the data do not allow to esta-
blish a specific mechanism, other resistance mechanisms, that have not been elucidated so 
far, might be involved. On the other hand, VU94, and particularly M007 (BORSA with oxacil-
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lin MIC ≤ 2 mg/L and both belonging to the predominant MLST CC25 lineage2), showed a 
considerably higher production of β-lactamases, after induction. This is in accordance with 
the plasmid profile analysis, since pBW15-like plasmids, such as pBORa53, are associated 
with an inducible hyperproduction of β-lactamases. These plasmids encode very likely for 
methicillinase15. Two β-lactamases have been detected in the membrane of VU94 pre-
viously, and one of them being a methicillinase4. For this reason, VU94 and M007 were 
probably able to hydrolyze oxacillin very efficiently, with regrowth within 12 h as a conse-
quence at 4× and 8× MIC, respectively. This indicates the need for high dosing strategies of 
penicillinase-resistant penicillins for β-lactamase hyperproducing BORSA. Unfortunately, 
oxacillin in combination with a β-lactamase inhibitor is not commercially available. 
Although, oxacillin against BORSA with oxacillin MIC ≥ 4 mg/L (M002, M008 and M015) 
reduced the bacterial counts at 4× and 8× MIC, the actual concentrations, i.e. 16–32 mg/L, 
were high. Concentrations above 4× MIC are considered clinically effective for time-
dependent antibiotics, such as oxacillin28. For β-lactams, the pharmacodynamic index that 
correlates best with clinical outcome is the time (t) that serum concentrations of the un-
bound fraction exceeds the MIC (t>MIC) and values of 40–50% or greater are considered 
necessary for effective treatment of S. aureus infections30. Therefore, it is very unlikely that 
for a drug with a high protein binding affinity (94%) and an unfavourable EC50, a free 
plasma concentration of ≥ 4–8 mg/L (corresponding to the MIC of M002, M008 and M015) 
for approximately 50% of the dosing interval (t>MIC) can be attained with current dosage 
strategies (IV 1–12 g/24 h). 
A recent case report highlights the fact that patients infected with non-β-lactamase 
producing BORSA, with oxacillin MIC ≥ 4 mg/L, and treated with β-lactams may lead to 
treatment failure31. The case report describes a patient with endocarditis, due to BORSA 
with oxacillin MIC ≥ 4 mg/L, who failed to respond to cloxacillin. This confirms our findings 
that treatment of infections caused by such BORSA with β-lactams is full of risk. 
Since this study showed that BORSA with oxacillin MICs ≥ 4 mg/L are difficult to eradi-
cate in vitro with β-lactam antibiotics, it is important to identify BORSA isolates by routine 
susceptibility testing. However, sixteen BORSA, including eight isolates with oxacillin MICs 
of 4 and 8 mg/L, tested with the Phoenix system were all considered MSSA. Apparently, 
this method is not suitable to differentiate between fully susceptible S. aureus strains and 
BORSA. BORSA isolates will thus be missed by routine susceptibility testing and as a conse-
quence, the (empiric) antibiotic therapy choice, i.e. oxacillin, is not useful for the eradica-
tion. 
In summary, out of the four antibiotics tested, oxacillin was, in vitro, non-effective 
against both BORSA with oxacillin MIC ≥ 4 mg/L and pBORa53-like plasmid containing 
BORSA with oxacillin MIC ≤ 2 mg/L. Further investigation into β-lactam dosing strategies 
against different BORSA strains is warranted in order to avoid treatment options consistent 
for MRSA infections. 
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General Discussion 
 
Staphylococcus aureus continues to be a predominant cause of community-acquired and 
nosocomial associated infections1. It is the most prevalent cause of endovascular infec-
tions, including catheter sepsis and infective endocarditis2,3, and the second most common 
cause of bacteraemia4. There are a number of factors that contribute to the success of S. 
aureus in evading host immunity and in establishing (persistent) infections. It is partly due 
to its ability to form biofilm5,6. Biofilm formation often prolongs the duration of debilitating 
infections since it restricts the access of many conventional antimicrobial agents to sessile 
bacterial communities and because of its recalcitrance to the innate7, as well as adaptive8, 
immune response. Several studies were undertaken to get a better understanding of how 
biofilm formation can be prohibited and whether mature biofilm can be disassembled. 
Staphylococcus aureus biofilm formation in relation to the genetic background 
In a natural environment, most bacteria grow aggregated to each other and to solid sur-
faces9. Therefore, biofilm communities are considered the predominant mode of bacterial 
life10. Cells within a biofilm are embedded by extracellular polysaccharides (EPS), which 
provides protection against a variety of environmental stresses, such as pH shifts, osmotic 
shock, desiccation and UV radiation11. It has been demonstrated that the S. aureus biofilm 
matrix could consist of different components, including polysaccharide intercellular adhe-
sin (PIA) or poly-ß(1,6)-N-acetyl-D-glucosamine (PNAG), extracellular DNA (eDNA), surface-
anchored microbial surface components recognizing adhesive matrix molecules 
(MSCRAMMs) and proteins. In order to find strategies to tackle or to prevent biofilm associ-
ated infections, it is necessary to get insight in the mechanisms of biofilm formation. Evi-
dently, the principles behind the capacity to form a biofilm are strain dependent. So far, it 
remains unelucidated which strains are more prone to become embedded by biomass. 
Under static conditions, we demonstrated in chapter 2 that the number of clonal lineages 
associated with multilocus sequence typing (MLST) clonal complex (CC)8 that displayed 
excessive biomass attachment to polystyrene surfaces was higher compared to a variety of 
isolates with other genetic backgrounds. Although the majority of MLST CC8 associated 
strains tested were classified as strong biofilm formers, 40% of these strains were not. This 
means that there is another underlying predisposing factor for strong biofilm formation 
that is not unravelled yet. Although all CC8 sublineages originate from the same progeni-
tor12, differences in the presence and expression of regulatory loci between subclones 
could be expected due to evolutionary events. As postulated, also the major components 
of biofilm matrices might be essential for the formation of robust biofilm, since it was 
found that matrices containing more PIA/PNAG were predominantly associated with re-
solving instead of persistent bacteraemia6. Most of the CC8 isolates did not demonstrate a 
dry crystalline colony morphology on Congo red agar (CRA), which was considered indica-
tive for PIA/PNAG formation13. 
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The importance of accessory gene regulator (agr) genotype for biofilm formation was 
recently discussed by Cafiso et al.14 and Kawamura et al.15 using strains isolated from pa-
tients with orthopaedic device-related infections. Based on their observations that agr-II 
genotype, spa-type t002, MLST CC5 associated strains were stronger biofilm formers than 
agr-I and agr-III strains, they stressed the importance of this agr genotype for biomass 
accumulation. However, in both studies the variety of clonal lineages of the isolates was 
limited or even unknown and not uniformly distributed compared to our examination. We 
observed at 0.1% glucose only strong biofilm formers among agr-II, spa-type t002, MLST 
CC5 associated strains and not in strains associated with MLST CC12 or CC15. All of their 
agr-I strains belonged to spa-type t1767, which is affiliated to MLST CC8, and were not 
included in our study. We are therefore convinced that the genetic background is a more 
appropriate predisposing factor for biofilm formation than agr-type. 
All together, these results suggest that especially the MLST CC8 (agr-I) genetic back-
ground deserves special attention in future biofilm exploratory studies as well as spa-type 
t002 isolates (agr-II) for orthopaedic infections. 
Biofilm formation among MLST CC8 isolates 
It is known that the CC8 lineage, including USA300, disseminated successfully16 and caused 
serious biofilm-associated infections17–19. Beside the ability to form biofilm, the extraordi-
narily success as a pathogen of various MLST CC8 subclones including the community-
associated methicillin-resistant S. aureus (CA-MRSA) USA300 has been attributed to their 
highly active agr quorum-sensing system12,20. Thus, the enhanced invasive potential is the 
consequence of abundant expression levels of virulence determinants, in particular α-toxin 
and α-type PSMs21,22. Based on the observation that both a biofilm can be established as 
well as toxins can be excreted by USA300, it is likely to assume that large changes in activ-
ity of global regulatory systems (i.e. agr and sarA) in the majority of MLST CC8 associated 
strains occur. If the turnover from repression to activation of agr is relatively quick, fast 
biomass accumulation followed by rapid dispersal of bacteria could be expected. 
It would be interesting to evaluate whether slow-developing but long-lasting biofilm 
communities do exist as well and to compare their (dis)advantages in terms of defence 
against host immune responses and antimicrobials. With our data this question remained 
unanswered, since biofilm formation was only assessed until 48 h. Although, S. aureus 
biofilm are generally considered fully mature within 24–48 h23,24, it would be possible that 
it takes longer for certain clones25. This sounds plausible since differences in the rapidity of 
agr RNAIII (de)activation have been noticed26. 
Biofilm formation among MLST CC5 isolates 
The strong biofilm producing capacity of some strains with spa-type t002, belonging to the 
MLST CC5 clone, could be clarified by a high percentage of dysfunctional agr as previously 
observed by Schweizer et al.27. In their study, 19 out of 190 (10%) USA300 blood isolates vs. 
78 out of 234 (33%) MLST sequence type (ST)5 strains were dysfunctional in agr, respec-
tively. This was higher than the overall percentage among blood stream isolates: 181 out 
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of 814 (22%) isolates. The prevalence of agr dysfunction among colonizing S. aureus strains 
was previously indicated as roughly 9%28. 
In general, agr-dysfunction (i), has been associated with a prolonged duration of bac-
teremia27,29; (ii), has been attributed to prior antibiotic administration (including ß-lactams 
and fluoroquinolones)30; (iii), has been correlated with slow-growing small colony vari-
ants31; (iv), has been linked with reduced killing by innate host thrombin-induced platelet 
microbicidal proteins (tPMPs) and consequently a strong ability to establish endovascular 
infection such as endocarditis32; (v), is less common among CA-MRSA versus healthcare-
associated (HA)-MRSA33; and (vi), showed a tendency toward higher mortality among pa-
tients infected with agr-dysfunctional S. aureus27. These observations were consistent with 
in vitro studies showing that knocking out agr enhances biomass accumulation by the 
mutants34,35. 
However, recently, doubts have arisen concerning the determination of agr-
dysfunction, since it was discovered that even though the lack of delta-hemolysin produc-
tion is a phenotypic marker for a nonfunctional agr locus, RNAIII transcription was not 
absent but rather late26. Although the agr-II genotype correlated clinically with vancomy-
cin treatment failure36, it was found that agr function, transcription and sequence did not 
influence vancomycin outcomes in an infective endocarditis model26. Therefore, it remains 
undefined as to how agr activity impacts treatment outcome within the agr-II (CC5) group. 
 
Another question to be answered is whether initial adhesion and biofilm formation of the 
various clonal lineages on polystyrene are in the same order of magnitude to other sur-
faces. Using flow-cells to grow biofilm on abiotic surfaces as glass, polycarbonate and 
titanium, USA300 showed only minor differences in film thickness, total biomass and sur-
face coverage37. Also, MLST CC8 strains easily adhered to human tissue such as airway 
epithelial cells38,39. 
 
Finally, there is a limitation in the quantification of biofilm employed by ourselves and 
others. Although the microtiter plate assay has been worldwide adopted as a useful 
biofilm performance test23,40, it’s relevance for the clinical setting, i.e. device-related at-
tachment of bacteria, has never been indisputably proven41. Moreover, a non-invasive 
diagnostic tool to detect biofilm in vivo is currently not available42,43, but would be highly 
advantageous. Infected implant or indwelling device removal, necessary to isolate the 
causative micro-organism is not always possible or desirable44 but often mandatory45, and 
many replaced catheters become reinfected46. Strains could under circumstances where 
preservation of the biomaterial is desirable only be indirectly isolated when quorum-
sensing induced dispersal is followed by spread via the bloodstream47. In case of device 
removal, screening for biofilm can be performed by a range of standardised methods. 
Beside microscopic imaging techniques, the role plate assay48, sonication and scraping 
methods are available49,50. Although the roll-plate assay is not appropriate for endoluminal 
evaluation of central venous catheters (CVCs), the roll-plate assay remains useful as a refer-
ence standard for catheter tip culture. We therefore chose this method for bacterial adher-
ence analysis when testing new anti-microbial adhesive and anti-thrombogenic coatings. 
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Prevention of biofilm formation 
Prevention of initial adherence of bacteria to indwelling devices is of unprecedented im-
portance to prohibit biofilm formation and consequently bacteraemia on the long term. 
Further improvements in biomaterials are essential since the interventions to prevent 
complications with CVCs are often unsuccessful51,52. In chapter 4 and 5 we assessed the 
dual application of silver particles and heparin in hydrophilic surface coatings in order to 
overcome bacterial adherence on and thrombotic occlusions of catheters. 
Advantages of silver as anti-adherent component in coatings are broad-spectrum an-
timicrobial activity, a slow appearance of resistance53 and the lack of cross-resistance to 
antibiotics54. A major concern about the clinical application of silver coatings is a general 
safety issue. Although silver is considered less toxic to human cells than other metals55,56, 
the potential hazard to human health of long-term exposure is not fully investigated57. 
Most research focuses on silver nanoparticles (1 – 110 nm)58, since nanoparticles were 
considered to prolong antimicrobial activity because of their large surface to volume ra-
tio59,60. It accounts for a sustained release of Ag+ ions at the coating-tissue interface61. It 
could be argued that slightly larger silver particles, i.e. microparticles of approximately 1 
μm, maintain strikingly refractory to microbial colonization whereas particles distribution 
throughout the body would be limited62. Since, it was demonstrated in vivo by Lankveld et 
al. that nanoparticles of smaller sizes were distributed more extensively to various kinds of 
tissues than the larger silver particles62. It is plausible that size-dependent distribution is 
coupled to size-dependent toxicity. Silver nano-particles have been demonstrated to bind 
to and transfer across cell membranes of lung fibroblasts, glioblastoma cells63, keratino-
cytes and macrophages64. Their internalisation and oxidative nature induces inflammatory, 
genotoxic, and cytotoxic characteristics57. Some suggest that the window between mini-
mum concentrations lethal to microbes and those toxic to the host is narrow65, since the 
intensity of toxicity seems strongly associated with the local available concentration57,64. 
Therefore the release of silver ions from the biomaterial should be kept under control, 
which will be the ultimate challenge for further studies. Our silver containing coatings 
remained antimicrobial after several stress-tests with high bacterial inocula under vigor-
ously shaking conditions and many refreshments of medium to remove released silver 
ions. However, as shown in chapter 5, coatings containing only heparin lost their anti-
adherent properties after only a few challenges, in concordance with a previously shown 
short-term controlled release of heparin from comparable coatings66. In contrast, silver and 
heparin synergistically maintained the adherence at a lower level than silver alone during 
all the consecutive challenges. Altogether, this suggests that the release of heparin from 
the coating is retarded by the presence of the silver particles, and that simultaneously the 
release of silver ions is augmented by co-transport upon binding to heparin molecules. To 
prove this novel concept, the release of heparin and silver from all coating compositions 
should be analytically measured over time. 
Although the addition of heparin to the silver coatings was remarkably successful in 
prevention of in vitro adherence of S. aureus, the effect of heparin is considerably unpre-
dictable in vivo. On one hand, heparin can specifically bind certain proteins that may pos-
sess antimicrobial activity67,68. On the other hand, heparin might stimulate biofilm forma-
tion when initial adherence could not be fully prohibited69. In a meta-analysis of different 
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CVCs, heparin-bonded catheters were associated with a significantly lower rate of catheter 
related blood stream infections (CRBSI) compared with standard catheters, but no reduc-
tion in colonisation was shown70. Since CVC colonization can be a precursor of CRBSI, it 
would be possible that heparin prohibited dispersal of attached bacteria. Silver-containing 
CVCs performed disappointingly in another meta-analysis not demonstrating any signifi-
cant reduction in colonization or CRBSI compared to standard non-surface modified poly-
urethane or silicone catheters71. However, many studies included in the meta-analysis 
suffered from substantial shortcomings in methodological quality. The fact that the forma-
tion of a fibrin sleeve and CVC-related infection are interrelated72 stresses the importance 
of designing biomaterials that suppress both initial attachment of micro-organisms and 
the deposition of fibrin and platelets. The preventive capacity of heparin or silver particles 
alone within a coating might be highly divergent from their combined counterparts. Be-
fore clinical assessment of our identified NVP/BMA coating formulations that effectively 
combine biocidal and anticoagulant features could be performed, they should meet the 
requirements of negligible silver losses in order that patients are not exposed to avoidable 
risk. Medical device regulation is currently a matter of debate since variable standards for 
device regulatory approval exist and post-marketing surveillance is poorly organized73,74. 
 
Another way to approach prevention of biofilm formation is the prophylactic permanent 
treatment with drugs that prohibit the initial attachment of bacteria. In chapter 7 we 
evaluated thioridazine and reserpine, which have proven functionality as an efflux pump 
inhibitor. Trans-membrane transporters, including efflux pumps, have been suggested to 
play a functional role during the biofilm maturation and disassembly process75,76. We con-
cluded that thioridazine and reserpine could only hinder biofilm accumulation of MLST 
CC8-associated S. aureus strains at 0.1% glucose, probably due to differences in the trans-
membrane transporter capacity among the tested strains with different MLST-associated 
genetic backgrounds, i.e. CC5, CC22 and CC30. Fluctuations in nutrient and oxygen levels 
inside the biofilm and the availability in the surroundings could lead to clonal lineage-
specific modification of tricarboxylic acid (TCA) cycle activity and consequently multiple 
gene regulator (mgrA) expression. It seems that mgrA plays a central role in efflux pump 
expression, but it also directly interferes with biofilm formation via agr and autolysis asso-
ciated regulators, i.e. cidA and lrgAB. Our observations of the influences of EPIs on biomass 
require further research focussing on gene expression of genes involved in biofilm forma-
tion and efflux and influx pump activity to confirm our presumptions. It is also worthwhile 
to evaluate the simultaneous exposure to EPIs and antibiotics or to combine two or more 
types of EPIs affecting an extended range of S. aureus trans-membrane transporters. 
One of the main efflux transporter proteins in S. aureus is NorA. As shown in chapter 6, 
we demonstrated that norA overexpression was restricted to a few clonal lineages associ-
ated with MLST CC5, CC30 and CC45. We did not find a correlation between S. aureus with 
mutations in the promoter region of norA and the level of efficacy of EPIs against the same 
strains under biofilm conditions. The discordance could be explained in terms of a weak 
correlation between mutations in the promoter region of norA and the actual expression 
on a protein level or by the presence of other trans-membrane transporters that play a 
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more crucial role in adjusting to nutrient availability and in the release of toxic molecules 
from the cytosol. 
Disassembly of the biofilm matrix 
The observed dormancy of bacteria in the deeper parts of the biofilm hinders the killing by 
antibiotics like ß-lactams and glycopeptides that require an active life-cycle or cell-wall 
turnover to exert their efficacy. Under planktonic conditions, ß-lactams covalently modify 
the active site of penicillin binding proteins (PBPs), enzymes that synthesize and alter 
bacterial peptidoglycan77, and consequently inhibit the cross-linking of linear strands of 
peptidoglycan into a fishnet-like polymer that surrounds the bacterial cell and confers 
osmotic stability. Furthermore, ß-lactams interfere in the balance between peptidoglycan 
synthesis and autolysis. Activation of the cell division machinery seems to be required for 
ß-lactam induced cell lysis77. It is a plausible scenario that nutrient deprivation deep within 
the biofilm limits cell division, an aspect that deserves further research attention. Besides 
slow cell division, the biofilm matrix provides a diffusion barrier to most antimicrobial 
compounds78. This would lead to subinhibitory concentrations deep inside a biofilm. As a 
result, ß-lactamase plasmid-related (hyper)induction might be the consequence. Accumu-
lation of the overproduced enzyme in the polysaccharide matrix in the immediate sur-
rounding vicinity of the bacteria impairs the penetration and efficacy of ß-lactams even 
more. As shown in chapter 8, the pBORa53-like plasmid-containing borderline oxacillin 
resistant S. aureus (BORSA) are more prone to ß-lactamase induction. Although these 
strains were not capable to produce large amounts of biomass (data not shown), multi-
species biofilm or multiclonal aggregates containing BORSA could potentially further 
increase the biofilm recalcitrance to beta-lactams. Previously observed high levels of ß-
lactamase inside biofilm were believed to originate from lysed bacteria or membrane 
vesicles liberated from embedded bacteria79. 
This highlights the fact that conventional resistance mechanisms might contribute to 
the bacterial survival inside biofilm. Simultaneous exposure to matrix destructive agents 
seems to be essential for efficacy of penetration-limited antibiotics. We evaluated in chap-
ter 3 whether rifampicin could serve as a pore-forming agents as adjunct to oxacillin. We 
argued that if rifampicin is able to destruct the biofilm matrix, then rifampicin should also 
be active against pre-formed biofilm of isogenic rifampicin-resistant mutants. Using an in 
vitro static, microtiter plate biofilm assay, we demonstrated that the addition of rifampicin 
to oxacillin neither reduced the viable count nor affected the amount of biomass. More-
over, the efficacy of rifampicin against biofilm established by the rifampicin-susceptible 
parent isolates was highly variable. So for this reason of unpredictability, it seems neces-
sary to re-evaluate rifampicin as standard adjunctive agent to empirically initiated therapy 
in patients with S. aureus infections with clinical suspicion of biofilm involvement. 
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Closing remarks 
Scientific progress in identifying the key bacterial and fungal biofilm associated (genetic) 
elements and unravelling the biofilm related pathways provides a platform for the devel-
opment of novel therapeutic agents against already established biofilm. An abundance of 
biofilm modifying or disruptive substances has already been tested in vitro against mature 
biofilm. It seems to be only a matter of time before the first intravenous applicable anti-
biofilm agent will get market approval. At the same time the development of improved 
biomaterials for (permanent) indwelling devices, such as heart valves, CVCs and prosthetic 
joints, continues to provide a better basis for the prevention of bacterial adherence and 
consequently biofilm formation. This is of ultimate importance since biofilm-associated 
infections remain inherently difficult to treat and device removal is still the mainstay of 
clinical management. 
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Summary 
 
During recent decades it has been discovered that many serious chronic and/or recurrent 
infections including endocarditis, osteomyelitis and CVC-related bacteremia are biofilm 
associated. Upon initial adherence to a surface, bacteria consequently become embedded 
in a selfproduced protective matrix consisting of a mixture of bacterial components and 
substances extracted from the environment. The biofilm matrix forms a surrounding pro-
tective barrier against host defences and antibiotic treatment. Unravelling the principles 
behind this survival strategy contribute to the goal-oriented design and application of 
preventive anti-biofilm technologies in biomaterial science and can lead to novel ways to 
reinforce the destruction of pre-existing mature biofilm. 
 
In contrast to Staphylococcus epidermidis biofilm, most Staphylococcus aureus biofilm are 
extracellular polysaccharides (mostly referred as PIA, PNAG or slime) independent, as we 
found when evaluating 254 S. aureus clinical isolates by means of Congo red agar (CRA) 
screening. On CRA plates, only 9% of the strains displayed a distorted morphology, associ-
ated with slime formation (chapter 2). CRA-screening is therefore not useful as a high-
throughput screening assay for S. aureus biofilm formation. To find out whether the ge-
netic background is a predisposing factor for biofilm development, the total accumulated 
amount of biomass in polystyrene micro-titre plates within 24 h was related to the genetic 
background. At the physiologic blood glucose concentration (0.1%), more than 60% of the 
S. aureus strains associated with multilocus sequence typing (MLST) clonal complex (CC)8 
produced large amounts of biomass compared to 0–7% for various other clonal lineages. 
The strong biofilm forming capacity of the CC8 associated strains was observed both for 
bloodstream isolates as well as for their commensal counterparts (chapter 2). Accessory 
gene regulator (agr) type II has been previously put forward as predisposing factor for 
promoting abudant biofilm formation. We did not find this correlation, since strains with 
agr-II genotype includes also genetic backgrounds that did not produce large amounts of 
biomass, such as CC15, CC12, and spa-types associated with MLST CC5. However, it was 
confirmed that various strains with spa-type t002 were indeed strong biofilm formers. In 
general, strains with spa-type t002 have been frequently isolated from patients with or-
thopaedic device-related infections. 
 
It is known that bacteria embedded in biofilm are far more recalcitrant to antibiotics than 
their planktonic counterparts. Nevertheless, rifampicin is often used as adjunctive agent to 
empirically initiated therapy in situations of clinical suspicion of biofilm involvement. The 
rationale for recommending rifampicin administration is based on the ability to penetrate 
into biofilm and a presumed activity against dormant bacteria. Rifampicin has been exten-
sively investigated for prosthetic device-related infections and found beneficial in terms of 
clinical and/or bacteriological cure rates. However, the number of studies for other indica-
tions is limited and the outcome often contradictory. Moreover, rifampicin resistant strains 
have emerged during treatment. As rifampicin diffuses more quickly into the biofilm than 
the companion agent, it would be logical that without proper destruction of biomass 
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rifampicin resistant subpopulations emerge. These could be responsible for persistent or 
re-occurring infections. It was hypothesized that if rifampicin possesses pore-forming or 
matrix destructive capabilities, rifampicin with a companion agent should be effective 
against rifampicin-resistant embedded bacteria. Using a static in vitro biofilm assay, this 
concept was evaluated in chapter 3 with oxacillin alone or in combination with rifampicin 
against biofilm formed by rifampicin-susceptible or isogenic rifampicin-resistant methicil-
lin-susceptible S. aureus (MSSA). Rifampicin (1 μg/mL) added to oxacillin enhanced the 
reduction in biomass produced by most rifampicin-susceptible isolates compared to ox-
acillin alone. However, the greater reductions achieved were highly variable, ranging from 
17 to 54% compared to 4% for oxacillin alone. Strains embedded by more biomass at the 
moment of initial exposure showed a diminished reduction in viable count. None of the 
biofilm formed by isogenic rifampicin-resistant mutants yielded a synergistic reduction in 
biomass and viable count upon rifampicin addition to oxacillin. Rifampicin as adjunctive 
agent is therefore unwarranted against biofilm formed by rifampicin-resistant strains and is 
unpredictable in case of unknown rifampicin susceptibility. Especially since rifampicin 
resistance can be easily induced in the absence of a companion agent, which might be the 
result of slower diffusion into the biofilm. 
 
Substances suitable for intravenous application that specifically destruct preformed ma-
ture biofilm are under investigation but are not or rarely available on the market yet. A 
more straight-forward approach is to prevent biofilm formation. Since biofilm formation 
mostly starts with initial attachment to a surface, this step should be hindered to prevent 
biofilm formation. As adhesion and thrombus formation are interrelated we aimed in 
chapter 4 and 5 to develop coatings for central venous catheters (CVCs) that are both anti-
microbial and anti-thrombogenic as well. For this purpose, hydrophilic bifunctional bio-
compatible coatings containing sodium heparin and silver particles were systematically 
developed. The coatings were examined in different in vitro test settings. Blood compatibil-
ity was assessed through thrombin generation and thrombocyte adherence assays, while 
exit-site experiments and long-term challenge tests were employed to investigate bacte-
rial adherence and killing. Adhesion of both reference strain (ATCC 29213) and clinical 
isolates of S. aureus was strongly inhibited by silver alone, but surprisingly, heparin aug-
mented the antimicrobial activity of silver, while maintaining its anticoagulant function. 
The effect of changing the coating’s hydrophilicity, the type of silver stabilization or the 
silver content was also assessed. The less hydrophilic SlipSkin® material (SS70:30), with a 
NVP/BMA molar ratio of 70/30, was expected to have slower release of embedded heparin, 
and –hence– a more sustained antimicrobial effect due to a long-lasting improved mobility 
of silver particles. Our expectations were confirmed with the pre-washing experiments, 
demonstrating that the longer the pre-wash with milliQ water, the more S. aureus cells 
adhered to SS90:10-Ag-Hep at the moment of bacterial exposure, while the number of 
adhered bacteria remained constant over time when SS70:30-Ag-Hep specimens were 
more intensively pre-washed. Doubling the silver content (SS70:30-Ag2x-Hep) did not im-
prove the long-term prevention of adherence of S. aureus and reduced the viable count in 
the time-kill assays to a similar extent as the specimens containing the standard content of 
silver (SS70:30-Ag-Hep). 
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All experimental results taken together with observations described in the literature 
pointed out that antimicrobial synergy of heparin and silver is best explained by binding of 
Ag+ ions to heparin within the swollen coating, consequently followed by release of Ag+-
heparin ligand-carrier complexes upon immersion of the coatings in an aqueous environ-
ment such as blood. 
 
It is generally accepted that the recalcitrance to antibiotics, and also the inability of the 
host’s immune system to clear S. aureus biofilm, cannot be solely attributed to the diffusion 
barrier formed by the matrix. Due to the cramped conditions inside the deeper parts of the 
biofilm, it is likely that locally a waste disposal problem exists. As described by others, the 
matrix structure is partially interspersed with channels that are considered essential for 
nutrition and oxygen support and waste drainage. Still, the supply of nutritious substances 
is believed to be insufficient, which may clarify the dormancy of embedded bacteria. The 
high consumption of nutrients, necessary to produce extracellular polymeric substances 
(EPS) for the matrix, very likely exacerbates the waste management difficulty. Enhanced 
extrusion of toxic components from the cytosol via upregulation of transmembrane trans-
porters has been suggested as a manner to help pass off toxins. 
In first instance we investigated whether certain clonal lineages of S. aureus were more 
prone to mutations in the promoter region of the norA gene. NorA is one of the main efflux 
transporter proteins in S. aureus. As notified in chapter 6, we showed that the overexpres-
sion of norA was associated with sequence types of all three known NorA alleles, i.e. norA 
wt, norA1199 and norAII. But the overexpressing strains were restricted to a few clonal 
lineages including (mainly methicillin resistant) S. aureus strains associated with MLST CC5, 
CC30 and CC45. The question remained whether these mutations would lead to augmen-
tation of efflux pump expression whenever these strains become embedded into a biofilm. 
Recent observations already pointed out that efflux pump inhibitors (EPIs) like reserpine or 
thioridazine could prevent in vitro biofilm formation of a single tested CC8-associated S. 
aureus strain. We incorporated strains associated with MLST CC8, CC22, CC5 and CC30 in 
our in vitro experiments to test whether reserpine and thioridazine could prohibit initial 
attachment. We confirmed that under 0.1% glucose conditions thioridazine effectively 
prevented biomass formation of CC8 associated strains (chapter 7). Interestingly, this 
genetic background was not linked to norA overexpression, since no mutations that could 
lead to norA hyperexpression were detected among our collection of CC8 isolates (n=41). 
There was no effect of EPIs on pre-mature biofilm of CC22 associated strains. Biomass 
production of CC30 and CC45 associated strains was specifically prevented by thioridazine 
at a higher supplemental glucose concentration, i.e. 1%. Independent of the genetic back-
ground, reserpine was inferior to thioridazine in the prevention of biomass accumulation 
at both tested glucose concentrations. Remarkably, at 1% glucose, biomass formation of 
MLST CC8-associated strains was elevated upon exposure to both EPIs. We presume that 
thioridazine and reserpine have a non-specific affinity for a variety of transporters, includ-
ing nutrient-importers and toxin exporters. This would consequently implicate that glu-
cose availability and/or metabolism influences the effects of EPIs on biofilm formation. 
Blocking glucose importers at 0.1% glucose (extracellular concentration) would result in 
suppression of biomass formation, especially among strains with a high carbohydrate 
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uptake capacity, since a deficiency in intracellular amount of glucose would lead to tricar-
boxylic acid (TCA) cycle activation. Enhancement of TCA cycle intermediates is known to 
correlate with biofilm repression. Abundantly imported amounts of carbohydrates at 1% 
glucose would theoretically result in intracellular acidification due to an inactive TCA cycle 
and the conversion to acetate. Concerning the CC8-associated strains, we hypothesized 
that blocking the efflux of acidic metabolites, such as acetate, promotes – instead of pre-
vents – biomass formation, while influx of glucose is not much affected by the excessive 
availability in the environmental medium. 
In conclusion, the glucose and oxygen presence within microbial biofilm communities 
is changing over time, which concomitantly modifies the TCA cycle activity of the embed-
ded bacteria. Unique accumulation molecules and metabolic heterogeneity have been 
observed on a large-scale basis by others. We hypothesized that the biofilm life-cycle turn-
over is clonal lineage specific, as is the expression of transmembrane transporters during 
the different consecutive stages of biofilm formation. This makes EPIs inappropriate in the 
prevention of early biomass accumulation. 
The impact of EPIs on pre-existing mature biofilm was also evaluated and biofilm disas-
sembly was less pronounced (CC8) or even absent (CC22, CC30 and CC45) compared to the 
prevention of biomass formation. It seems that the penetration barrier of mature biofilm 
for most antibiotics also clearly exist for the EPIs themselves. 
 
The biofilm matrix could retain waste materials by improper functioning of down-
regulated transmembrane transporters, but could also keep excreted substances necessary 
for their defence in their immediate surrounding vicinity. As noticed previously, entrap-
ment and accumulation of ß-lactamases inside the biofilm occurs. Borderline oxacillin-
resistant S. aureus (BORSA) are potentially interesting in this context, since these strains 
have been associated with the hyperproduction of ß-lactamases (penicillinases and/or 
methicillinases). In chapter 8 we investigated a collection of BORSA isolates in order to 
unravel whether they could be killed under planktonic conditions with a standard ß-lactam 
antibiotic, i.e. oxacillin. Time-kill curves analysis was also performed with comparative 
alternatives of oxacillin, such as vancomycin, daptomycin and linezolid. Plasmid profile 
analysis revealed that a part of our collection of BORSA strains, with oxacillin MIC ≤ 2 mg/L 
and including the BORSA reference strain VU94, possesses a pBORa53-like plasmid that 
encodes for ß-lactamases including methicillinases. In the other BORSA, with oxacillin MIC 
≥ 4 mg/L, pMW2-like penicillinase-encoding plasmids were identified. The pBORa53-like 
plasmid containing BORSA showed markedly more regrowth in the time kill curve studies 
when testing in the presence of oxacillin. The oxacillin killing activity was also attenuated 
against BORSA with oxacillin MIC ≥ 4 mg/L compared to ATCC 29213 (MSSA reference 
strain), since the pharmacodynamic parameter (EC50 or εC50) revealed that the potency of 
oxacillin was markedly reduced (approximately 10×). Since these BORSA do not produce 
methicillinases upon induction by oxacillin, it was anticipated, but yet not proven, that 
these BORSA obtained modifications in the penicillin-binding proteins (PBPs) 1, 2 and/or 4 
genes. Further investigation into ß-lactam dosing strategies against different type of 
BORSA strains is warranted in order to avoid putative therapy failure. We discovered that 
not all BORSA are equally interesting for biofilm related research. Especially the pBORa53-
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like plasmid-containing BORSA should be evaluated in biofilm experimental settings, since 
they are the most sensitive to ß-lactamase (methicillinase) induction. However, a recently 
performed pilot experiment (data not shown) revealed that our pBORa53-like plasmid-
containing BORSA, which belonged to the associated MLST clonal lineage CC25 were not 
capable to produce large amounts of biomass at 0.1% glucose, when compared to the 
MSSA and MRSA isolates associated with MLST CC8. Nevertheless, it could be interesting to 
introduce BORSA strains in multi-species biofilm. 
Additional to the main purpose of these findings, we examined an alternative method 
to evaluate time-kill data. When performing time-kill analysis, it should be recommended 
to take pharmacodynamic parameters into account as efficacy markers in addition to tradi-
tional end-points, like “time to 99.9% kill” or presenting the number of remaining CFU/mL 
at a certain time point. These traditional methods to present efficacy data do not properly 
reflect all available time-kill data, including e.g. regrowth or alterations in the growth rate 
over time. By taking the absolute difference in log10 viable count between growth or killing 
in the absence and presence of an antibiotic, i.e. the area between the curves over 24h 
(ABC0–24h), all available time-kill data could be incorporated in the concentration-effect 
parameters. 
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In de laatste decennia heeft men ontdekt dat chronische en recidiverende infecties waar-
onder endocarditis, osteomyelitis en centraal-veneuze catheter (CVC)-gerelateerde bacte-
riëmieën biofilm geassocieerd zijn. Na initiële aanhechting van bacteriën aan een opper-
vlak zorgen deze er vervolgens voor dat ze zich inkapselen in een zelfgeproduceerde ma-
trix bestaande uit bacteriële componenten en substanties die zijn onttrokken uit hun 
nabije omgeving. Deze biofilm matrix waarin de bacteriën zich bevinden biedt bescher-
ming tegen het menselijke afweersysteem en antimicrobiële therapieën. Het ontrafelen 
van de mechanistische principes van deze overlevingsstrategie van bacteriën, zal bijdra-
gen aan doelgerichte anti-biofilm toepassingen om al gevormde biofilm te kunnen afbre-
ken en aan het ontwikkelen van biomaterialen die biofilm vorming kunnen voorkomen. 
 
In tegenstelling tot Staphylococcus epidermidis biofilm bestaat de matrix van Staphylococ-
cus aureus biofilm zelden uit extracellulaire polysaccharides, ook wel aangeduid als bacte-
rieel slijm of PNAG (Poly-ß(1,6)-N-acetyl-D-glucosamine). Dit is overeenkomstig onze be-
vindingen met de Congo rood agar (CRA) test van 254 klinische S. aureus isolaten. Bij de 
beoordeling van de kolonies op de agar platen bleek dat slechts 9% van de stammen een 
afwijkende morfologie, kenmerkend voor slijmvormende stammen, vertoonden (hoofd-
stuk 2). De CRA screenings test is om deze reden niet geschikt als diagnostische bepa-
lingsmethode om biofilmvorming van S.aureus mee aan te tonen. Om na te gaan of de 
genetische achtergrond van de bacterie een predisponerende factor is voor biofilmvor-
ming, werd de totale hoeveelheid biomassa die in 24 uur werd geproduceerd gerelateerd 
aan de genetische achtergrond van de betreffende bacterie. Bij een fysiologische glucose 
concentratie van 0,1% was 60% van de S. aureus stammen met een multilocus sequence 
typing (MLST) klonaal complex (CC)8 geassocieerde genetische achtergrond in staat een 
bovengemiddeld grote hoeveelheid biomassa te genereren terwijl dit voor stammen met 
andere genetische achtergronden maar in 0-7% van de gevallen gold. De goede biofilm 
vormende eigenschap van de CC8 geassocieerde stammen werd zowel bij bloedstroom als 
commensale isolaten waargenomen (hoofdstuk 2). Recent werd verondersteld dat het 
accessory gene regulator (agr) type II een predisponerende factor zou kunnen zijn voor het 
bevorderen van overmatige biofilm vorming. Deze correlatie hebben wij niet kunnen 
bevestigen. Immers stammen met genetische achtergronden die geen sterke mate van 
biomassa vorming vertoonden, zoals spa-typen gerelateerd aan MLCT CC15, CC12 en CC5 
behoren tot agr type II. Echter verschillende stammen met spa type t002 gerelateerd aan 
CC5 bleken wel degelijk sterke biofilm vormende eigenschappen te bezitten. Dit is over-
eenkomstig de bevindingen in de dagelijkse praktijk: stammen met spa type t002 worden 
veelvuldig geïsoleerd bij orthopedische patiënten met kunstmateriaal geassocieerde infec-
ties. 
 
Bacteriën omgeven door een biofilm zijn vele malen meer recalcitrant voor antibiotica dan 
wanneer deze in planktonische omstandigheden verkeren. Desalniettemin, wordt rifampi-
cine vaak als additief toegevoegd aan reeds empirisch geïnitieerde antibiotische therapie, 
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met name in situaties met klinische verdenking op biofilm betrokkenheid. De reden voor 
de toevoeging van rifampicine is gebaseerd op de eigenschap van goede penetratie in 
biofilm en een veronderstelde activiteit tegen bacteriën in “ruste”. De toepassing van 
rifampicine bij prothese-gerelateerde infecties is uitvoerig bestudeerd en zowel ten aan-
zien van de kans op klinische verbetering als op vermindering van het aantal bacteriën is 
de meerwaarde aangetoond. Echter, het aantal uitgevoerde onderzoeken met rifampicine 
voor andere indicaties is beperkt en/of de uitkomsten zijn tegenstrijdig. Ook is gebleken 
dat rifampicine resistente subpopulaties kunnen ontstaan tijdens rifampicine behandeling. 
Aangezien rifampicine vermoedelijk sneller diffundeert in de biofilm dan het antibioticum 
waaraan het is toegevoegd, is het logisch dat zonder goede afbraak van biomassa rifampi-
cine resistente subpopulaties ontstaan. Deze kunnen vervolgens aanleiding geven tot 
persisterende of recidiverende infecties. Indien rifampicine in staat zou zijn om poriën te 
vormen in de biofilm, of de matrix zou kunnen afbreken, dan zou rifampicine toegevoegd 
aan empirische therapie in staat moeten zijn om biofilm gevormd door rifampicine-
resistente S. aureus stammen te verwijderen. Deze hypothese werd in hoofdstuk 3 getest 
middels een statische in vitro biofilm opstelling waarbij biofilm, gevormd door rifampicine 
gevoelige of isogene rifampicine-resistente methicilline gevoelige S. aureus stammen, 
werden blootgesteld aan oxacilline alleen en in combinatie met rifampicine. Rifampicine (1 
mg/L) toegevoegd aan oxacilline leidde bij rifampicine-gevoelige stammen in vrijwel alle 
gevallen tot een sterkere afname van de geproduceerde biomassa in vergelijking met 
blootstelling aan alleen oxacilline. De additionele reductie in biomassa varieerde voor de 
combinatie tussen de 17% en 54% in vergelijking met een afname van gemiddeld 4% voor 
oxacilline alleen. Stammen die initieel omgeven werden door meer biomassa waren min-
der gevoelig voor behandeling met rifampicine en oxacilline, zoals bleek uit het feit dat het 
aantal levende bacteriën per biofilm minder afnam. Een synergistische reductie in biomas-
sa of in aantal levende bacteriën per biofilm ten gevolge van oxacilline en rifampicine 
blootstelling werd niet bereikt bij isogene rifampicine resistente mutanten. Om deze reden 
is rifampicine niet geschikt als additieve strategie tegen biofilm gevormd door rifampicine 
resistente stammen. Tevens is de meerwaarde van rifampicine onvoorspelbaar wanneer de 
rifampicine gevoeligheid onbekend is. Bovendien kan rifampicine resistentie op eenvou-
dige wijze worden geïnduceerd in de biofilm in lokale afwezigheid van een ander antibio-
ticum. De kans hierop is aanwezig aangezien andere antibiotica langzamer diffunderen in 
de biofilm dan rifampicine. Daarom wordt in de kliniek gewacht met het toevoegen van 
rifampicine tot de bacteriële load verlaagd is.   
 
Verschillende stoffen die een reeds gevormde volgroeide biofilm kunnen aantasten of 
afbreken, en die intraveneus kunnen worden toegediend, zijn nog niet of nauwelijks op de 
markt beschikbaar. Een alternatieve manier om biofilm vorming te lijf te gaan is het voor-
komen van biofilm vorming door middel van preventieve maatregelen. Aangezien biofilm 
vorming start met aanhechting aan een oppervlak, is het duidelijk dat deze initiële stap 
verhinderd moet worden. Zoals beschreven in hoofdstuk 4 en 5 zijn adhesie en trombus 
vorming aan elkaar gerelateerd. Om die reden werd een coating ontwikkeld voor centraal 
veneuze katheters (CVCs) die zowel antimicrobieel als antitrombogeen is. Om dit te berei-
ken werden op systematische wijze hydrofiele bifunctionele biocompatibele coatings 
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ontwikkeld die zowel natriumheparine als zilver deeltjes bevatten. De coatings werden 
getest met behulp van verschillende in vitro meetopstellingen. De compatibiliteit met 
bloed werd onderzocht door middel van trombine generatie metingen en door microsco-
pisch naar de aanhechting van trombocyten te kijken. Bacteriële aanhechting en afdoding 
werden geanalyseerd met behulp van langdurige blootstellingsexperimenten en de zoge-
naamde katheter-tip test. De adhesie van zowel een S. aureus referentie stam (ATCC 29213) 
als die van klinische isolaten werd in hoge mate verhinderd door coatings met alleen zilver. 
Het effect van zilver werd versterkt indien ook heparine in de coating was opgenomen. De 
anticoagulerende werking van heparine werd niet tenietgedaan door de aanwezigheid 
van zilver. Het effect van aanpassing van de hydrofiliciteit van de coating, de wijze waarop 
het zilver was gestabiliseerd en het veranderen van de hoeveelheid zilver per coating werd 
eveneens onderzocht. Het was de verwachting dat de minst hydrofiele samenstelling van 
het coatingsmateriaal SlipSkin® (SS70:30), met een NVP/BMA molaire ratio van 70/30, zou 
leiden tot een tragere afgifte van heparine. Dit zou dan bijdragen aan een verlengd anti-
microbieel effect vanwege het feit dat de zilverdeeltjes onder invloed van heparine lang-
duriger en tevens gelijkmatiger uit de coating zullen vrijkomen. Dit werd bevestigd met 
een experiment waarbij de coatings werden voorgewassen met milliQ water om langdurig 
gebruik te simuleren. Aangetoond werd met de SS90:10-Ag-Hep materialen, dat hoe lan-
ger er werd voorgewassen, des te meer S. aureus bacteriën konden aanhechten zodra de 
coatings werden blootgesteld aan bacteriën. Daarentegen bleef het aantal aangehechte 
bacteriën constant indien de SS70:30-Ag-Hep coatings intensiever werden voorgewassen. 
Het verdubbelen van de geïncorporeerde hoeveelheid zilver (SS70:30-Ag2x-Hep) had geen 
effect op de lange termijn preventie ter voorkoming van S. aureus aanhechting. Tevens 
bleek het aantal bacteriën dat werd gedood per tijdseenheid gelijk aan de coatings met de 
standaard hoeveelheid zilver (SS70:30-Ag-Hep).  
Wanneer we alle resultaten van de afzonderlijke experimenten gezamenlijk bekijken 
en deze vergelijken met de literatuur dan kan de waargenomen antimicrobiële synergie 
tussen heparine en zilver het best verklaard worden door binding van de zilverionen aan 
de heparinemoleculen in de opgezwollen coating gevolgd door het vrijkomen van de 
gevormde complexen na immersie van de coating in een waterige omgeving zoals bloed. 
 
De algemeen geaccepteerde opvatting betreffende de recalcitrantie van S. aureus biofilm 
tegen antibiotica en het lichaamseigen afweersysteem is dat dit niet volledig kan worden 
toegeschreven aan de diffusiebarrière die gevormd wordt door de biofilmmatrix. De dichte 
opeenstapeling van bacteriecellen in de diepere lagen van de biofilm zouden er voor 
kunnen zorgen dat lokaal de afvalstoffen niet goed kunnen worden afgevoerd. Anderen 
beschreven dat de matrix kanalen bevat die als essentieel worden beschouwd voor de 
aanvoer van voedingsstoffen en zuurstof en de drainage van afvalstoffen. Desondanks 
wordt de beschikbaarheid van voedingssubstanties als ontoereikend beschouwd en vormt 
daarmee de gangbare verklaring voor de latentie van de omgeven bacteriecellen. De grote 
interne consumptie van nutriënten tijdens de opbouw- en/of uitbreidingsfase van de 
biofilm om voldoende extracellulaire polymere substantie (EPS) te vormen zorgt hoogst-
waarschijnlijk voor een exacerbatie van het afvalstoffenprobleem. Er wordt verondersteld 
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dat via upregulatie van transmembraan transporters toxische componenten uit het cytosol 
verwijderd kunnen worden.   
In eerste instantie onderzochten wij of bepaalde S. aureus klonale complexen vatbaar-
der zijn voor mutaties in de promoterregio van het norA gen. NorA is één van het meest 
voorkomende efflux transporter eiwitten in de celwand van S. aureus. In hoofdstuk 6 is 
beschreven dat norA overexpressie voorkomt bij stammen van alle drie de bekende se-
quentie typen van het norA allel, namelijk norA wt, norA1199 en norAII. Echter overexpres-
sie kwam slechts bij een beperkt aantal klonale complexen voor. Dit waren voornamelijk 
methicilline-resistente S. aureus geassocieerd met MLST CC5, CC30 en CC45. De cruciale 
vraag die resteert is of de mutaties in de promotor regio van het S. aureus norA gen tot 
overexpressie van efflux pompen zou leiden indien deze stammen omgeven worden door 
een biofilm. Recent is met een enkele CC8-geassocieerde S. aureus stam waargenomen dat 
efflux pomp inhibitoren (EPIs) zoals reserpine of thioridazine preventief in vitro biofilm 
vorming konden verhinderen. Om te onderzoeken of initiële aanhechting van andere 
stammen ook door reserpine en thioridazine voorkomen kan worden werden verschei-
dene MLST CC8, CC22, CC5 en CC30 geassocieerde stammen getest met behulp van in vitro 
opstellingen. Zoals beschreven in hoofdstuk 7, kon bevestigd worden dat bij een glucose 
concentratie van 0,1% thioridazine inderdaad in staat is om biomassa vorming door CC8 
geassocieerde stammen te verijdelen. Opvallend is dat bij deze genetische achtergrond 
overexpressie van norA onwaarschijnlijk is aangezien in de gehele collectie van CC8 isola-
ten (n=41) geen mutaties in de promotorregio van norA werden gevonden die gerelateerd 
zijn aan norA overexpressie. De EPIs hadden geen effect op reeds volgroeide biofilm van 
stammen geassocieerd met MLST CC22. De biomassa productie van stammen geasso-
cieerd met MLST CC30 en CC45 werd specifiek geremd bij een hogere glucose concen-
tratie van het medium, namelijk 1%. Onafhankelijk van de genetische achtergrond bleek 
dat bij beide geteste glucose concentraties reserpine inferieur was ten opzichte van thiori-
dazine in de preventie van biomassa vorming. Opmerkelijk is dat bij 1% glucose de bio-
massa vorming van de MLST CC8 geassocieerde isolaten bevorderd werd zodra deze wer-
den blootgesteld aan de EPIs. Mogelijk hebben thioridazine en reserpine een niet specifie-
ke activiteit voor een diversiteit aan transporters, zoals voor het opnemen van voedings-
stoffen en het uitscheiden van toxische componenten. Derhalve impliceert dit dat de 
beschikbaarheid van glucose en/of het metabolisme ervan de effecten van EPIs op biofilm 
vorming beïnvloedt. Het blokkeren van de glucose toevoerkanalen bij een extracellulaire 
glucose concentratie van 0,1% zou moeten resulteren in een vermindering van de biofilm-
vorming, met name bij stammen met een grote opnamecapaciteit van koolhydraten, 
aangezien een intracellulaire deficiëntie in glucose zal leiden tot activatie van de tricar-
boxylzuur (TCA) cyclus. Het is bekend dat verhoging van TCA cyclus intermediairen gecor-
releerd is aan biofilm repressie. Overvloedige influx van koolhydraten bij een glucose 
concentratie van 1% zou theoretisch resulteren in een intracellulaire verzuring ten gevolge 
van een inactieve TCA cyclus en de conversie naar acetaat. Betreffende de CC8-
geassocieerde stammen kwamen we tot de hypothese dat het blokkeren van efflux pom-
pen voor het verwijderen van zure metabolieten zoals acetaat, zou resulteren in een be-
vordering – in plaats van de preventie – van biomassa vorming, terwijl de influx van gluco-
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se niet veel beïnvloed zal worden door de overvloedige beschikbaarheid van glucose in 
het omgevingsmedium. 
Ten gevolge van fluctuatie in de tijd van de hoeveelheid glucose en zuurstof in micro-
biële populaties in biofilm verandert de activiteit van de TCA cyclus van de ingebedde 
bacteriën ook voortdurend. Unieke accumulatie moleculen en metabole heterogeniciteit 
zijn reeds veelvuldig beschreven in de literatuur. Wij veronderstelden dat de overgang van 
de opeenvolgende fasen van biofilmontwikkeling specifiek zijn per genetische achter-
grond en daarmee tevens ook de expressie van de afzonderlijke transmembraan transpor-
ters tijdens de verschillende fasen. Hierdoor zijn EPIs ongeschikt als preventief middel 
tegen de initiële accumulatie van biomassa.  
Het effect van EPIs op reeds bestaande volgroeide biofilm werd ook bestudeerd. De 
afbraak en/of het uiteenvallen van volgroeide biofilm was minder uitgesproken (CC8) of 
zelfs volledig afwezig (CC22, CC30 en CC45) in vergelijking met de effecten die zijn bereikt 
ter preventie van biomassa vorming. Ogenschijnlijk lijkt de penetratiebarrière van vol-
groeide biofilm die bestaat voor diverse antibiotica ook te bestaan voor de EPIs zelf.  
 
Indien de transmembraan transporters disfunctioneel of downgereguleerd zijn kan de 
biofilm matrix afvalmaterialen vasthouden evenals uitgescheiden substanties die noodza-
kelijk zijn voor zelfbescherming van de bacterie in de directe leefomgeving. Zo kunnen ß-
lactamases (penicillinases en/of methicillinases) opgesloten raken en vervolgens accumu-
leren in de biofilm. In dat verband zijn “borderline” oxacilline resistente S. aureus (BORSA) 
isolaten potentieel interessant aangezien deze stammen geassocieerd zijn met een over-
productie van ß-lactamases. Hoofdstuk 8 beschrijft de resultaten van afdodingsexperi-
menten van een aantal BORSA isolaten onder planktonische condities met een standaard 
ß-lactam-antibioticum zoals oxacilline en met andere vergelijkbare  antibiotica zoals dap-
tomycine, vancomycine en linezolid. Met behulp van een plasmide profiel analyse is ge-
bleken dat de BORSA stammen met een oxacilline MIC van ≤ 2 mg/L en de BORSA referen-
tiestam VU94, een pBORa53-achtig plasmide heeft dat codeert voor ß-lactamases inclusief 
methicillinases. Bij BORSA isolaten met een oxacilline MIC van ≥ 4 mg/L werd een pMW2-
achtig plasmide geïdentificeerd. De pBORa53-achtige plasmide bevattende BORSA stam-
men vertoonden meer hergroei in de afdodingscurves in een oxacilline bevattend groei-
medium. Ook bij de andere groep BORSA isolaten met een oxacilline MIC van ≥ 4 mg/L was 
de afdodingscapaciteit drastisch verminderd in vergelijking met de MSSA referentie stam 
ATCC 29213, zoals bleek uit de pharmacodynamische parameter (EC50 of εC50) die sterk 
gereduceerd was (ongeveer 10×). Aangezien deze BORSA stammen geen methicillinases 
produceren werd gesuggereerd dat in deze isolaten modificaties in de genen van de peni-
cilline-bindende peptiden (PBPs) 1, 2 en/of 4 zijn opgetreden. Meer onderzoek naar de 
doseringsstrategie van ß-lactam-antibiotica bij verschillende BORSA stammen lijkt nood-
zakelijk om mogelijk therapiefalen te voorkomen. We hebben vastgesteld dat niet alle 
BORSA’s even interessant zijn voor biofilm gerelateerd onderzoek. Met name de pBORa53-
achtige plasmide bevattende BORSA zouden verder geëvalueerd moeten worden onder 
biofilm condities, aangezien deze stammen het meest gevoelig zijn voor ß-lactamase 
(methicillinase) inductie. Echter, een recent uitgevoerd pilot experiment liet zien dat de 
pBORa53-achtige plasmide bevattende BORSA uit onze collectie, welke allemaal geassoci-
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eerd zijn met MLST CC25, niet in staat zijn grote hoeveelheden biomassa bij 0,1% glucose 
te genereren in vergelijking met de MLST CC8 geassocieerde MSSA en MRSA isolaten. 
Desondanks kan het relevant zijn om biofilmonderzoek met BORSA stammen uit te voeren, 
aangezien deze ook kunnen voorkomen in multi-species biofilm.   
Naast de hoofddoelstelling van dit onderzoek is een alternatieve methode geëvalueerd 
voor het analyseren van data verkregen uit afdodingscurves. Onze aanbeveling is dat aan 
de al bestaande traditionele eindpunten, als markers voor effectiviteit, zoals “de tijd totdat 
99,9% van de bacteriën is afgedood”, of het aantal CFU/mL na een bepaalde tijdsperiode, 
nieuwe pharmacodynamische parameters toegevoegd zouden moeten worden. De tradi-
tionele eindpunten om effectiviteit in uit te drukken zijn geen goede weergave van het 
totaal aan data afkomstig van afdodingsexperimenten. Processen zoals hergroei of ve-
randeringen in de groeisnelheid van de bacteriën tijdens het experiment worden niet 
verdisconteerd in de traditionele parameters. Door het absolute verschil in log10 eenheden 
levende bacteriën te nemen tussen de groeicurve zonder antibioticum en de afdodings-
curve in aanwezigheid van een antibioticum kan de oppervlakte tussen beide curven over 
24 uur berekend worden (ABC0-24h) en daarmee alle beschikbare data verwerkt worden in 
een concentratie-effect parameter. 
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aaa Autolysin adhesion protein 
AgNP Silver nanoparticle 
agr Accessory gene regulator 
AIP Auto inducing peptide 
ATCC American type culture collection 
aur Metalloprotease aureolysin 
bap Biofilm-associated protein 
bbp Bone sialoprotein-binding protein 
BHI Brain heart infusion (broth) 
BMA n-butyl methacrylate 
BORSA Borderline oxacillin resistant Staphylococcus aureus 
BSI Blood stream isolates 
BURP Based upon repeat pattern 
CAMBH Cation adjusted Mueller Hinton Broth 
CA-MRSA Community-associated methicillin/multidrug-resistant Staphylococcus aureus 
CC Clonal complex 
ccpA catabolite control protein A 
c-di-GMP 3’-5’-cyclic diguanylic acid 
can Collagen-binding adhesin 
CF Cystic fibrosis 
ClfA/B Clumping factor A and B 
CoNS Coagulase-negative staphylococci 
CLSI Clinical laboratory and standards institute 
CPS Counts per second (intensity) 
CRA Congo red agar 
CRBSI Catheter-related bloodstream infections 
CTAD Citrate-theophilline-adenosine-dipyridamole 
CVC Central venous catheter 
Eap Extracellular adherence protein 
ebh Extracellular matrix bindinghomoloque 
ebpS Elastin-binding protein 
ECP Extracellular proteases 
eDNA Extracellulair deoxyribonucleic acid 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-linked immunosorbent assay 
emp Extracellular matrix binding protein 
eno Laminin binding protein 
EPI Efflux pump inhibitor 
EPS Extracellular polymeric substance / Exopolysaccharides 
EUCAST European committee on antimicrobial susceptibility testing 
FbpA Fibrinogen binding protein 
FnbA/B Fibronectin-binding protein A and B 
HA-MRSA Healthcare/Hospital-associated methicillin-resistant Staphylococcus aureus 
hld δ-hemolysin, PSM-δ 
LDH lactate dehydrogenase 
MBC Minimal bactericidal concentration 
MIC Minimal inhibitory concentration 
MLST Multi Locus Sequence Typing 
MSCRAMM Microbial surface components recognizing adhesive matrix molecules 
MSSA Methicillin Susceptible Staphylococcus aureus 
MRSA Methicillin/Multi- Resistant Stahylococcus aureus 
NMP N-methylpyrrolidone 
Abbreviations 
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PBP Penicillin-binding protein 
PEG Polyethylene glycol 
PIA Polysaccharide intercellular adhesin 
PNAG Poly-ß(1,6)-N-acetyl-D-glucosamine 
PRP Platelet-rich blood plasma 
PSM Phenol soluble modulin 
PVL Panton-Valentine leucocidin 
PVP Polyvinylpyrrolidone 
rot Repressor of toxins 
RT/rt-PCR  Reverse transcription polymerase chain reaction or Real time polymerase chain reaction 
sarA Staphylococcal accessory regulator 
SasG Surface protein G 
SCCmec Staphylococcal cassette chromosome mec 
scpA/B Cysteine proteases staphopain A/B 
SCV Small Colony Variant 
sdrC/D/E Serine-aspartate repeat-containing proteins C, D and E 
spa Staphylococcal protein A 
spoVG Stage V sporulation protein G 
SS SlipSkin® (coating) 
sspA V8 serine protease 
ST Sequence type 
TCA Tricarboxylic acid (cycle) 
TSB Trypticase soy broth 
UTI Urinary tract infection 
XPS X-ray photoelectron spectroscopy 
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